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Alzheimer’s disease (AD) is the most common cause of dementia worldwide
and a leading cause of death in the United States. Rare cases of autosomal dominant
familial AD (fAD) result from genetic mutations in three key genes: amyloid precursor
protein (APP), and two APP processing-related genes (presenilin-1 (PSEN1), and
presenilin-2 (PSEN2)), supporting the theory that altered APP metabolism is a central
cause of AD. However, which product of APP metabolism is causal remains a matter
of investigation. A probable source of this lack of understanding stems from the poor
disease model systems that have been utilized in the field for many years. Recently,
advances in human induced pluripotent stem cell (iPSC) technology has enabled the
study of uniquely human diseases, such as AD, in human tissue. However, the
inability to precisely and efficiently genetically engineer human iPSCs has limited their
use in effectively studying monogenic human diseases like fAD.

In this thesis I first describe my work involved in developing CRISPR/Cas9
gene editing technology for use in human stem cells. Our CRISPR/Cas9-based
genome-editing framework allows the selective introduction of mono- and bi-allelic
sequence changes, such as single fAD-causing pathogenic mutations, with high
efficiency and accuracy. We show that editing accuracy is increased dramatically by
incorporating silent CRISPR/Cas-blocking mutations along with pathogenic mutations.
As well, by characterizing and exploiting a stereotyped inverse relationship between
a mutation’s incorporation rate and its distance to the CRISPR/Cas9 cleavage site,
we achieve predictable control of zygosity. Homozygous introduction requires using a
guide RNA targeting close to the intended mutation, whereas heterozygous
introduction can be accomplished by distance-dependent suboptimal mutation
incorporation or by using mixed repair templates. Additionally, we establish a method
termed “CORRECT” for precise and scarless gene editing. Together, our findings will
greatly facilitating the study of human disease and development of more human
disease models by enabling efficient introduction of specific sequence changes in
human stem cells using CRISPR/Cas9.
In later chapters I discuss how we used our novel CRISPR/Cas9 gene editing
framework to investigate in human neurons how APP and PSEN1 mutations may
converge in their actions in promoting AD-related phenotypes. We generated a
comprehensive panel of isogenic knock-in human iPSCs, which were differentiated
into disease-vulnerable cortical neurons. Initial global transcriptomic profiling of

mutant neurons revealed overlapping effects of the mutations on expression of ADrelated genes, suggesting an AD gene associated-network effect, as well as
endosomal-related genes. Endocytic dysfunction, as measured by enlargement of
Rab5+ early endosomes, was found in all APP and PSEN1 pathogenic mutant
neurons analyzed. By comparing heterozygous and homozygous cells we found APP
and PSEN1 mutations have discordant effects on Aβ production but similar effects on
the precursor to Aβ, β-C-terminal fragment of APP (β-CTF), which accumulates in all
APP and PSEN1 mutant neurons. Importantly, endosomal dysfunction in these human
neurons correlates with endogenous accumulation of β-CTF, and not with longer Aβ
peptides, and could be rescued by pharmacological modulation of β-secretase
(BACE) but not g-secretase. These data provide a new piece of evidence for β-CTF
being an important common product of APP metabolism that significantly contributes
to AD pathology.
In summary, by developing the technology to engineer next-generation human
AD model systems using CRISPR/Cas9 and iPSCs, our results not only provide
insight into the mechanism by which familial APP and PSEN1 mutations may cause
AD, but also provide knowledge that could be critical for the development of novel
therapeutics that may help to treat AD.

To everyone ever affected by Alzheimer’s Disease.
To all of my family and friends.
To Jerry, my love.
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CHAPTER I: INTRODUCTION

Rationale for thesis work

Ever since the German physician Alois Alzheimer discovered abnormal
deposits in the brain of a 51year-old patient suffering from memory impairments in
1906 (Alzheimer, 1916; Alzheimer et al., 1995), the effort to better understand and
treat what we now know as Alzheimer’s disease (AD) has endured. More than one
century later, and after years of research into the basic biological mechanisms
underlying AD, researchers are still hard at work trying to discover a cure for this
unthinkably devastating disease. The lack of any effective AD therapeutics
underscores the underlying complexities of the disease and indicates that new and
improved ways of studying AD may be invaluable to the field.
AD is currently defined by the presence of two key neuropathological findings,
extracellular plaques composed of amyloid-beta (Aβ) (Tanzi et al., 1987), and
intracellular neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau
(Grundke-Iqbal et al., 1986; Wischik et al., 1988). While the majority of AD cases
occur sporadically (sAD), genetic studies have demonstrated that single mutations in
either the amyloid precursor protein (APP) gene, or presenilin genes (PSEN1 and
PSEN2), are sufficient to cause a rare, early-onset, familial form of AD (fAD)
(Alzheimer's Disease Collaborative Group, 1995; Goate et al., 1991; Levy-Lahad et
al., 1995; Rogaev et al., 1995; Schellenberg et al., 1992; St George-Hyslop et al.,
1992; Van Broeckhoven et al., 1992). These genetic findings, along with the
1

discovery that presenilins form the catalytic component of the γ-secretase complex
responsible for cleaving APP and generating Ab, implies that APP metabolism is
essential to AD pathogenesis (De Strooper et al., 1998; Goldgaber et al., 1987;
Kang et al., 1987; St George-Hyslop et al., 1987; Tanzi et al., 1987). As a result, the
leading theory of AD pathogenesis is known as the “amyloid cascade hypothesis”,
which places extracellular Ab as the most upstream trigger of neurodegenerative
processes in the disease (Hardy and Higgins, 1992; Hardy, 2006).
To date, more than 200 fAD mutations in APP, PSEN1 and PSEN2 have
been described, and while the effects of many of these mutations on Aβ production
have been studied extensively, a common unifying mechanism describing how these
mutations lead to the development of AD has yet to be determined (Barber, 2012).
Confounding many of these early studies is their use of non-human and/or nonneuronal cellular systems that rely on massive overexpression of AD-associated
proteins, typically in rodent models (Götz and Ittner, 2008). Moreover, these widely
used non-physiological models fail to adequately recapitulate all known human AD
hallmark pathologies, and therefore may limit the discovery of effective AD
therapeutics. Generation of a physiologically relevant human neuronal model system
may be the key to unlocking future discoveries of basic disease mechanisms and
novel therapeutic targets. This thesis describes an effort to develop gene editing
and human stem cell technologies, and ultimately implement these tools to better
understand common disease mechanisms underlying AD caused by fAD mutations.

2

Epidemiology and clinical manifestation of AD

AD is classified as a type of neurodegenerative dementia, which is a broad
description of a family of brain disorders that cause chronic and gradual loss of
memory, language, problem solving skills and executive functioning. Ultimately, the
disease culminates in a loss of ability to perform everyday activities as well as a loss
of one’s independence (Alzheimer's Association, 2017). AD comprises
approximately 60-70% of all dementias, making it the most common type of
neurodegenerative disease, affecting over 5 million people in the US and more than
40 million people worldwide (Alzheimer's Association, 2017; Scheltens et al., 2016).
The primary risk factor for AD is aging, as epidemiological studies have shown that
the risk of developing AD approximately doubles every five years after the age of 65
(Alzheimer's Association, 2017). Prevalence of AD correlates with population
lifespan and as global population demographics change in the coming decades, the
number of cases of AD worldwide is also expected to dramatically shift. Specifically,
it is estimated that today approximately 5.7 million Americans are living with AD,
however with predicted future population aging, this number is expected to triple by
2050 (Alzheimer's Association, 2017).
AD is the only one of the top 10 leading causes of death that cannot be
prevented, cured or slowed (Alzheimer's Association, 2017). Between years 2000
and 2015 the number of deaths known to be associated with AD has increased 125
percent, while deaths due to the most common cause of death (heart disease) has
significantly decreased (Alzheimer's Association, 2017). The lifetime cost of care
3

for an individual living with AD dementia is estimated to be over $300,000, and it is
expected that in the US the total payments in 2018 for all individuals with AD is more
than 250 billion dollars. Therefore, if no effective therapies are discovered, the
financial burden of AD will increase to a projected 1.1 trillion dollars by 2050
(Alzheimer's Association, 2017).
Clinically, symptoms may present differently amongst patients with AD. Early
in AD progression individuals are often able to function independently. However, in
more moderate and severe stages of AD individuals may become frequently
confused about where they are, have personality and behavioral changes, and
ultimately require assistance in basic activities of daily living and may lose their
ability to communicate (Alzheimer's Association, 2017). Once the AD progresses to
the latest stages, brain regions involved in motor control and other basic bodily
functions become affected, ultimately impairing movement and requiring the patient
to be cared for full-time or hospitalized. Lung infection (aspiration pneumonia) is a
common concomitant issue in late stage AD, contributing to death in many cases
(Alzheimer's Association, 2017).
Diagnosis of AD is not straightforward, as many presenting symptoms overlap
with other dementias of a different cause. Therefore, diagnosing AD requires careful
examination obtaining family medical records, patient reporting, cognitive testing,
blood testing to rule out other potential causes of dementia, and, in more recent
years, brain imaging for Ab or tau (Alzheimer's Association, 2017). Despite these
improved methods of clinical examination, bona fide AD can only be fully diagnosed
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upon autopsy and identification of hallmark AD neuropathological features. In the
future, with the development of biomarkers, revised strategies to diagnose AD early
are anticipated. While this improvement in no way offsets the demand for novel
therapeutics to treat AD, early diagnosis will help ease the burden of the disease by
allowing a patient’s family and caregivers to adequately prepare for treatment and
may aid in the development of interventions to delay AD progression.

AD neuropathology: APP and generation of Ab

Neurologically, AD is associated with global brain atrophy and loss of
synapses (Scheltens et al., 2016). In addition, there are two key hallmark
neuropathological features that define AD: 1) Extracellular plaques comprised of an
aggregated peptide called amyloid beta (Ab) (Tanzi et al., 1987), and 2) intracellular
neurofibrillary tangles comprised of hyperphosphorylated microtubule-associated
protein tau (Grundke-Iqbal et al., 1986; Wischik et al., 1988). Ab is generated by
sequential cleavages of the amyloid precursor protein (APP). Human APP, located
on chromosome 21, is a ubiquitously expressed transmembrane protein with
particularly high expression in the central nervous system (CNS). APP is normally
alternatively spliced into approximately one of 10 variants 639-770 amino acids in
length. The major isoform in the CNS is APP695, however all isoforms can lead to
the generation of Ab (Wang et al., 2017a). Although a consensus as to the normal
function of APP has yet to be reached, much is known about how the protein is both
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trafficked and metabolized in normal and disease conditions (Gandy and Greengard,
1994; O'Brien and Wong, 2011; Van Der Kant and Goldstein, 2015).
Although Ab is the most well-known disease-associated derivative of APP,
APP actually is both processed by both non-amyloidogenic and amyloidogenic
pathways via a series of secretase enzymes or enzyme complexes (Figure 1). APP
predominantly (~90-99% of the time) is processed in the non-amyloidogenic
pathway. APP is first cleaved by a-secretase to generate an N-terminal fragment
called soluble APPa (sAPPa) and a C-terminal fragment (CTF) 83 amino acids in
length (C83, or a-CTF). a-CTF is then further processed by another secretase
complex called g-secretase, releasing the APP intracellular domain (AICD) and a 3
kDa peptide product (P3). To generate Ab, APP must be cleaved first by bsecretase at Asp1 (the first amino acid in the Ab sequence), which yields an Nterminal soluble APPb fragment (sAPPb) as well as a CTF that is 99 amino acids in
length (C99 or b-CTF). b-CTF can then be further processed by γ-secretase to yield
AICD as well as full-length Ab (Haass et al., 2012; O'Brien and Wong, 2011).
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Figure 1. Amyloidogenic and non-amyloidogenic processing of APP.
APP undergoes a serious of catalytic cleavages by different secretase
enzymes and enzyme complexes. In the non-amyloidogenic pathway (left)
APP is initially cleaved by a-secretase, which results in the production of aCTF (C83) and sAPPa. a-CTF can then be further processed by g-secretase,
yielding the soluble P3 fragment and the AICD. In the amyloidogenic
pathway, APP is instead first cleaved by b-secretase, which results in
generation of b-CTF (C99) and sAPPb. b-CTF is then further cleaved by gsecretase, which results in the production of AICD as well as full length Ab.
In pathological conditions, Ab can form aggregates and deposit into
extracellular amyloid plaques.

In actuality, the majority of b-secretase processing actually occurs at the
Glu11 position in Ab (b’ site), which generates a shorter b’-CTF 89 amino acids in
length. b’-CTF can also be further cleaved by g-secretase, generating AICD as well
as truncated Ab (Figure 2) (Wang et al., 2017a). Additionally, APP can be
processed by a b-secretase homologue called BACE2, which, as a q-secretase,
7

precludes the generation of Ab (Figure 2) (Wang et al., 2017a). BACE 2 is not
highly expressed in the brain (Bennett et al., 2000; Sun et al., 2006; 2005).

Figure 2. Non-canonical processing of APP
APP is predominantly cleaved by a-secretase (blue) to generate sAPPa and
a-CTF (C83), which is further processed by g-secretase to generate truncated
non-pathogenic Ab peptides. A minority of APP is processed by b-secretase
cleavage enzyme 1 (BACE1; b-secretase), which cleaves APP at both
Asp1(b, minority of BACE1 cleavage) and Glu11 (b’) (numbering of Ab
sequence), generating b-CTFs that are either 99 (C99) or 89 (C89) amino
acids in length, respectively. These b-CTFs can be further processed by gsecretase, however only C99 b-CTF produces full length Ab. APP can also
be cleaved by BACE2 (a q-secretase) which generates a CTF 80 amino acids
in length (C80) and can be further processed by g-secretase to generate
truncated Ab and AICD. Red portion depicts Ab sequence of APP. Adapted
from (Wang et al., 2017a).
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g-secretase is a highly conserved protein complex composed of homomeric
assembly of the catalytic subunit PSEN1 (or PSEN2), nicastrin, anterior pharynx 1
(Aph1) and the presenilin enhancer 2 (PEN2). Recent characterization of gsecretase structure and function has been illuminating in that we now better
understand how g-secretase processes b-CTF to generate Ab (Figure 3). In an
initial endopeptidase cleavage between amino acids 50/49 or 49/48, g-secretase
cleaves b-CTF and releases one of two AICD fragments of different lengths (Figure
3). g-secretase then continues to make several successive tri- or tetra-peptide
carboxypeptidase cleavages of the longer Ab substrate (Takami et al., 2009). This
processive activity most commonly yields shorter and less hydrophobic fragments of
Ab, typically 38 or 40 amino acids in length (Ab38 and Ab40, respectively) (Figure
3). Ab40 is the most abundant Ab species generated by g-secretase processing in
normal conditions, however levels of longer Abs like the 42 or 43 amino acid form
(Ab42 or Ab43) are increased in disease (Iwatsubo et al., 1995; Scheuner et al.,
1996a). Longer Abs are much more hydrophobic and prone to aggregation and
therefore are more predominant in the extracellular Ab plaques characteristic in AD
(Jarrett et al., 2002). Typically, soluble Ab that is regularly generated and released
into the extracellular space can be readily cleared from the brain parenchyma
(Castellano et al., 2011; Paresce et al., 1996; Wyss-Coray et al., 2003). In disease
conditions, however, Ab clearance mechanisms can also be impaired, resulting in
the greater likelihood of accumulated soluble Ab to oligomerize, fibrillize and
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ultimately aggregate into bona fide amyloid plaques (Selkoe, 2006; Selkoe and
Hardy, 2016).

Figure 3. g-secretase processing of bCTF and Ab generation.
b-CTF is cleaved intramembranously by the g-secretase complex. Initially, gsecretase makes an endopeptidase cleavage of b-CTF between amino acids
49-48 or 50-49, generating Ab peptides of either 48 or 49 amino acids in
length. Additionally, AICDs are generated that differ in length by 1 amino acid.
Subsequently, through a series of carboxypeptidase cleavages 3 or 4 amino
acids of the Ab peptides are removed, most commonly resulting in the
generation of Abs 38 or 40 amino acids in length. In AD, there is an
accumulation of longer Ab species, which are more hydrophobic and prone to
aggregate.
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APP trafficking and proteolytic processing

APP is a type 1 single-pass transmembrane protein that is trafficked through
the constitutive secretory pathway (Figure 4). After being synthesized in the
endoplasmic reticulum (ER), nascent APP polypeptides are transported to the Golgi
apparatus and trans-golgi network (TGN) where it undergoes numerous
posttranslational modifications (Haass et al., 2012). The TGN is the major residence
of APP in neurons (Hartmann et al., 1997; Xu et al., 1997). Only a small fraction of
APP (approximately 10%) ultimately reaches the plasma membrane (Haass et al.,
2012; Thinakaran and Koo, 2008). At the cell surface, APP can be rapidly
internalized by clathrin-mediated endocytosis and is sorted into the early endosome
(Haass et al., 2012; Thinakaran and Koo, 2008). Internalized APP is then trafficked
into the late endosome-lysosomal pathway for degradation, or trafficked back to the
plasma membrane or to the TGN (Haass et al., 2012; Small and Petsko, 2015;
Thinakaran and Koo, 2008) (Figure 4).
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Figure 4. Trafficking and processing of APP.
APP is a single-pass transmembrane protein that matures through the
classical secretory pathway. (1) Nascent APP molecules (shown as black
bars) are generated and modified through the secretory pathway. Once APP
reaches the cell surface it can be rapidly internalized via clathrin-mediated
endocytosis (2). (3) Once endocytosed APP is trafficked through early
endosomes it can subsequently be trafficked either to the TGN or cell surface
through retromer or recycling endosomes, respectively. APP can also be
trafficked to late endosomes and lysosomes for degradation. Reprinted with
permission from (Haass et al., 2012).
APP is predominantly cleaved by a-secretase at the cell surface (Haass et al.,
2012; Sisodia, 1992), whereas amyloidogenic b-secretase cleavage of APP
predominantly occurs in endosomal compartments (Haass et al., 2012; Huse et al.,
2000; Rajendran et al., 2008) (Figure 5). As an aspartyl protease, b-secretase
12

(BACE1) has an optimal activity at low pH and is therefore most active in both early
and late endosomes (Vassar, 1999). Mature and active g-secretase complexes are
located predominantly within both the plasma membrane at the cell surface as well
as within endosomal-lysosomal compartments (Dries and Yu, 2008; Kaether et al.,
2006). While g-secretase subunits can be found in other organelles associated with
the secretory pathway, these are thought to be unassembled complexes and
inactive. Therefore, Ab is predominantly generated in endosomal compartments,
while P3 is mostly generated at the cell surface (Figure 5). Ab resulting from
amyloidogenic processing of APP in endosomes can either be secreted or trafficked
to late endosomes and lysosomes for degradation (Haass et al., 2012).
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Figure 5. Amyloidogenic versus non-amyloidogenic processing is
regulated by trafficking and compartmentalization of APP.
Non-amyloidogenic processing of APP predominantly occurs at the cell
surface, as this is where the majority of a-secretase resides. Amyloidogenic
processing occurs within endocytic organelles, where b-secretase is more
abundant and active. g-secretase is present both at the cell surface and
within endocytic compartments (Haass et al., 2012).

Endocytosis and trafficking of APP is intricately regulated. Much of this
regulation is mediated by members of the low-density lipoprotein receptor (LDLR)
family (Bu, 2009; Li et al., 2001) (Figure 6). Many LDLR family members serve as
receptors for apolipoprotein E (APOE) (Bu, 2009; Pitas et al., 1987), which is highly
associated with AD pathogenesis, thereby implicating LDLRs in AD biology.
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Moreover, variants in a number of LDLRs have been shown to be associated with
late-onset AD risk (Gopalraj et al., 2005; Kang et al., 1997; Karch and Goate, 2015;
Wang et al., 2017b). LRP1, one LDLR family member, can bind APP directly or
indirectly and promote rapid APP endocytosis, which has been shown to significantly
increase Ab production (Bu, 2009; Cam et al., 2005; Liu et al., 2007). In contrast,
another LDLR, LRP1B, competes for interaction with APP and retains APP at the
cell surface leading to reduced Ab production (Cam et al., 2004). Similarly,
APOER2 decreases APP endocytosis and Ab generation by enhancing APP
interaction with other cell surface proteins and increases its retention at the plasma
membrane (Bu, 2009; Hoe et al., 2005). The most widely studied LDLR related to
AD is SORL1. SORL1 (and also the related SORCS1) is associated with AD in a
variety of ways, most significant, is the discovery of SORL1 variants associated with
sAD (Kuwano et al., 2013; Rogaeva et al., 2009). More recently, even coding
mutations in SORL1 have been found to cause an extremely rare inherited version
of AD (Cuccaro et al., 2016; Vardarajan et al., 2015; 2014). SORL1 shares
homology with intracellular sorting receptors and is trafficked from endosomes back
to the plasma membrane or TGN by the retromer complex. SORL1 binds APP, and
therefore co-traffics APP away from endosomes, reducing the likelihood of
amyloidogenic processing of APP in endocytic vesicles and Ab production
(Andersen et al., 2005; O'Brien and Wong, 2011; Offe et al., 2006). It is thought that
disease-associated SNPs in SORL1 exert pathogenicity by reducing SORL1
expression or affinity for APP, leading to enhanced amyloidogenic APP processing
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(Vardarajan et al., 2015; Young et al., 2015). Trafficking of APP is further regulated
by a complex network of sorting nexins (SNXs), Rab-GTPases as well as
intracellular adaptor proteins (Haass et al., 2012) (Figure 6). In sum, perturbations
in intracellular trafficking processes may be inherently and intricately associated with
AD pathogenesis, perhaps in part by altering APP processing and generation of
amyloidogenic peptides.

Figure 6. Regulation of APP trafficking in the endosomal-lysosomal
system.
APP is predominantly processed in the non-amyloidogenic pathway at the cell
surface. When APP is endocytosed APP can be processed to generate Ab in
endocytic compartments. Most Ab is ultimately secreted into the extracellular
space however some is trafficked to late endosomes or lysosomes where it
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can accumulate intracellularly. Endocytosis of APP (and therefore regulation
of amyloidogenic processing) is coordinated by low-density lipoprotein family
members and APOE. LRP1, which is endocytosed rapidly, enhances APP
endocytosis and amyloidogenic processing, whereas LRP1B and APOER2
helps to retain APP at the cell surface and promote non-amyloidogenic
processing. APOE4 promotes APP endocytosis and amyloidogenic
processing. SORL1 is a retromer receptor and shuttles APP out of
endosomes back to the TGN (or cell surface) thereby reducing amyloidogenic
APP processing. Additionally, trafficking and transit through the endosomallysosomal system is regulated by Rab-GTPases (which function by
hydrolyzing GTP as shown in the adjacent box). Reprinted and modified with
permission (Bu, 2009).

AD neuropathology: Tau

In addition to amyloid plaques, the second hallmark neuropathological feature
of AD is neurofibrillary tangles (NFTs). These intracellular inclusions are comprised
of hyperphosphorylated microtubule associated protein tau (MAPT or tau) (GrundkeIqbal et al., 1986). Tau is a soluble cytosolic protein that that normally functions to
bind, stabilize, and promote the flexibility of microtubules (Weingarten et al., 1975).
In neurons, microtubules are a critical component of axons, serving as a track for
shuttling of proteins and vesicles between the cell body and synapse (Avila et al.,
2002; Ebneth et al., 1998; Millecamps and Julien, 2013; Spires-Jones and Hyman,
2014). Typically, in neurons tau is not present in dendrites, however in AD, axonal
tau becomes hyperphosphorylated, resulting in its dissociation from microtubules
and mislocalization to the somatodendritic compartment (Götz et al., 1995; Hoover
17

et al., 2010; Miller et al., 2014). Mislocalized hyperphosphorylated tau can also
aggregate, forming fibrils and the characteristic NFTs (Götz and Ittner, 2008; Guo
and Lee, 2011). These pathological changes are detrimental to the health of a
neuron, as aggregated hyperphosphorylated tau can form seeds and sequester
normal functioning tau and other essential microtubule-associated proteins (MAPs)
(Alonso et al., 1997; Guo and Lee, 2011). Together, these changes lead to
disruptions in normal microtubule assembly and function, disrupting axon integrity
and transport, which may ultimately lead to degeneration.
Interestingly, tau pathology (NFTs) correlates better with cognitive decline
and AD severity than does Ab burden, suggesting that tau may serve as a
downstream causal feature of neurodegeneration (Braak and Braak, 1991).
Furthermore, within the last decade, there has been a growing consensus that tau
may act as a prion-like protein and spread from diseased neurons to non-diseased
neurons to propagate pathology (Fu et al., 2016; Kaufman et al., 2016; Sanders et
al., 2014; Wu et al., 2016). These two fundamental discoveries provide undeniable
evidence that tau plays a critical role in AD progression. However, whether tau truly
is the causal effector of degeneration in AD, and how tau neuropathology is related
to changes in Ab metabolism remains a topic of great debate in the field.

AD genetics: Familial AD and the amyloid cascade hypothesis

The majority of AD cases (over 99%) occurs late in life and sporadically
(sporadic AD or sAD), that is with no known genetic cause. Approximately less than
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1% of AD occurs much earlier in life, due to the inheritance of an autosomal
dominant familial AD (fAD) mutation (Karch and Goate, 2015). The idea that rare
forms of AD could be inherited came prior to even the identification of APP, from
studying patients with Down Syndrome (DS), which is caused by the presence of an
additional part or all of chromosome 21. It was discovered that individuals with DS
caused by an additional full copy of chromosome 21 develop AD neuropathology
(Masters et al., 1985), however patients with a partial trisomy (not including the APP
gene) do not (Guerreiro et al., 2012). This discovery was particularly meaningful
only once Ab was identified as the major component of the amyloid plaque, and APP
was genetically mapped to chromosome 21 (Goldgaber et al., 1987; Kang et al.,
1987; Robakis et al., 1987; Roher et al., 1986; St George-Hyslop et al., 1987; Tanzi
et al., 1987). Together, this was the earliest evidence that excess Ab produced in
DS is due an additional copy of APP may be sufficient to cause AD.
It is now known that early-onset fAD can be caused by mutations in either
APP, PSEN1 or PSEN2. To date more than 30 fAD APP mutations, including rare
fAD caused by APP gene duplication (Rovelet-Lecrux et al., 2006), have been
identified and account for approximately 14% of all fAD cases. The majority of fAD
APP point mutations cluster around the sites of Ab processing (Figure 7). Initially,
APP fAD mutations were extremely valuable discoveries as they revealed numerous
aspects of the molecular underpinnings of AD pathology. The widely studied APP
Swedish mutation (APPswe, KM670/671NL) was shown to increases Ab in patient
plasma up to 3-fold by enhancing b-secretase cleavage efficiency and generation of
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b-CTF (Citron et al., 1992; 1994; Mullan et al., 1992). Recently, a protective APP
mutation (APP-A673T) lying adjacent to the Swedish mutation was discovered,
thereby further implication altered APP processing at the b-secretase cleavage site
as inherently associated with development of AD (Jonsson et al., 2012). Similarly,
the disease-causing APP Flemish mutation (APP-A692G) is situated at the site of asecretase processing and is therefore predicted to exert its pathogenicity by limiting
a-secretase cleavage and as a result enhancing amyloidogenic processing by bsecretase (De Jonghe et al., 1998; Hendriks et al., 1992). Some evidence also
points to a role of the APP-A692G mutation in altering processing of APP by gsecretase, which leads to enhanced amyloid production(Tian et al., 2010). Multiple
pathogenic APP mutations exist at the C-terminal region of the Ab sequence in APP
(Chartier-Harlin et al., 1991; Goate et al., 1991; Murrell et al., 2000; 1991). These
mutations cluster around the g-secretase processing site and therefore are thought
to exert their pathogenicity by altering g-secretase function. Past cellular studies
have demonstrated that these C-terminal APP mutations may not alter total Ab
levels, but instead shift processing to increase the levels of longer more
amyloidogenic Ab42, highlighting a potential important role of Ab aggregation in AD
pathogenesis (De Jonghe et al., 2001; Tamaoka et al., 1994). Together, the
discovery of multiple fAD patients with characteristic pathology and mutations in the
APP gene makes it clear that the processing of APP plays a central causal role in
AD pathogenesis.
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Figure 7. APP fAD mutations.
Schematic of APP, fAD mutations and processing sites. Mutations
associated with early-onset familial AD are shown. APP fAD mutations tend
to cluster around sites of secretase cleavages, thereby influencing processing
patterns. One mutation is protective against AD (A673T, shown in green).
The Ab region of APP is indicated in red. Mutations studied in this thesis
(APPswe, APP-A763T, APP-A692G, APP-V717G) are colored.

Since the discovery of APP fAD mutations, nearly 200 other fAD mutations
have been discovered, mapping to chromosome 14 and chromosome 1 (Kelleher
and Shen, 2017a; Levy-Lahad et al., 1995; Rogaev et al., 1995; Schellenberg et al.,
1992; St George-Hyslop et al., 1992). These two genes are now known to be
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PSEN1 and PSEN2, respectively, which, as describes above, encode the catalytic
component of the g-secretase complex necessary for the generation of Ab (De
Strooper et al., 1998; De Strooper, 2007). While only 13 dominant mutations in
PSEN2 have been identified, over 180 mutations have been found in PSEN1,
accounting for nearly 80% of all fAD cases (Giri et al., 2016). Generally, mutations
in PSEN1 and PSEN2 are distributed throughout the protein. Similar to the Cterminal mutations in APP, PSEN1 and PSEN2 mutations have been shown to also
shift processing of APP to generate relatively more of the longer Ab42 peptides
compared to the shorter Ab40 (increasing the Ab 42:40 ratio) (Borchelt et al., 1996;
Citron et al., 1992; Duff et al., 1996; Kelleher and Shen, 2017a; Scheuner et al.,
1996b). While the mechanistic explanation for how these mutations affect gsecretase are still being fully fleshed out, the discovery of mutations in these two
genes that are inherently related to Ab generation amplifies the causal relationship
between AD and APP processing, and places emphasis on the relative amounts of
longer Abs as the primary contributing factor important in AD pathogenesis.
These abovementioned discoveries of causal direct genetic links between
altered APP processing, Ab and disease, bolstered the development of the “amyloid
cascade hypothesis”. The amyloid cascade hypothesis posits that changes in APP
processing and/or brain Ab homeostasis can result in the aggregation of Ab and
formation of amyloid plaques (Hardy and Higgins, 1992). Importantly, the
hypothesis predicts that these early changes in Ab metabolism are sufficient to
initiate a series of related pathological changes including the hyperphosphorylation
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and aggregation of tau into NFTs, and ultimately neurodegeneration. While the
strongest evidence supporting this hypothesis comes from the familial AD genetics
described above, a large amount of in vitro and in vivo evidence has also
accumulated over the past two decades. In particular, in vitro evidence has shown
that Ab can be toxic to primary mouse neurons, and that toxicity appears to be
abolished when tau is knocked-out (Rapoport et al., 2002; Roberson et al., 2007).
Moreover, Ab has been shown to induce tau phosphorylation, promote synapse loss,
and trigger neuroinflammation, all of which are characteristic of AD pathogenesis
(Jin et al., 2011; Koffie et al., 2009). In vivo, overexpression of mutant APP and
PSEN1 dramatically enhances tau aggregation in a mouse model expressing human
tau, and augments cognitive and behavioral impairments in these animals (Oddo et
al., 2003).
Although these genetic and experimental data provide a considerable amount
of support for the amyloid cascade hypothesis, other findings call the hypothesis into
question. Most notable is the finding that some individuals have very high amyloid
burden in their brains but up until death they are cognitively normal, suggesting that
amyloid deposits may not always trigger toxicity (Davis et al., 1999). Moreover, in a
related neurodegenerative disorder called frontotemporal dementia (FTD) – caused
by familial mutations in the MAPT (tau) gene – there is tau pathology (NFTs) and
neurodegeneration in the absence of changes in Ab (Dumanchin et al., 1998; Hong
et al., 1998; Hutton et al., 1998). This indicates that Ab is not always necessary to
trigger tau pathology and neurodegeneration. Regardless, it seems undeniable that
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APP and Ab play a critical role in AD development, although the exact mechanism
by which altered APP metabolism results in disease remains elusive.

AD genetics: Sporadic AD and genetic risk factors

The complexity of AD pathogenicity has been further underscored by more
recent discoveries of genetic risk factors of late-onset sAD. For a long time, the only
known late-onset AD-associated risk gene was APOE. APOE encodes the protein
apolipoprotein E and is located in humans on chromosome 19. There are 3 APOE
alleles called e2, e3 and e4. One copy of the APOE e4 allele increases risk for
developing late-onset AD by 3-fold while two copies of e4 increases risk for AD 12fold (Corder et al., 1993; Scheltens et al., 2016; Strittmatter et al., 1993; Verghese et
al., 2011). APOE e2 allele carriers tend to be protected from development of AD
(Corder et al., 1994). APOE is the primary cholesterol carrier in the brain and plays
a role in a variety of biological processes in the central nervous system. Specifically,
APOE is associated with cholesterol metabolism, lipid trafficking, inflammation,
synaptic function, neurogenesis, as well as APP trafficking, endocytosis and Ab
production (Bu, 2009; Liu et al., 2013). The underlying mechanism linking APOE e4
to AD is seemingly complex and has been shown to involve aberrant changes in Ab
deposition and aggregation as well as clearance (Corder et al., 1993; Scheltens et
al., 2016; Strittmatter et al., 1993; Verghese et al., 2011). Non Ab-associated
mechanisms linking APOE e4 and AD include an effect on the endosomal-lysosomal
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system, tau homeostasis, synaptic plasticity, neuroinflammation and lipid
homeostasis (Chung et al., 2016; Krasemann et al., 2017; Nuriel et al., 2017a;
2017b; Shi et al., 2017).
Recent technological advances in genome-wide association studies (GWAS)
and next generation sequencing (NGS) have been revolutionary in discovering other
sAD-associated genes. sAD risk genes broadly can be categorized into three main
pathways –immune response, lipid metabolism and endocytosis – with many of
these risk genes falling into two or even more of these biological categories (Table
1).

25

Table 1. Late-onset AD risk genes and their biological associations.
Gene

APOE

CLU

SORL1
ABCA7

CR1

CD33
MS4A
TREM2

BIN1

CD2AP

PICALM

EPHA1
HLADRB5/HLADRB1

Function
Lipid transport,
endocytosis,
cytoskeletal dynamics
Synapse turnover,
endocytosis,
chaperone protein
Endocytosis, APOE
receptor,
processing/trafficking
of APP
Lipid homeostasis,
Phagocytosis
Complement
activation, Ab
clearance
Clathrin-mediated
endocytosis, Cell
signalling
Immune function,
signal transduction
Inflammatory
response
Synaptic vesicle
endocytosis, APP
trafficking,
cytoskeletal dynamics
Receptor-mediated
endocytosis,
cytokinesis,
cytoskeletal
dynamics, synapse
funciton
Clathrin-mediated
endocytosis
Synaptic
development, immune
function, neural
development
Immune function,
histocompatibility

Pathway

Immune response

References
(Corder et al., 1993; Roses M D,
1996; Saunders, 2000; Saunders et
al., 1993)
(Byun et al., 2014; Harold et al.,
2009; Jones and Jomary, 2002;
Rosenberg and Silkensen, 1995)
(Andersen et al., 2005; Cuccaro et
al., 2016; Gustafsen et al., 2013;
Kuwano et al., 2013; T Cuenco et
al., 2008; Vardarajan et al., 2015;
Young et al., 2015)
(Hollingworth et al., 2011; Holton et
al., 2013)
(Biffi et al., 2012; Kok et al., 2011;
Kucukkilic et al., 2018; Wilson et al.,
1987)
(Siddiqui et al., 2017; The Alzheimer
Disease Neuroimaging Initiative et
al., 2013)
(Antúnez et al., 2011; Ma et al.,
2015; Zhu et al., 2017)
(Guerreiro et al., 2013; Jonsson et
al., 2013; Ulrich et al., 2017)

Endocytosis,
synapse function

(Calafate et al., 2016; Harold et al.,
2009; Ubelmann et al., 2017)

Lipid metabolism,
endocytosis
Lipid metabolism,
immune response,
endocytosis

Endocytosis, lipid
metabolism
Lipid metabolism,,
Immune response

Immune response
Endocytosis,
immune response
Immune response

Immune response,
synapse function

(Chen et al., 2015; Hollingworth et
al., 2011; Monzo et al., 2005;
Ubelmann et al., 2017)
(Harold et al., 2009; Kok et al.,
2011; Schjeide et al., 2011; Xiao et
al., 2012)
(Hollingworth et al., 2011; Karch and
Goate, 2015; Karch et al., 2012;
Lambert et al., 2013; Wang et al.,
2015)

Immune response

(Giri et al., 2016; Karch and Goate,
2015; Lu et al., 2017)

Endocytosis,
synapse function
Endocytosis,
synapse function
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INPP5D

MEF2C
CASS4
PTK2B

NME8
ZCWPW1
CELF1

Cytokine signaling,
Immune function
Myogenesis, synapse
formation
Cell migration, cell
adhesion
Calcium homeostasis,
MAP kinase signaling
Ciliary function,
neuronal cell
proliferation
Epigenetic regulation,
neural development
mRNA editing, PremRNA splicing

Cell-cell adhesion,
angiogenesis
Cell signaling, neural
development,
SLC24A4/RIN3 endocytosis

Immune response
Immune response,
synapse function

Synaptic function

FERMT2

DSG2

PLD3
UNC5C
AKAP9

ADAM10

SORCS1

LRP1

Cell-cell adhesion
Signal transduction,
epigenetic
modification,
endosomal-lysosomal
defects
Neural development
Signal transduction,
tau dynamics
Neurogenesis, cell
adhesion, APP
processing
Endocytosis, APOE
receptor,
processing/trafficking
of APP
Endocytosis, APOE
receptor,
processing/trafficking
of APP

Endocytosis

Lipid metabolism

(Jing et al., 2016; Karch and Goate,
2015; Scheltens et al., 2016;
Yoshino et al., 2017)
(Clark et al., 2013; Karch and
Goate, 2015; Lambert et al., 2013;
Nowakowska et al., 2010)
(Beck et al., 2014; Giri et al., 2016;
Karch and Goate, 2015)
(Alier and Morris, 2005; Beck et al.,
2014; Jiao et al., 2015)
(Karch and Goate, 2015; Kim et al.,
2002; Liu et al., 2016; 2014b)
(Allen et al., 2015; Karch et al.,
2016)
(Giudice et al., 2016; Hinney et al.,
2014; Karch et al., 2016)
(ADGC, Alzheimer’s Disease
Neuroimaging Initiative et al., 2016;
Apostolova et al., 2018; Karch and
Goate, 2015)
(Giri et al., 2016; Kajiho et al., 2003;
Karch and Goate, 2015; Nixon,
2017)
(Hartlieb et al., 2014; Karch and
Goate, 2015; Lambert et al., 2013)

(Cruchaga et al., 2014; Fazzari et
al., 2017; Karch and Goate, 2015)
(Wetzel-Smith et al., 2014)
(Logue et al., 2014; Venkatesh et
al., 2016)
(Kim et al., 2009; Suh et al., 2013;
Vassar, 2013)

Endocytosis, lipid
metabolism
Endocytosis, lipid
metabolism
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(Reitz et al., 2011; Xu et al., 2013)

(Bu, 2009; Shinohara et al., 2017;
Wang et al., 2017b)

Neuroinflammation is a central feature in AD and several immune-associated
genes with variants that are associated with late-onset AD have been identified
(Karch and Goate, 2015). It has been shown in numerous rodent and human
studies that amyloid plaques in the brain are surrounded by activated immune cells
(Condello et al., 2015; Nimmerjahn et al., 2005; Yuan et al., 2016) and that many of
the late-onset associated genes that have been identified by GWAS are uniquely
expressed at high levels in brain immune cells (e.g., microglia) (Efthymiou and
Goate, 2017; Sims et al., 2017). Some of these immune-related risk genes include
CR1, CD33, CLU, EPHA1, MS4A and TREM2. Neuroimmune cells are important
phagocytic scavenging cells necessary for the maintenance of a healthy brain.
Therefore, it is thought that perturbations in these processes may alter protein
homeostasis in the brain parenchyma and lead to the accumulation of Ab (Hickman
et al., 2008; Nimmerjahn et al., 2005). For example, CD33 and TREM2 are thought
to contribute to disease by impairing clearance of Ab (Griciuc et al., 2013; Rivest,
2015; Ulrich et al., 2017). It has also been shown that the complement cascade is
elevated in AD and can contribute to disease pathology (Eikelenboom et al., 1989;
Hong et al., 2016; Shen et al., 1997), therefore variants in CR1, which could confer
risk to AD or be neuroprotective, may be associated with disease by either
enhancing or attenuating the complement response (Karch and Goate, 2015).
Besides APOE, late-onset AD genes associated with lipid metabolism include
CLU, ABCA7, SORL1, DSG2. APOE and CLU (also known as Apolipoprotein J,
APOJ) are thought to share similar roles in AD pathogenesis, with their contribution
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to Ab clearance being most widely studied (Castellano et al., 2011; DeMattos et al.,
2004; Verghese et al., 2013; Zandl-Lang et al., 2018). These lipoproteins can
directly bind to Ab and also lipoprotein receptors that may play a role in Ab
clearance and APP metabolism (Bu, 2009; Cam et al., 2004; Offe et al., 2006;
Sagare et al., 2007). ABCA7 is important mediator of cholesterol metabolism and is
associated with plaque burden in AD brains as well as cognitive decline (Karch et
al., 2012; Kim et al., 2013; Shulman et al., 2013). Genes involved in lipid
metabolism also play a pivotal role in regulating endocytosis and intracellular
trafficking, all of which depend on the regulation and coordination of lipoproteins and
lipoprotein receptors (Bu, 2009; Holtzman et al., 2012; Pitas et al., 1987).
Many genes known to regulate endocytic processes, which are important in
APP processing and synaptic activity, have been implicated in late-onset AD risk.
These endocytosis genes include SORL1, SORCS1, LRP1, BIN1, PICALM, CD2AP,
EPHA1, RIN3, MEF2C (Giri et al., 2016; Karch and Goate, 2015). SORL1, SORCS1
and LRP1 are all APOE receptors and are known to regulate endocytosis and
intracellular trafficking of multiple cargos including APP (Andersen et al., 2005;
Karch and Goate, 2015; Reitz et al., 2011; Rogaeva et al., 2009; Shinohara et al.,
2017; Young et al., 2015). BIN1, PICALM and CD2AP are associated with receptormediated endocytosis and not only play a role in trafficking APP and Ab production,
but may also affect overall cellular proteostasis and aberrant protein aggregation
(Calafate et al., 2016; Cormont et al., 2003; Monzo et al., 2005; Moreau et al., 2014;
Tian et al., 2013; Ubelmann et al., 2017). In addition, these genes may play a vital
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role in synaptic vesicle trafficking and recycling (Di Paolo et al., 2002; Dustin et al.,
1998; Harel et al., 2008). EPHA1 is a critical gene involved in synapse formation
and neurodevelopment. Through involvement in cell membrane processes, EPHA1
is implicated in immune function, and synaptic plasticity (Lai and Ip, 2009; Martínez
et al., 2005; Sakamoto et al., 2011). RIN3 encodes a protein that functions as a
guanine nucleotide exchange for small GTPases, including Rab5. RIN3 stimulates
and stabilizes Rab5 on early endocytic/endosomal vesicles (Kajiho et al., 2003;
2011; Nixon, 2017). In addition, APOE and CLU are important regulators of
endocytosis, capable of binding a variety of endocytic lipoprotein receptors (Bu,
2009; Byun et al., 2014). A more detailed discussion of endocytic sAD risk genes
and endosomal-lysosomal dysfunction in AD is provided below.

Endosomal-lysosomal trafficking dysfunction in AD

The endocytic pathway is integral to the normal functioning of neurons.
Through endocytosis neurons respond to extracellular trophic factors; recycle
plasma membrane receptors and other integral membrane proteins in response to
neurotransmitters; and relay extracellular signals to intracellular biosynthetic
pathways (Cosker and Segal, 2014; Parton and Dotti, 1993). By endocytosis,
molecules from the cell surface (such as APP, neurotransmitter receptors, signaling
molecules, etc.) are trafficked through a series of intracellular compartments, where
they can be modified or degraded in a biologically meaningful way (Haass et al.,
2012; Hu et al., 2015; Nixon et al., 2000). Upon internalization by endocytosis, cell
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surface proteins are first sorted into early endosomes, where they can then be
recycled back to the plasma membrane or TGN, or transported to late-endosomes
and lysosomes for degradation (Figure 6) (Hu et al., 2015). Endocytosed molecules
can be recycled and sorted away from the degradative pathway in a few different
ways (Figure 8): Cargos can be recycled back to the PM in a fast and direct
manner; or in slow recycling, where cargos are first directed to recycling endosomes
before reaching the cell surface (Hu et al., 2015). Additionally, cargos in endocytic
compartments can be trafficked by the retromer complex, in a retrograde direction
from the endosome to the TGN, or directly for the endosome back to the cell surface
(Small and Petsko, 2015). Endosomal and lysosomal compartments are
characteristically acidic, necessary for the many degradative hydrolases and other
proteases important for protein homeostasis, which function optimally in these acidic
conditions (Hu et al., 2015). The careful coordination of trafficking of cargos and
vesicles through endosomal and lysosomal compartments is carefully controlled by a
family of GTPase proteins called Rab proteins (Figures 6 and 8) (Doherty and
McMahon, 2009; Stenmark, 2009).
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Figure 8. Endocytic trafficking into and out of the early endosome.
Cargos (such as cell surface proteins or extracellular proteins) are sorted into
the early endosome by endocytosis (mediated by Rab5). There are
subsequently three trafficking pathways out of the early endosome. (1)
Cargos may be trafficked towards the degradation pathway. This results in
the formation of intraluminal vesicles and degradation in the late endosome
and lysosome. (2) Cargos may be trafficked back to the cell surface. This
can occur rapidly and directly (mediated by Rab4) or through the recycling
endosome (mediated by Rab11). (3) In the retrograde pathway, cargos are
trafficked back to the TGN in a process coordinated by the retromer complex.
Given its role as a “central hub” in endocytic sorting, pathological changes in
early endosome function/morphology can have broad and dramatic effects on
overall intracellular trafficking and the endosomal-lysosomal system. Adapted
from (Small et al., 2017).
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As described above, APP is a type 1 transmembrane protein that is
endocytosed and trafficked through the endosomal-lysosomal system. Moreover,
amyloidogenic versus non-amyloidogenic processing of APP occurs in a tightly
regulated fashion almost entirely dependent upon its intracellular trafficking.
Specifically, early endosomes are of particular relevance to AD, as it is thought that
it is in these structures where APP meets b- and g-secretases to generate Ab (Haass
et al., 2012). Therefore, any perturbation in the endocytic pathway that alters the
trafficking of APP and influences the time APP spends in endosomal compartments
may have consequential effects on the development of AD pathology.
Early endosomal dysfunction is one of the earliest neuronal pathologies of AD
observed in sAD patients prior to deposition of extracellular Ab (Cataldo et al., 2000;
Ginsberg et al., 2010a; 2010b). These endosomal changes suggest that neurons
may become intracellularly compromised much earlier than when overt Ab plaque or
tau tangle pathology accumulates. Early endosomes are a central hub in
intracellular membrane and protein trafficking. Imbalances in trafficking into- and out
of this organelle may therefore have severe consequences on the overall health of a
neuron (Small et al., 2017) (Figure 8). While it remains elusive what exactly causes
upstream early endosome dysfunction in AD pathogenesis, multiple studies which
have focused on using non-human overexpression models have indicated that
intracellular accumulations of APP fragments, either b-CTF or longer Abs (e.g.,
Ab42) may be the drivers (Jiang et al., 2010; Treusch et al., 2011; Xu et al., 2016).
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As will be discussed in later chapters, this hypothesis remains to be adequately
tested in human neurons, particularly in the absence of transgenic overexpression.
As described in detail above, genetic association studies have revealed
variants in multiple different endocytic/endosomal trafficking-related genes (e.g.,
SORL1, BIN1, CD2AP, PICALM, RIN3, etc.) as strongly linked to late-onset sAD
(Karch and Goate, 2015). These genetic findings implicate, at least in some cases
of AD, endocytic dysfunction as an initial primary upstream pathological event. For
example, SORL1 mutations or SORL1 knock-down/knockout reduces transport of
cargos (including APP) out of endosomes via retromer-mediated routes (Andersen
et al., 2005; Gustafsen et al., 2013; Reitz et al., 2011; Small and Petsko, 2015).
This leads to dysregulated sorting of endosomal proteins, including APP,
accelerated Ab generation and endosome enlargement (Andersen et al., 2005;
Gustafsen et al., 2013; Reitz et al., 2011; Small and Petsko, 2015). Similarly, BIN1
and CD2AP also functions to traffic cargos out of early endosome (Ubelmann et al.,
2017). BIN1 is important in shuttling cargos out of endosomes towards the cell
surface via the recycling pathway, while CD2AP is important in mediating sorting out
of early endosomes and towards the degradative pathway (Ubelmann et al., 2017).
Deficiencies in retromer core proteins (VPS26, VPS35) as well as variants in other
key retromer genes have been linked with AD (Small and Petsko, 2015). These ADrelated changes in retromer biology are thought to reduce the overall function of
retromer, leading to impaired sorting of cargos out of endosomes and
dysfunction/enlargement of early endosomes. Mutations in PICALM, which is an
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important regulator of trafficking into the endosome, suggest that endocytic influx,
and not just efflux, is also inherently linked to AD (Thomas et al., 2016).
Furthermore, genetic associations with RIN3 directly implicate activity of Rab
proteins, such as Rab5, as being associated with AD pathogenesis (Kajiho et al.,
2003; 2011; Xu et al., 2018).
As mentioned above, neuronal APOE receptors are key regulators of
endocytosis, thereby implicating APOE in endosomal dysfunction. In studies
investigating the pathogenicity of the APOE4 allele, it was found that APOE4 can
result in endosomal enlargement by accelerating endocytosis and impair normal
endosomal recycling (Chen et al., 2010; He et al., 2007; Li et al., 2012; McColl et al.,
2003; Nuriel et al., 2017b; Ye et al., 2005; Zhao et al., 2017). APOE is one of many
different lipid/cholesterol-associated genes linked with AD. Interestingly, it is known
that altering overall levels or trafficking of cholesterol in neurons also leads to
alterations in endocytosis and endosomal enlargement (Jin et al., 2004; Marquer et
al., 2014).
Taken together, all of these lines of evidence provide a compelling case for
endosomal dysfunction being a principle upstream pathological event. Enlarged
endosomes, caused by increased endocytosis or reduced recycling may also result
in more APP residing in early endosomes, leading to greater amyloidogenic
processing and Ab generation (Haass et al., 2012; Jiang et al., 2010; Small et al.,
2017). Whether or not endosomal dysfunction in sAD is a pathogenic mechanism
converging on Ab production or is instead itself a principle driver of disease remains
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unclear. Furthermore, whether or not the early endosome abnormalities hallmark in
late-onset AD are also common to fAD caused by APP and PSEN mutations is in
great need of further investigation.

AD models

Much of the knowledge we have today about AD pathogenesis and
underlying AD mechanisms has critically depended on the development of adequate
and representative experimental model systems. The breakthrough discoveries of
familial mutations capable of causing early-onset AD (and FTD) has enabled the
development of numerous in vivo and in vitro experimental model systems, with the
hope that discoveries made in these systems would translate to more common sAD
as well. The most widely used models in the AD field have been transgenic mouse
models. These models have been instrumental in the discovery of many important
disease mechanisms, however, as will be described below, they also are undeniably
problematic. The first ever APP transgenic mouse model was published in 1991
(Quon et al., 1991), however it was not until 1995 that the first models actually
demonstrating AD-associated amyloid pathology were published. Specifically, these
mice were called the PDAPP and Tg2576 mouse and were designed to
transgenically overexpress human APP with either the Indiana (V717F) or Swedish
(KM670/671NL) fAD mutations, respectively (Games et al., 1995; Hsiao et al., 1996;
Rockenstein et al., 1995). While in both of these models amyloid plaques similar to
those in human AD patients are found in mouse brains by approximately 10-11
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months of age, neither of these mice develop NFTs (or any robust tau pathology) nor
have measurable neurodegeneration and neuronal loss. This, of course, contrasts
greatly with human patients, who have only a single heterozygous fAD APP
mutation, yet develop a brain full of amyloid plaques, NFTs and have profound
neuronal loss. Similar problems were also seen in early PSEN1 transgenic models.
Namely, overexpression of mutant PSEN1 (such as M146V) results in a predictable
increase in longer Ab 42 peptides in the brain, however these mice don’t display any
plaque pathology, NFTs, neurodegeneration, or cognitive deficits even at up to 2.5
years of age (Duff et al., 1996; Qian et al., 1998). Furthermore, even transgenic
mice overexpressing both mutant human APP and PSEN1 fail to demonstrate any
NFT pathology or robust neurodegeneration, despite the accelerated accumulation
of Ab plaques in the brain (Borchelt et al., 1997; Holcomb et al., 1998). The failure
of these mouse models to recapitulate the seminal pathological features of human
AD highlights how the use of mouse models in AD research may be confounding,
and points to the many key differences between rodents and humans.
Years later, the first AD mouse model was developed that demonstrates both
Ab as well as NFT pathology. Specifically, it took the expression of three different
mutant transgenes (APPswe, PSEN1-M146V and MAPT-P301L) to result in both
hallmark clinical AD pathologies, with corresponding synaptic and cognitive
changes. This mouse is commonly known in the field as the triple-transgenic (or
3xTg) mouse (Oddo et al., 2003). The mere notion that it took additional
overexpression of human tau (MAPT) with an FTD-causing familial mutation, further

37

highlights the differences between human and mouse tau biology, and raises
questions as to the degree to which conclusions made from these mice are broadly
relevant to human AD. More recently, the first non-overexpression AD mouse
models have been generated and used to study disease mechanisms. Briefly,
researchers replaced the mouse APP gene with human APP bearing up to 3
different fAD mutations (APPswe, APP-I716F, APP-E693G), which is expressed at
normal physiological levels controlled by the endogenous mouse APP promoter
(Saito et al., 2014). These mice develop aggressive amyloidosis and demonstrate
plaque pathology starting at 2 months. These mice also show microgliosis and
increased numbers of reactive astrocytes, synaptic loss and cognitive impairment.
However, likely due to the absence of mutant tau overexpression, APP knock-in
mice fail demonstrate any NFT pathology, once again underscoring the limitations of
even the “best” mouse models (Saito et al., 2014). Most interestingly, the scientists
behind this novel APP knock-in mouse reported that many of the phenotypes
reported in APP overexpression models could not be reproduced in their system.
This led the authors to conclude that up to 60 percent of the phenotypes identified in
APP-overexpressing mice could in fact be artifacts of overexpression, therefore
potentially calling into question the findings of thousands of past research papers
(Saito et al., 2014).
In vitro cell culture models have also been abundantly used in the AD field. In
particular, these models have been instrumental in the understanding of the
mechanism of Ab production, APP trafficking, and endosomal-related changes in
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AD. Many in vitro studies utilize primary cultures of mouse disease-vulnerable
neurons, often comparing wildtype and transgenic mice overexpressing mutant
human APP and or PSEN1 (Saraceno et al., 2013; Trinchese et al., 2004). This
approach has been instrumental in deciphering how APP is processed and trafficked
in neurons, however, as described above, is confounded by overexpression of
mutant protein in non-human cells. Mouse primary neurons are somewhat difficult to
maintain in culture, and therefore have in many cases been supplanted by the use of
proliferating non-neuronal (and in many cases non-human) cell lines. For example,
human embryonic kidney cells (HEK) and mouse neuroblastoma (N2A) cells have
been engineered to stably overexpress wildtype and mutant APP and/or PSEN1
(Borchelt et al., 1996; Jiang et al., 2010; Kim et al., 2015; Tarassishin et al., 2004;
Xu et al., 1997). These models have revealed interesting insights into the potential
pathogenicity of fAD mutations and have been widely used to investigate APP
trafficking in wildtype and mutant conditions (Choy et al., 2012; Sannerud et al.,
2016; Sullivan et al., 2011). Furthermore, overexpression of full-length APP and
APP cleavage products have provided insight into the pathways contributing to
endosomal dysfunction in AD (Jiang et al., 2010; Kim et al., 2015; Xu et al., 2016).
In vitro non-neuronal cell culture models are often chosen for use as they are
self-renewing and can be easily genetically manipulated. Although these systems
are scalable and easy to use, they also have considerable drawbacks. As with most
mouse models, in vitro cell culture models heavily rely on transgenic overexpression
of fAD mutant APP and/or PSEN1, which is a dramatic departure from patients who
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contain only a single heterozygous fAD mutation. Moreover, studying AD
phenotypes in non-neuronal cells calls into question whether findings are also
applicable to neurons, which are post-mitotic, highly compartmentalized and polar.
Importantly, in terms of studying intracellular trafficking, overexpression models are
especially concerning, as the normal trafficking and processing of proteins (including
APP which is intricately processed) is likely aberrantly affected by being present in
cells at a saturating level.
The abovementioned drawbacks of common in vivo and in vitro models
highlight the imminent need for the generation of new model systems that are more
physiologically comparable to the AD patient condition. Specifically, being able to
study AD processes in human neurons in the absence of overexpression will not
only help to decipher which previously identified phenotypes may be relevant to
human neurons but will undoubtedly enable the discovery of novel disease
mechanisms or serve as a valuable platform for testing novel therapies. Fortunately,
with the recent development of iPSC and CRISPR/Cas9 technology, generating
models that enable the study of genetically tractable human AD-vulnerable neurons
is now feasible.

Induced pluripotent stem cell (iPSC) technology

Yamanaka and colleagues first demonstrated that mouse fibroblasts could be
reprogrammed into pluripotent embryonic-like cells. They showed that expression of
only 4 transcription factors (Oct4, Sox2, Klf4 and c-Myc) was sufficient to induce
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reprogramming in both mouse and human somatic cells into iPSCs (Park et al.,
2008; Takahashi and Yamanaka, 2006). Since this initial discovery, many different
protocols have been developed to generate iPSCs from a wide variety of donor cell
types (fibroblasts, glia, B lymphocytes, amniotic fluid-derived cells, cells in blood and
urine) and using a diversity of strategies (viral delivery of reprogramming factors,
liposome or electroporation-mediated transfection of linear DNA, direct protein
deliver, etc.) (Singh et al., 2015). iPSCs are like embryonic stem cells (ESCs) in that
they are self-renewing and are capable of differentiating all three germ layers
(mesoderm, ectoderm and endoderm). As a result, iPSCs are capable of generating
virtually any cell type, including many different types of neurons similar to those
found in the human brain. The potential of this technology to propel biomedical
science forward led Dr. Yamanaka to receive the 2012 Nobel Prize in Medicine.
iPSC technology provides great promise for modeling and studying
monogenic diseases, such as fAD caused by APP or PSEN1 mutations. Since the
development of iPSC technology, dozens of papers have been published describing
the use of iPSCs to study neurodegenerative diseases (Bahmad et al., 2017; Xie
and Zhang, 2015; Yang et al., 2016). Of these studies, several groups have utilized
iPSCs for modeling AD. Most studies proceeded in the following manner: Dermal
fibroblasts are isolated from skin biopsies of AD patients (with a known fAD mutation
or with sAD). At the same time, fibroblasts are also obtained from an unaffected
individual to serve as a control. These somatic cells are then reprogrammed into
iPSCs, which can be differentiated into AD-vulnerable cells such as cortical neurons
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following a variety of established protocols. Using this approach, past studies have
demonstrated that APP and PSEN1 fAD and even sAD patient-derived iPSCs
display disease-relevant phenotypes associated with APP processing, Ab generation
and tau pathology, and have even revealed potential new mechanisms underlying
AD pathogenesis (Duan et al., 2014; Israel et al., 2012; Kondo et al., 2013; Moore et
al., 2015; Muratore et al., 2014; Ortiz-Virumbrales et al., 2017; Shi et al., 2012;
Sproul et al., 2014).
Patient-derived iPSCs have demonstrated the potential applications of this
technology for modelling AD but many of these past studies are complicated by
several outstanding technical issues. One of the greatest and most poorly
understood problems with human iPSCs is the donor-to-donor variability and cellular
heterogeneity. For example, in past studies using patient-derived iPSCs, it was
found that some iPSC lines with an fAD mutation successfully demonstrated ADassociated phenotypes while other iPSC lines (even with the same fAD mutation)
failed to do so (Israel et al., 2012; Kondo et al., 2013). This issue of clonal iPSC-line
heterogeneity is concerning, as it raises the question of what the most appropriate
control should be. If phenotypic variability is common between different patientderived iPSC lines, then surely, variability exists across non-diseased “control” iPSC
lines too. This unexplained variation may come from the differences in genetic
background between the diseased and healthy donors’ cells. Therefore, one
confounding factor in using patient-derived iPSCs and comparing them to control
iPSCs is that it is generally unclear whether phenotypic differences seen are due to
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a particular disease-associated mutation of interest or differences in genetic
background between control and patient samples. This is of particular importance
when comparing subtle phenotypes, which may be expected in iPSC-derived
neurons with only a single heterozygous mutation and no transgenic overexpression.
Furthermore, iPSC-derived neurons are typically analyzed only approximately 30-60
days after induction of differentiation, whereas patients with fAD mutations typically
develop AD after approximately 40 years. Therefore, an additional concern is that a
single heterozygous mutation may not be sufficient to allow for subtle phenotypes to
be resolved.
Taken together, the drawbacks described above highlight the need to
generate isogenic iPSC control and mutant cell lines differing only at the site of the
mutation of interest. Additionally, tools to be able to study mutations in both a
heterozygous and homozygous context would be very helpful to amplify subtle
disease-relevant phenotypes while maintaining physiological levels of mutant protein
expression. Fortunately, the recent developments in genome editing technology
now means generating isogenic wildtype, homo- and heterozygous fAD mutant
iPSCs is a possibility.

CRISPR/Cas9 gene editing

For over a decade there has been a considerable effort made in developing
gene editing technology for use in human cells, such as iPSCs. These initially
included zinc finger nucleases (ZFNs) as well as transcription activator-like effector
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nucleases (TALENs), but more recently CRISPR/Cas9 has supplanted both of these
early technologies. While the potential utility of CRISPR/Cas9 gene editing
technology in biomedicine is vast, one of the most promising uses of the technology
is for engineering next-generation iPSC model systems that overcome confounding
issues associated with patient-derived stem cell models.
The bacterial CRISPR/Cas9 (clustered regularly interspaced short
palindromic repeats /CRISPR-associated protein 9) system is a versatile tool for
precise, sequence-specific gene editing in many organisms and model systems
(Cho et al., 2013; Cong et al., 2013; Hruscha et al., 2013; Hsu et al., 2014; Jinek et
al., 2013; Mali et al., 2013), including iPSCs (Hsu et al., 2014; Mali et al., 2013). The
CRISPR/Cas9 gene editing system, derived from the bacterial adaptive immune
system in Streptococcus pyogenes (Horvath and Barrangou, 2010), consists of the
nuclease Cas9 and a guide RNA, which directs Cas9 to the DNA target through a 20
bp programmable sequence. The guide RNA targets Cas9 to a specific genomic
locus by RNA-DNA base pairing adjacent to an NGG protospacer adjacent motif
(PAM) on the DNA (Figure 9A). Both the presence of the PAM and guide RNA
binding are required for Cas9 to introduce a site-specific double-strand break (DSB),
which occurs 3 bp upstream of the PAM motif (Jiang et al., 2015; Marraffini and
Sontheimer, 2010). The CRISPR/Cas9 complex has been shown to be very efficient
at introducing DSBs in the DNA of many cell types and model systems, commonly
resulting in bi-allelic modifications (Canver et al., 2014; Dow et al., 2015; Platt et al.,
2014). In most cases these DSBs are repaired by the non-homologous end-joining
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(NHEJ) pathway, leading to nonspecific insertions, deletions or other mutations,
commonly referred to as ‘indels’ (Hsu et al., 2014; Jinek et al., 2013). This is
convenient for generating gene knockouts, which are most easily created by nonspecific modification of both alleles by NHEJ (Figure 9B).

Figure 9. CRISPR/Cas9 gene editing.
A) CRISPR/Cas9 gene editing works by targeting to any genomic NGG
(PAM) sequence a guide RNA (commonly a single guide RNA called an
sgRNA) and Cas9 nuclease. This results in a double-stranded DNA break
(DSB). B) DSBs are most commonly repaired by the error prone nonhomologous end-joining pathway (NHEJ), which results in random base
insertions or deletions (called “indel” mutations). C) In rare cases, the cell
may utilize homology-directed repair (HDR), which makes use of a DNA
template provided (such as a single stranded DNA oligo, ssODN) with
homology to the sequence surrounding the DSB. If this repair template is
modified to contain a specific mutation of interest, that change will be
incorporated into the edited genome.
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In rare cases the cellular repair mechanism can utilize another DNA molecule,
such as the homologous allele or an exogenously introduced DNA template, to
repair the chromosome break by homology-directed repair (HDR)(Hsu et al., 2014).
Introducing a modified donor template, such as a single-stranded oligo DNA
nucleotide (ssODN), can yield intended base changes that can be utilized to knockin (KI) specific mutations (Cong et al., 2013; Horvath and Barrangou, 2010) (Figure
9C). For example, patient derived iPSCs containing a fAD APP or PSEN1 mutation
can be engineered using CRISPR/Cas9 to correct the pathogenic mutation back to
the wildtype allele to generate isogenic control cell lines. More promising, however,
is the use of CRISPR/Cas9 editing in a standardized wildtype iPSC line, to introduce
any disease-causing mutations desired and generate (heterozygous and
homozygous) isogenic mutant iPSCs without ever needing to access patient
material. Although CRISPR/Cas9 has already been extensively and efficiently used
to study gene function by engineering gene knockouts (KO) through NHEJ (Jiang et
al., 2015; Marraffini and Sontheimer, 2010; Wang et al., 2013), precise editing by
HDR to engineer sequence-specific changes such as disease-causing point
mutations is inefficient (Canver et al., 2014; Cong et al., 2013; Dow et al., 2015; Platt
et al., 2014; Wang et al., 2013). This limitation has unfortunately prevented the
widespread use of CRISPR/Cas9-mediated gene editing for use in disease
modeling. Furthermore, systematic, targeted introduction of base-changes by HDR
at only a single allele using CRISPR/Cas9 had not been reported, making it difficult
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to use this gene editing system for modeling the many important human diseases
(such as fAD) that are caused or influenced by heterozygous changes.

Overview of thesis work

In this introduction, I have described how decades of research have mostly
converged on altered APP metabolism, and more specifically Ab, as the key
pathological trigger in AD. This work has focused predominantly on studying causal
fAD mutations in APP and PSEN1, using transgenic overexpression of mutant
human protein in mouse models as an approach for deciphering how Ab may confer
pathogenicity. Despite the clear genetic link between APP, PSEN1 (or PSEN2) and
Ab, it is still uncertain how a variety of mutations in one of three different genes
causes a common disease. Furthermore, recent discoveries have called into
question whether or not Ab is the only disease-associated pathological protein
fragment important in the development of AD (Kim et al., 2015; Xu et al., 2016).
This apparent complexity is underscored by the recent failures of clinical trials
testing the efficacy of multiple novel anti-amyloid therapeutics (Egan et al., 2018;
Mullard, 2017). It is therefore now, more than ever, time to reassess the state of the
AD research field and consider what experimental and technical improvements can
be made to help better understand AD biology.
Early on in our attempt to study neurodegeneration, our group presumed that
to better understand the mechanisms underlying a uniquely human disease such as
AD, it would be valuable to perform experiments in human tissue. Naturally we
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turned to using human iPSCs, which, as described above, can be used to generate
human disease-vulnerable cortical neurons. We were particularly drawn to the
unresolved basic question in the field of how a large number of fAD mutations in
APP and PSEN genes can result in a common disease signature. Given the
promise of CRISPR/Cas9 editing, we thought that instead of depending on the highly
variable process of obtaining biopsies from rare fAD patients, reprogramming patient
fibroblasts into iPSCs and differentiating cells into neurons, it would be helpful
instead to generate a standardized wildtype iPSC line into which we could knock-in
any fAD mutation we wished to study. With this approach in mind, the main goal of
my thesis work was as follows: Use CRISPR/Cas9 gene editing and iPSC
technology to determine in human neurons common cellular mechanisms
underlying both APP and PSEN1 fAD mutations.
Initially, I began my first CRISPR/Cas9 gene editing experiments in January
2013, only days after the manuscripts detailing the first usage of the technology in
human cells were made publicly available. Quickly we realized that CRISPR/Cas9
technology was particularly underdeveloped, specifically for its use in engineering
specific sequence changes in stem cells. In Chapter II, I will begin by describing two
major prohibitive issues we noticed with using CRISPR/Cas9 in iPSCs. Specifically,
CRISPR/Cas9-mediated knock-in is incredibly inaccurate, and it is virtually
impossible to efficiently generate both heterozygous and homozygous mutant knockin cell lines using standard approaches. I will describe how we overcame these
issues by systematically interrogating patterns of HDR-mediated mutation
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incorporation using next generation sequencing (NGS) technology ultimately to
develop a universal framework for precise and efficient introduction of mutations with
CRISPR/Cas9. In Chapter III, I will expand on this established approach and
discuss a related CRISPR/Cas9-based strategy we developed called CORRECT,
which specifically enables scarless introduction of an intended sequence or
mutation.
Chapter IV will focus on describing how we actually implemented our novel
CRISPR/Cas9 gene editing platform to generate and study a large and
comprehensive panel of isogenic APP and PSEN1 fAD mutant iPSCs.

Probing

differentiated mutant iPSC-derived neurons revealed unexpected overlapping
common cellular and molecular AD-relevant phenotypes. Specifically, using “-omics”
technologies, we discovered that dysregulation of both AD- and endocytosisassociated genes is a pathogenic feature common to APP and PSEN1 mutant cells.
Endocytic dysfunction was confirmed in all mutant neurons analyzed and was shown
to be specifically correlated with endogenous accumulation of β-CTF, and not
changes in Ab levels. Furthermore, endosomal enlargement phenotypes could be
pharmacologically rescued by inhibition of β-secretase, but not by treatment with
novel g-secretase modulators. Together these data reinforce a developing consensus
in the AD field, namely, that β-CTF may be an important common product of APP
metabolism that significantly contributes to AD pathology. At the end of each chapter
describing experimental results I will discuss the significance and implications of the
work presented. I will discuss how our work fits in the broader scientific literature and
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describe some future research directions. Chapter V will contain a final outlook and
perspective of the work presented in this thesis, and Appendix I includes details of
important methods and materials relevant to Chapters II-IV.
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CHAPTER II: EFFICIENT INTRODUCTION OF SPECIFIC
HOMOZYGOUS AND HETEROZYGOUS MUTATIONS USING
CRISPR/Cas9

Background and rationale

CRISPR/Cas9 is a versatile system for gene editing, which, when applied to
iPSC technology, holds great potential for enabling the development of nextgeneration model systems of neurodegenerative diseases such as AD. Our goal
was to leverage these two technologies and to use CRISPR/Cas9 to introduce a
series of disease-causing fAD APP and PSEN1 mutations in wildtype human iPSCs.
Moreover, we aimed to generate both homozygous and heterozygous knock-in cell
lines, so that in differentiated AD-vulnerable cortical neurons, mutation-load
dependent phenotypes could be adequately determined and subtle phenotypes
could be more significantly exaggerated (in homozygous cells).
At the time of our initial experiments using CRISPR/Cas9, little was known
about how useful the technology would be for editing human stem cells. When we
started the project, the only published work on CRISPR/Cas9 editing was studies
demonstrating that the CRISPR/Cas9 complex is very efficient at introducing DSBs
in the DNA of many cell types (Canver et al., 2014; Dow et al., 2015; Platt et al.,
2014) and was convenient for generating gene knockouts, easily created by
generating shifts in the reading frame of the targeted gene leading to premature stop
codons on both alleles (Hsu et al., 2014; Jinek et al., 2013). This is because most
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commonly after a DSB occurs, the broken chromosome is repaired by the errorprone process of NHEJ, which does not allow introduction of specific sequence
changes but rather random base insertions or deletions, also known as “indel”
mutations (Hsu et al., 2014; Jinek et al., 2013). Generating a specific sequence
change, like the introduction of a single APP or PSEN1 fAD mutation, requires the
cell to utilize a much rarer DNA repair mechanism called HDR (Hsu et al., 2014).
Accomplishing this most commonly involves simultaneously introducing a modified
DNA repair template, such as a single stranded oligonucleotide (ssODN), containing
both homologous sequence to the genomic region around the DSB and the intended
sequence changes, which can be incorporated into the edited genome (Figure 9).
Unfortunately, we quickly realized CRISPR/Cas9-mediated mutation knock-in
by HDR was incredibly difficult, and overcoming this problem needed to be the first
major focus of our experimental efforts. Furthermore, we expected these same
issues were being faced by multiple groups around the world trying to implement
CRISPR/Cas9 in their favorite model system. Therefore, improving CRISPR/Cas9
technology and developing a new approach for efficient and precise knock-in would
be a widely valued effort. The following results are adapted from our recent
publications (Kwart & Paquet et al., 2017; Paquet & Kwart et al., 2016).
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CRISPR/Cas-blocking mutations increase HDR accuracy by preventing reediting

Knocking-in pathogenic mutations requires that only the amino acid change
caused by these mutations occurs at a targeted locus, while the neighboring amino
acids stay unaltered. While attempting to introduce either the APPswe or PSEN1M146V fAD mutations into iPSCs using CRISPR/Cas9, we detected HDR by
presence of an intended mutation provided via the cognate ssODNs, however most
HDR events also contained unwanted indels (Figure 10). This was a problematic
result as such indels would lead to unwanted amino acid changes.

Figure 10. HDR is usually corrupted by unwanted indels.
APP sequencing alignment showing concomitant HDR (blue arrow) and
indels (orange arrow) after editing.

The additional unwanted indels we noticed in HDR sequencing reads
presumably resulted from the known high nuclease activity of CRISPR/Cas9 (Cong
et al., 2013; Dow et al., 2015; Wang et al., 2013), which may continuously re-cut
edited loci until sufficient modification by NHEJ prevents further targeting. If so, we
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reasoned that this re-editing may be blocked by simultaneously introducing
mutations into the NGG PAM sequence or guide RNA binding sequence, which
CRISPR/Cas9 requires for targeting (Hsu et al., 2014), as shown in prokaryotes
(Jiang et al., 2013). The efficacy of potential blocking mutations had not yet been
systematically studied in eukaryotic cells, therefore we tested their effect on HDR
accuracy in our established wildtype human iPSCs (see Appendix I for info on iPSC
generation) and, for comparison, HEK293T cells. We introduced Cas9-eGFP and a
single-guide RNA (sgRNA) plasmid together with five pooled repair ssODN
templates, which in addition to the APPswe or PSEN1-M146V pathogenic mutation
also contained a putative silent CRISPR/Cas-blocking mutation (Figure 11A-B).
Although we expect mutations in either of the guanines of the PAM to be most
effective in blocking CRISPR/Cas9 activity because the PAM (NGG) sequence is
required for Cas9 binding to DNA (O'Connell et al., 2014; O'Geen et al., 2015; Wu et
al., 2014), insertion of silent mutations is not always possible at that site due to
individual reading frames and codon usages of different edited loci. Therefore, we
tested CRISPR/Cas-blocking mutations at various positions upstream in the 20 bp
guide RNA targeting sequence that are believed to disturb guide RNA hybridization
to target DNA (Hsu et al., 2013; Pattanayak et al., 2013) and thus reduce
CRISPR/Cas9 activity. As a control, we added an ssODN containing a silent
mutation outside of the guide RNA targeting sequence, which allowed identification
of its incorporation by deep sequencing, but should not block CRISPR/Cas-targeting
(Figure 11B).
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A

B

Figure 11. Schematic of experimental setup for CRISPR/Cas-blocking
mutation analysis.
A) Experimental setup for gene editing analysis by NGS. Cas9 and sgRNA
expressing plasmids were transfected along with ssODNs. GFP+ cells were
sorted out by FACS and CRISPR/Cas9 editing was analyzed by NGS. B)
Schematic of pooled ssODNs used to test effects of CRISPR/Cas-blocking
mutations.

We analyzed genomic loci of Cas9-eGFP-expressing cells by Next
Generation Sequencing (NGS) (See Appendix I for details of sequencing analysis)
and determined the fraction of HDR reads (reads where there was incorporation of
the pathogenic mutation on the ssODN template). Overall HDR rates for these
experiments were approximately 2-3% (data not shown). Next, we filtered to
determine the number of HDR reads that were “accurate”, i.e., without undesirable
indel modifications. We found that a large majority of genomes that incorporated the
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pathogenic and control mutation had further indel modifications at both loci, resulting
in low levels of accurate HDR (only 6 to 35%; see Figure 12A-B). In contrast, the
presence of a CRISPR/Cas-blocking mutation in the PAM dramatically increased
accurate HDR rates in iPSCs and HEK293 cells at both loci (Figure 12A-B). The
remaining “inaccurate” HDR reads all contained indel mutations, which were likely
generated by NHEJ events prior to or during homology-directed repair that did not
block further editing. Silent mutations in the sgRNA targeting site increased accurate
HDR in both iPSCs and HEK293 cells at the APP locus, illustrating that for this
locus, optimal guide RNA binding is crucial for CRISPR/Cas9 activity (Figure 12A).
At the PSEN1 locus accurate HDR was only modestly increased by some of the
guide RNA targeting site mutations (Figure 12B). This indicates that the activity of
the PSEN1-targeting sgRNA is less affected by mutations at the guide RNA binding
sequence. Results did not differ when ssODN templates from the abovementioned
pool were transfected separately into HEK293 cells (Figure 13).
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Figure 12. CRISPR/Cas-blocking mutations increase HDR accuracy.
A-B) Percentages of accurate HDR (HDR only events, i.e., without
concomitant indels) for blocking or control mutations at APP (A) and PSEN1
(B) loci in pooled transfected iPSCs and HEK293 cells. Values represent
mean ± SEM (n=3). ***P < 0.001, **P < 0.01, *P < 0.05, 1-way ANOVA.
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Figure 13. Analysis of CRISPR/Cas-blocking mutations using un-pooled
ssODNs
Accurate HDR editing rates (HDR only events, i.e., without concomitant
indels) from 5 unpooled templates containing intended pathogenic and
CRISPR/Cas-blocking or non-blocking control mutations. Percentages of
accurate HDR for reads containing B or C mutations at the APP (A) and
PSEN1 (B) locus in HEK293 cells. Values represent mean ± SEM (n=3). ND
= not detected; n.s. = not significant. ***P < 0.001, **P < 0.01, 1-way ANOVA.

Single CRISPR/Cas-blocking had much reduced efficacy in the sgRNA target
sequence at the PSEN1 locus compared to APP, suggesting the PSEN1 sgRNA can
overcome minimal sequence mismatches. We therefore tested the efficacy of using
multiple blocking mutations positioned in the guide RNA target seed sequence and
found an improvement of editing accuracy that was comparable to that of PAM58

blocking mutations (Figure 14A). This result corroborates previous studies, which
found that multiple consecutive mismatches within the guide RNA seed sequence
largely prevent targeting by the CRISPR/Cas9 complex (Hsu et al., 2013; Kuscu et
al., 2014; Pattanayak et al., 2013). Unfortunately, it may be impossible to use
multiple consecutive sgRNA-blocking mutations that are silent. Therefore, we tested
the efficacy of using multiple silent blocking mutations in the guide-RNA target
sequence. We also found that improvements in editing accuracy comparable to that
of PAM-blocking mutations were seen when multiple silent blocking mutations in the
sgRNA sequence were incorporated (Figure 14B). Additionally, we confirmed that
the frequency, position, and size of all indels detected in these abovementioned
experiments followed the distribution expected from previous studies (Mali et al.,
2013; Yang et al., 2013) (Figure 15).
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Figure 14. Multiple CRISPR/Cas-blocking mutations in the sgRNA target
sequence increase editing accuracy.
Accurate HDR editing rates (HDR only events, i.e., without concomitant
indels) in a pool of transfected iPSCs determined for the PSEN1-M146V
locus. A) Introducing several blocking mutations within the first 6 bases of the
guide RNA target sequence blocks re-editing as efficiently as PAM-altering
CRISPR/Cas-blocking mutations. B) Accurate HDR editing rates using an
ssODN with three interspersed silent guide RNA-altering CRISPR/Casblocking mutations as a repair template in a pool of transfected iPSCs. HDR
events with only partial incorporation of blocking mutations result in reduced
overall HDR-mediated editing accuracy (see top read, only ‘A’ incorporated).
For (A) and (B) values represent mean ± SEM (n = 3). ***P < 0.001, one-way
ANOVA.
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Figure 15. Analysis of CRISPR/Cas9-induced indels in gene edited
iPSCs and HEK293T cells.
Plots depicting frequency of indels at each position around the targeted locus
in all NGS reads with editing events from the analysis shown in Figure 12.
Insertions are plotted at the location where they begin, and deletions are
plotted across all deleted base positions (top). Histogram illustrating
distribution of indel sizes (bottom).

Surprisingly, when studying the HDR events at APP and PSEN1 loci in detail,
we noticed that between 6% and 11% of the HDR reads contained more than one
CRISPR/Cas-blocking or non-blocking control mutation (Figure 16). Since each
ssODN repair template provides only one control or CRISPR/Cas-blocking mutation,
the cells must have used multiple distinct ssODNs from the pool for repair,
presumably in multiple rounds of HDR that occurred after repeated Cas9 editing.
These data indicate that at a given locus at least 3 rounds of cut-and-repair events
can occur before a genomic edit is final. This hypothesis is further supported by the
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fact that at both loci these “double HDR” events more often contain a non-blocking
control mutation than a CRISPR/Cas-blocking mutation (Figure 16).

Figure 16. CRISPR/Cas-blocking mutations are incorporated in multiple
rounds of re-editing.
A-B) Proportion of NGS reads containing putative single, double, or triple
HDR events (left) for APP (A) and PSEN1 (B). Putative “double HDR”
examples of the most frequent reads that either contain a non-blocking
control mutation C with an additional CRISPR/Cas-blocking mutation B, or do
not contain C and have two different CRISPR/Cas-blocking mutations
(middle). Reads that contain the non-blocking mutation (C+) are more
frequently re-edited to incorporate a CRISPR/Cas-blocking mutation (“double
HDR”) than reads containing a blocking mutation B instead of the nonblocking mutation C (C-). To facilitate data analysis, all replicates were
pooled to increase read numbers for rare events.
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Taken together, our results provide direct evidence that CRISPR/Cas9 will
continuously re-edit a genomic locus, even after HDR occurs, until sufficient
modification prevents further activity. This prevalent and deleterious process can be
blocked by introducing a modified repair template with CRISPR/Cas-blocking
mutations, preferably in the PAM. This simple modification can increase the number
of accurately edited alleles up to tenfold (6% for non-blocking vs. 60% for blocking
mutations at the PSEN1 locus, see Figure 12), which in diploid cells has the
potential to increase the probability of editing both alleles accurately by 100-fold (6%
x 6% = 0.36% vs. 60% x 60% = 36%, assuming independent editing of both alleles).
Therefore, CRISPR/Cas-blocking mutations can dramatically influence the feasibility
of a desired genome editing experiment.

CRISPR/Cas9 editing results mostly in bi-allelic changes

We tested our approach of simultaneous introduction of either the APPswe or
PSEN1-M146V mutations together with CRISPR/Cas-blocking mutations by
generating single-cell-derived clones of iPSCs. While we could readily isolate a
number of clones with bi-allelic HDR-mediated incorporation of both pathogenic and
CRISPR/Cas-blocking mutations without additional indels (data not shown), almost
all clones that had seemingly undergone only mono-allelic mutation incorporation
(HDR at only one allele as assessed using an RFLP assay; see methods Appendix
I for details) contained unwanted indels at the “non-HDR” allele (Figure 17).
Therefore, heterozygous lines could not be readily isolated by mono-allelic HDR
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alone. Previous studies have identified a similar tendency for CRISPR/Cas9 editing
to mostly result in bi-allelic indel modifications (Dow et al., 2015; Wang et al., 2013).
This tendency, in addition to the established known high activity of the
CRISPR/Cas9 complex (Cong et al., 2013; Dow et al., 2015; Wang et al., 2013),
makes it plausible that potential targets in a cell are all edited at a similar rate in the
presence of Cas9 and sgRNA, thereby dramatically reducing the probability of
isolating cells in which only one allele is edited by HDR while the other allele is
unmodified. This observation raised the question of how, if not by mono-allelic HDR,
to isolate clones heterozygous at the intended site without indels at the other allele.
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Figure 17. Mono-allelic HDR clones contain indels on the other nonHDR allele.
A) Sanger sequencing reads of both APP alleles of a single-cell clone with
mono-allelic HDR (blue arrow), determined using the PolyPeak Parser tool
(see Appendix I). The non-HDR allele is altered by NHEJ in the sgRNA
target sequence (orange arrow). B) Single-cell clones with HDR on one allele
are mostly altered by NHEJ on the non-HDR allele (APP n=26, PSEN1 n=34).
C) Indel position and size in mono-allelic HDR single-cell-derived iPSC
clones.
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A monotonic inverse relationship between the rate of mutation incorporation
and distance from the CRISPR/Cas9 cleavage site

While studying deep sequencing data from genomes edited using ssODNs
bearing both pathogenic and PAM-altering CRISPR/Cas-blocking silent mutations,
we observed that sequencing reads that had incorporated a silent CRISPR/Casblocking mutation by HDR did not always contain the pathogenic mutation (Figure
18). These reads were most abundant when the pathogenic mutation and
CRISPR/Cas9 cleavage site were not in close proximity. This observation is
consistent with earlier reports of a distance effect influencing mutation incorporation
by HDR using other gene editing systems (Beumer et al., 2013; Elliott et al., 1998;
Rivera-Torres et al., 2014; Taghian and Nickoloff, 1997; Yang et al., 2013). More
recent studies in mouse and human cancer cells (Bialk et al., 2015; Inui et al., 2014)
suggested a similar effect for CRISPR/Cas9 editing, however, the molecular basis of
this distance phenomenon, and how it depends on guide RNA sequence, repair
template composition, base position or genomic context remains to be elucidated.
We reasoned that if a predictable relationship between distance and mutation
incorporation exists at multiple loci, it could be exploited to selectively control
mutation incorporation at each allele based on probability alone. In other words, if
the two HDR events depicted by NGS reads in Figure 18 represented the two
alleles of a single cell, heterozygous editing of a pathogenic mutation will be
achieved.
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Figure 18. Pathogenic mutation is not always incorporated by
CRISPR/Cas9-mediate HDR.
PSEN1 sequencing alignment showing HDR-mediated introduction of a
CRISPR/Cas-blocking mutation (red arrow) with or without the pathogenic
mutation (blue arrow).

To systematically characterize this distance effect, we performed an
unbiased scan of oligo mutation incorporation rates at both the APP and PSEN1
locus, using one sgRNA per locus combined with a pool of 20 different ssODNs.
Each ssODN contained a unique CRISPR/Cas-blocking 3 bp barcode sequence (in
this experiment we did not restrict ourselves to silent mutations) as well as a single
intended point mutation at increasing distances from the CRISPR/Cas9 cleavage
site (Figure 19A, oligo sequences can be found in Appendix I). Cas9, sgRNA and
ssODN pools were transfected into iPSCs and HEK293T cells. Gene editing
outcomes at APP and PSEN1 loci was assessed by NGS, using the CRISPR/Casblocking barcode sequence to identify reads with HDR-mediated incorporation of
each ssODN. Strikingly, we found a clear monotonic inverse relationship between
the rate of mutation incorporation and distance from the CRISPR/Cas9 cleavage site
that did not differ significantly for APP and PSEN1 in either iPSCs or HEK293 cells
67

(Figure 19B-C). Moreover, when comparing 100bp ssODNs to longer ssDNA or
dsDNA HDR repair templates the distance relationship was similar (Figure 20),
suggesting that such a phenomenon is not influenced by the repair templates
themselves but instead arises from an intrinsic property of the CRISPR/Cas9mediated DSB.

Figure 19. A monotonic inverse relationship between mutation
incorporation and distance from the CRISPR/Cas9 cleavage site.
A) Pooled ssODNs used to scan mutation incorporation rates based on cutto-mutation-distance. Barcode mutations (red) identify HDR-reads and
mutation M position during NGS analysis. B-C), A monotonic relationship
underlies the rate of mutation M incorporation and cut-to-mutation distance
during HDR in both iPSCs (B) and HEK293 cells (C) (n=4 for iPSCs, n=3 for
HEK293); goodness of fit: R2(APP) = 0.75(iPSC) / 0.96(HEK293), R2(PSEN1)
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= 0.94(iPSC) / 0.97(HEK293); curves for APP and PSEN1 are not significantly
different, two-tailed t-test: p=0.31(iPS) / 0.06(293).

Figure 20. Longer ssDNA or dsDNA HDR templates do not influence
mutation incorporation probabilities related to cut-to-mutation distance.
A) Schematic describing the generation of large ssDNA and dsDNA HDR
repair templates for the PSEN1 locus (see Appendix I for more details). B)
The monotonic relationship between incorporation of intended mutations (M)
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by HDR and cut-to-mutation distance is not altered by providing longer
ssDNA and dsDNA templates (n=2). Red hashed trendline shows previously
determined 100-nt oligo scan result (from Figure 19B) for comparison.

To address whether loci, guide RNA activity or ssODNs sequence differences
also influence this relationship we utilized three sgRNA/ssODN pairs (see oligo
sequences in Appendix I) to target a DSB at short, intermediate and long distances
from the APPswe or PSEN1-M146V pathogenic mutation sites in iPSCs (Figure 21).
Each ssODN repair template contained a silent CRISPR/Cas-blocking mutation in
addition to the intended pathogenic mutation, and the presence of both mutations
was analyzed by NGS.
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Figure 21. Analysis of the "distance effect" using 3 independent
sgRNA-ssODN pairs in iPSCs.
A) Experimental setup using three sgRNA/ssODN pairs per locus with
increasing cut-to-mutation distance. Edited iPSCs were analyzed by NGS (or
grown for clonal analysis in Figure 22). B-C) Incorporation rate of APP and
PSEN1 pathogenic mutations at increasing distance from the cut site targeted
by three distinct sgRNA/ssODN pairs is governed by distance. Incorporation
rates (solid dots represent mean ± SEM, note SEM is too small to be visible,
(n=3)) match almost exactly the curves for each locus previously determined
by oligo scan (hashed trend line ± SD of raw data from Figure 19B). ***P <
0.001, 1-way ANOVA.

As expected, we found that at both the APP and PSEN1 locus, sgRNAs
targeting a DSB at short distances from the pathogenic mutation (2bp for APP71

sgRNA12, 9bp for PSEN1-sgRNA5) resulted in very efficient incorporation of both
mutations, whereas the rate of incorporation of the pathogenic mutation dropped
significantly with increasing distance (Figure 21B-C). Notably, the incorporation
rates for each sgRNA/ssODN pair matched almost exactly the curves for each locus
determined by the oligo scan data (Figure 19B, plotted as dashed lines in Figure
21B-C). Together, the finding of similar distance-incorporation relationships for
multiple independent sgRNAs, as well as multiple ssODN and longer repair
templates at several genomic loci in two cell types suggests that a generalizable and
predictable “distance effect” may govern incorporation of any intended sequence
change during gene editing by HDR.

Using the distance effect for efficient introduction of targeted homo- and
heterozygous mutations

Our data imply that the cut-to-mutation distance needs to be minimized for
efficient homozygous incorporation of a mutation. For example, to yield 25%
homozygous clones the probability of mutation incorporation per allele needs to be
above 50% (50% x 50% = 25%), which requires a cut-to-mutation distance below
approximately 10 bp (see Figure 19B-C). The distance effect also predicts that as
cut-to-mutation distances increase and probability of mutation incorporation drops,
the odds of generating a mono-allelic alteration should increase. To examine
whether the distance effect could be exploited to not only introduce targeted
homozygous but also heterozygous mutations, we first determined an overall
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probability of mutation incorporation (i.e. single allele frequencies for pathogenic
mutation) for iPSCs by combining our oligo scan data from APPswe and PSEN1M146V loci (determined in Figure 19B). By assuming that HDR takes place
independently at both alleles, we calculated the expected distance ranges that would
favor homozygous, heterozygous and wildtype genotypes at a given distance by
multiplying single allelic probabilities (Figure 22A, see Appendix I for details of
calculation).

Figure 22. Exploiting the “distance effect” to predict zygosity using
CRISPR/Cas9-mediated HDR in iPSCs.
A) Predicted distance ranges for desired zygosities, calculated based on oligo
scan data (Figure 19B and Appendix I). B) Frequency of different APP and
PSEN1 mutation genotypes in single cell clones with bi-allelic HDR of
blocking mutations. Indicated zygosities fit to predicted values. HDR clones =
number of Sanger sequenced clones that had all undergone bi-allelic
incorporation of a CRISPR/Cas-blocking mutation as determined by RFLP
analysis.
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To experimentally test these predictions, we derived single-cell clones from
iPSCs electroporated with the three sgRNA/ssODN pairs as described in Figure
21A. We isolated clones that had undergone bi-allelic incorporation of the silent
CRISPR/Cas-blocking mutation as determined by RFLP assay (approximately 2-3%
of clones on average) and assessed their zygosity for the pathogenic mutation by
Sanger sequencing (Figure 22B). Notably, we found that the rate of homo- and
heterozygosity correlated well with our predictions based on the “distance effect”
(Figure 22A). The APP sgRNA/ssODN pair targeting 2 bp away from the pathogenic
mutation yielded 100% clones homozygous for the pathogenic mutation, whereas
the APP sgRNA/ssODN pair targeting 23 bp away yielded more than twice as many
heterozygous as homozygous clones. About half of the clones for this distance did
not contain the pathogenic mutation on either allele. The APP sgRNA/ssODN pair
targeting 45 bp away from the mutations did not yield any clones containing the
pathogenic mutation, even though this mutation was present in the ssODNs used as
an HDR template (Figure 22B). Similar results were also obtained for PSEN1
(Figure 22B). We noted that for PSEN1 sgRNA5 (cut-to-mutation distance 9 bp),
more homozygous clones were generated than predicted based on distance (67%
actual vs. 20-40% predicted). This may reflect differences in usage of the other allele
as a repair template for HDR at some loci or arise from subtle differences in DSB
response and repair. Taken together, our results demonstrate that (1) choosing the
optimal cut-to-mutation distance is crucial for efficient HDR-based genome editing,
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and (2) the distance effect facilitates selection of the most efficient guide RNAs for
engineering both homo- and heterozygous HDR-mediated gene modifications.

Selection for heterozygous mutations using mixed HDR templates

As shown above, the selection of a suitable guide RNA is limited not only by
its specificity and activity for the targeted locus, but also by the requirement for a
PAM close to the intended target site. For a given sequence these requirements
may be too restrictive and result in cases where no suitable guide RNA is available
for homo- or heterozygous knock-in by our approach. Choosing a guide RNA with a
targeting site more than 10 bp away from the mutation may still yield homozygous
clones, albeit at much lower efficiencies, however obtaining heterozygous clones
with a guide RNA that targets very close to the mutation site (<3 bp, Figure 22A) is
highly unlikely.
We reasoned that this problem could be circumvented by equimolar mixing of
two ssODNs that both harbor a CRISPR/Cas-blocking mutation, with only one
containing the pathogenic mutation (Figure 23). We tested this approach on the
APP locus using the most closely targeting sgRNA available, which in our previous
analysis did not yield any heterozygous clones (APP-sgRNA12, see Figure 23A).
When analyzing single cell-derived clones with bi-allelic incorporation of the
CRISPR/Cas-blocking mutation by RFLP and Sanger sequencing, we did indeed
find an appreciable number of clones heterozygous for the intended pathogenic
mutation, thereby validating the approach. Unexpectedly, we observed a higher
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frequency of clones homozygous for the pathogenic mutation than the predicted
50% (Figure 23A). This increased frequency is consistent with the increased
incorporation rate of the ssODN containing both the CRISPR/Cas-blocking and
pathogenic mutation, as determined by NGS of edited loci in pooled cells from the
same experiment (Figure 23A). The ssODN containing the pathogenic mutation
might be favored because the mutation lies in the sgRNA seed sequence, which
may more effective at blocking CRISPR/Cas as described above.
This observation motivated us to test an alternative approach of again using
APP-sgRNA12 and mixing two ssODNs that contained either only the intended
pathogenic mutation, or a CRISPR/Cas-blocking mutation, but at identical positions
in the sgRNA target site (Figure 23B). Strikingly, and as expected, nearly half of the
clones were heterozygous for the pathogenic mutation at one allele and contained
the CRISPR/Cas-blocking silent mutation at the other. Deep sequencing confirmed
incorporation of both oligos at nearly equal rates (Figure 23B). The rate of wildtype
clones was not assessed, because the silent mutation present in the wildtype
ssODN template did not introduce a restriction site for RFLP screening. However,
given the ~50% ssODN incorporation rates determined by deep sequencing, about
25% of HDR clones are predicted to be wildtype. We also demonstrated at the
PSEN1 locus the ability to mix repair templates to predictably and significantly
increase the number of heterozygous clones obtained using the PSEN1 sgRNA that
cleaves closest to the M146V mutation site (PSEN1-sgRNA5, Figure 23C).
Together, these data support the strategy of using a mixture of two oligonucleotides
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to introduce different sequences at each allele and thereby obtain desired
heterozygous modifications in spite of the constraints of the targeted locus.

Figure 23. Introduction of heterozygous or homozygous mutations into
iPSCs by using mixed HDR templates.
A-B) Mixed ssODN editing approach at the APP locus with blocking
mutations in both (A) or one (B) ssODNs (top); zygosity quantification of
single-cell clones and incorporation rates of CRISPR/Cas-blocking mutation B
and pathogenic mutation M determined by NGS analysis (bottom). Note that
for the M/B approach in B, both oligos are incorporated at near equal levels,
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as they have similar blocking activities, whereas for the M+B/B approach in A,
the M+B ssODN is preferentially incorporated, presumably due to a
synergistic blocking effect of both M and B. For the clone quantification in (B)
the rate of wildtype clones was not assessed, because the silent mutation did
not introduce a restriction site for screening. C) Mixed ssODN editing
approach at the PSEN1-M146V locus (top). Using an sgRNA with the
smallest possible cut-to-mutation distance (PSEN1-sgRNA5, 9bp), two
ssODNs were provided, each containing the same silent PAM-altering
CRISPR/Cas-blocking mutation B, but only one containing the pathogenic
mutation M. Frequencies of pathogenic mutation genotypes in single cell
clones with bi-allelic HDR of B (left) and incorporation rates of CRISPR/Casblocking and pathogenic mutations by NGS (right). Note that due to the 9bp
distance to the cleavage site, the incorporation of M is lower than 50% (as
expected from the distance effect).

Conclusions

I began this chapter by highlighting a major problem with CRISPR/Cas9 gene
editing technology, which, at the time of these studies, was not very well
communicated. Specifically, we noticed early in our utilization of CRISPR/Cas9 in
wildtype iPSCs that not only was HDR-mediated mutation incorporation rare, it was
incredibly inaccurate due to the innate high activity of the CRISPR/Cas9 complex.
As a result, HDR-mediated mutation incorporation is almost always corrupted by
additional unwanted indel mutations, making it nearly impossible to use
CRISPR/Cas9 for precise gene editing in iPSCs. Related to this is also the problem
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of generating heterozygous clones, since the highly active CRISPR/Cas9 complex
virtually always introduces unwanted indel mutations at the non-HDR allele in a
single cell. In the work described above, we overcame these two technological
barriers and report a CRISPR/Cas9-based genome editing framework that allows for
selective introduction of specific mono- and bi-allelic sequence changes with high
efficiency.
Utilizing human iPSCs and HEK293 cells, we first established that by
simultaneously introducing a CRISPR/Cas9-blocking point mutation in the PAM or
guide RNA binding sequence, accurate HDR-mediated incorporation of an intended
pathogenic mutation can be significantly increased up to 10-fold per allele. Next, by
systematically characterizing HDR-mediated mutation introduction at varying
distance to the CRISPR/Cas9 cleavage site, we determined a predictable,
monotonic inverse relationship between distance of an intended sequence change
and its rate of incorporation, thereby corroborating and extending previous evidence
of such a distance effect (Beumer et al., 2013; Bialk et al., 2015; Elliott et al., 1998;
Inui et al., 2014; Rivera-Torres et al., 2014; Taghian and Nickoloff, 1997; Yang et al.,
2013). Additionally, we exploited this relationship to derive distance ranges that
enable the selection of the most suitable sgRNAs for the efficient generation of
homo- and heterozygous clones. Furthermore, we demonstrated that heterozygous
changes can also be achieved by reducing the relative concentration of the intended
mutation in the repair template by mixing mutant with non-mutant repair templates.
In this work we introduced pathogenic mutations, but it should be noted that our
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approach of manipulating cut-to-mutation distance or repair template concentration
can be applied to any intended sequence change at virtually any loci.

Discussion

The findings in this study establish a framework for efficient CRISPR/Cas9mediated introduction of targeted mono- and bi-allelic mutations into eukaryotic cells
by characterizing the dynamics of homologous recombination and highlight the utility
of this technology for studying genetic disorders. The widespread use of
CRISPR/Cas9 to induce specific genomic changes depends on strategies to
increase homologous recombination, while at the same time reducing non-specific
repair, such as NHEJ. Recently, several groups have demonstrated increased HDR
rates by either cell cycle synchronization (Lin et al., 2014), activation of β3adrenergic-receptors (Yu et al., 2015), or shRNA knockdown or pharmacological
inhibition of components of the NHEJ pathway (Chu et al., 2015; Maruyama et al.,
2015). Although these studies provide valuable improvements, they do not block
CRISPR/Cas9 activity after HDR has occurred, which we show leads to repeated
editing of genomic loci in a majority of cases due to the high activity of the
CRISPR/Cas9 complex. One approach to reduce this undesirable re-cutting may be
to titrate down Cas9 or guide RNA levels to reduce overall activity or use a modified
Cas9 that does not fully cleave the DNA (e.g., a nickase) (Ran et al., 2013).
However, in our hands this resulted in a drop in overall HDR rates to a level that
makes manual single cell clone picking impractical (data not shown). We therefore
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kept Cas9, sgRNA and ssODNs at a constant concentration at which HDR was most
efficient. Our approach of using CRISPR/Cas-blocking silent mutations significantly
increases accurate HDR events up to 10-fold for a given allele, with the potential to
provide a nearly 100-fold increased probability of detecting desired HDR events at
both alleles. These dramatic benefits provided by CRISPR/Cas-blocking mutations
can be combined with other complementary approaches described above to further
improve HDR efficiency.
In addition to improving the rate of accurate HDR, understanding the
dynamics of homologous recombination of a repair template at a genomic locus
targeted by CRISPR/Cas9 is crucial to efficiently direct the outcome of such a
targeting event. We addressed this by systematically interrogating HDR-mediated
incorporation of multiple repair templates at two independent genomic loci in two
different cell types by high-throughput NGS analysis. This unbiased approach
allowed us to extend previous evidence for a distance effect (Beumer et al., 2013;
Bialk et al., 2015; Elliott et al., 1998; Inui et al., 2014; Rivera-Torres et al., 2014;
Taghian and Nickoloff, 1997; Yang et al., 2013) and define a specific inverse
relationship between the distance of a base from the site of CRISPR/Cas9 cleavage
and the rate of its incorporation by HDR. The length of gene conversion tracts we
determined for CRISPR/Cas9 editing in human iPSCs and HEK293 cells was very
similar to tract length observed for TALENs in human iPSCs and other human cell
types (i.e., incorporation drops significantly between 10-20 bp) (Rivera-Torres et al.,
2014; Yang et al., 2013), however, it differed markedly from that observed with zinc
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finger nucleases in Drosophila (over 3,000 bp) (Beumer et al., 2013) and restriction
enzymes in rodent cells (80-200 bp) (Elliott et al., 1998; Taghian and Nickoloff,
1997). This divergence might reflect species differences, for example varying
activities of repair pathways, or differences in the types of cleavage, e.g. sticky ends
for restriction enzymes versus blunt ends for TALENs and CRISPR/Cas9, which
may affect strand resection and repair. Variations in analysis may also play a role,
for example some studies used selection markers, which may increase the
representation of rare events, especially if the number of analyzed clones is small.
We therefore note that controlling zygosity by exploiting the distance effect may work
best in systems where short gene conversion tracts are more likely, whereas oligo
mixing is a more universally applicable approach.
The distance effect we observed for CRISPR/Cas9 editing in human cells
seems likely to reflect intrinsic features of the repair mechanism since in our initial
survey it did not depend markedly on cell type, genomic locus, guide RNA, or nature
of the repair template. What determines this dependence on distance? One
possible explanation, described two decades ago in the context of restrictionenzyme-induced transgene conversion by HDR in mouse ESCs (Elliott et al., 1998),
is that different size deletions arise after nuclease-mediated DSBs and that only the
part of the repair template overlapping these deletions is used during HDR. If small
deletions or resections are more common than large ones, this would result in fewer
incorporations of mutations more distal to the cleavage site (Figure 24). Our data
support this idea, because they not only confirm that deletions are more likely small
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than large and center around the Cas9-mediated DSB, but also indicate no
significant change of the distance dependency by altering the size and type of HDR
repair templates used.

Figure 24. Possible mechanism underlying the distance effect for HDRmediated mutation incorporation with CRISPR/Cas9.
CRISPR/Cas9 causes a DSB at a genomic locus, which leads to variable size
deletions or strand resections in different cells. Genomes with small deletions
or resections are more common than large ones, which is reflected in the
distribution of deleted bases after NHEJ (top left). During HDR, only the part
of the repair template overlapping this deletion may be used, which results in
fewer mutations incorporations more distal to the cleavage site (bottom left,
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data pooled for APP and PSEN1 from Figure 19C). Graphs depict our actual
data.

Although it remains to be determined whether our proposed mechanism is the
correct explanation, the observation of a reproducible and stereotyped distance
effect has two major implications for the field of gene editing: First, it demonstrates
that HDR is most efficiently achieved by selecting a guide RNA that causes a DSB
close to the intended sequence change. Second, it defines optimal distance ranges
to generate mono- or bi-allelic modifications, significantly improving guide RNA
selection procedures that until now have focused principally on on-target activity and
predicted off-target effects. As we show, the most efficient way of obtaining a clone
heterozygous for a pathogenic mutation is to introduce it together with bi-allelic
CRISPR/Cas-blocking silent mutations, which prevent destruction of both alleles by
NHEJ. The different zygosities at both alleles are achieved by reducing the
probability of the introduction of the pathogenic mutation by either modulating
distance between cleavage site and mutation (distance effect) or mixing pathogenicmutant and non-mutant oligos.
Our improved CRISPR/Cas9-based gene editing framework also streamlines
the modeling of genetic diseases in human iPSC models, by avoiding typical
drawbacks associated with use of patient-derived models. These include scarce
availability or low quality of patient cell lines with mutations of interest, particularly for
rare diseases, as well as the potential for inefficient reprogramming and/or poor
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somatic cell differentiation quality. Furthermore, making comparisons in isogenic cell
lines prevents confounding genetic background effects (Bellin et al., 2012; Tiscornia
et al., 2011). Knocking-in pathogenic mutations in human disease-relevant cells is
more physiological than overexpression, which is commonly used in transgenic
animal or cellular disease models, and also permits study of heterozygous mutations
that underlie many important human diseases. When performed in a standardized
iPSC or embryonic stem cell line, our approach not only allows efficient generation
of knock-in models, but also cross-comparison between lines with different
mutations in the same genetic background.
Since the completion of the CRISPR/Cas9 studies presented in this thesis
there has been a large amount of work to further develop and improve the gene
editing field. Specifically, the development of a new CRISPR technology,
CRISPR/Cpf1 has offered promise for enabling efficient and precise sequence
changes (Zetsche et al., 2015). However, as will be described below, we believe
there are considerable drawbacks to this new technology and Cpf1 may not be a
widely useful replacement for CRISPR/Cas9. Cpf1 is another bacterial RNA-guided
nuclease which is a member of a class II CRIPSR/Cas system. Cpf1 differs from
Cas9 in many ways. Cpf1 is a much smaller and simpler nuclease compared to
Cas9 and is guided by a smaller sgRNA molecule than is needed for Cas9 targeting.
Unlike Cas9, Cpf1 targets a T-rich PAM (TTTN) at the 5’ end of the sgRNA target
sequence (Cas9 targets NGG at the 3’ end of the target sequence) and makes a
staggered cleavage of the DNA at 19bp after the PAM on the targeted strand and
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23bp on the other strand (Zetsche et al., 2015). As a result, the DSB has 5’
overhangs (“sticky ends”). The fact that Cpf1 results in a cleavage with overhangs in
intriguing, as strand resection and overhang generation is known to be as an
essential first step for initiating HDR (Elliott et al., 1998). Furthermore, many
researchers believe that the generation of sticky ends may greatly facilitate the
insertion of much longer tracts of DNA more effectively. Unfortunately, there have
been no investigations in human cells (including stem cells) demonstrating whether
Cpf1 indeed improves HDR rates or conversion tract length. Furthermore, future
studies would be necessary to determine whether the distance effect we determined
for Cas9 editing in human cells holds true or is altered when instead using Cpf1.
There are potentially other drawbacks to using Cpf1 over Cas9. Since Cpf1
cleaves 19-23bp from the PAM site and since most editing events (HDR or indels)
take place closest to the cut-site, repetitive editing is more likely, since modifications
would less commonly alter the PAM and prevent re-editing. Furthermore, if blocking
mutations are also proven to be effective for Cpf1, then incorporating these
mutations in the PAM, which is at a considerable distance from the cut site, may be
difficult due to the distance effect. Therefore, even if HDR rates are somewhat
improved using Cpf1, the problems of re-editing and inaccurate HDR may be
considerably worse when using Cpf1. At this time, all of these concerns are
speculative, and therefore additional studies are required to address them.
While CRISPR/Cas9, as reported here and by others, mostly generates biallelic modifications, TALENs are capable of introducing heterozygous changes,
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likely due to their known lower editing activities, such that when HDR occurs at one
allele the unedited allele is spared from NHEJ. However, compared to
CRISPR/Cas9, efficient and widespread use of TALENs has been hampered by their
difficult design and assembly, and the need for extensive clone screening because
of lower editing rates (Ding et al., 2013). The strategy we describe, by harnessing
the efficiency of CRISPR/Cas9-based targeting with approaches to enabling precise
control of zygosity, provides a more efficient method for introducing both homo- and
heterozygous sequence changes in a predictable manner. What’s more, this
approach facilitates the simultaneous modification of several loci in the same
standardized model systems, helping open important research avenues such as
studying combinations of disease-associated mutations or risk factors to better
understand multifactorial diseases.
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Chapter III: PRECISE AND EFFICIENT SCARLESS GENOME
EDITING IN STEM CELLS USING “CORRECT”

Background and Rationale

While attempting to edit the APP and PSEN1 loci in human iPSCs, we noted
that up to 95% of the genomes that had incorporated the intended sequence change
by CRISPR/Cas9-mediated HDR were corrupted by additional indel mutations
(described in Chapter II). These “inaccurate” edits arise from subsequent re-editing
of a previously edited locus by the CRISPR/Cas9 complex (Figure 25A), which will
re-cut target loci until they are sufficiently modified to prevent further detection by
CRISPR. We demonstrated that undesirable re-editing could be largely prevented
by inserting mutations into HDR repair templates within sequences required by
CRISPR/Cas9 for targeting (Figure 25B). These simple repair template
modifications can increase editing accuracy up to 10-fold per allele, and therefore
assuming independent allelic editing, may increase the probability of accurately
editing both alleles in a single cell by up to 100-fold, which, for manual clone picking,
can make the difference between a practical versus impractical genome editing
experiment. Furthermore, we found that in most cases CRISPR/Cas9 editing in
iPSCs is bi-allelic, because non-HDR edited alleles are virtually always disrupted by
indels caused by NHEJ. Therefore, the only way to generate precise accurately
edited iPSCs was to introduce CRISPR/Cas-blocking mutations at both alleles in the
genome (see Chapter II).
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Figure 25. Schematic summarizing editing outcomes and CRISPR/Casblocking mutations in human stem cells.
A) Following a CRISPR/Cas9-mediated double strand break (1) a majority of
loci will be repaired through the error-prone NHEJ pathway resulting in
random indel mutations (2). In approximately 1-10% of cases HDR
introduces an intended sequence change provided by a homologous DNA
repair template (3). However, this sequence change is accurate (i.e. not
corrupted by additional CRISPR/Cas9 editing) only in a very small minority of
cases (as low as 6% as described above) (4). In the majority of the HDR
events, the CRISPR/Cas9 complex will re-cut (5) and cause additional indels
(up to 95% of HDR events at the PSEN1 locus as described above) (6). (B)
HDR-mediated editing using an sgRNA targeting near the APPswe site (light
blue arrow). Commonly, re-editing after incorporation of the intended APPswe
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mutation by HDR results in inaccurately edited genomes (orange arrow).
Introducing CRISPR/Cas-blocking mutations in the guide RNA target
sequence or PAM prevents further target detection and re-cutting and
therefore improves HDR accuracy up to 10-fold per allele.

While the introduction of CRISPR/Cas-blocking mutations in coding regions
should in most cases not cause any unexpected problems, as they can be silent
(leaving the encoded amino acid unchanged), introducing these additional mutations
into non-coding regions such as introns, regulatory regions or non-coding RNAs may
have unwanted consequences. Furthermore, introducing silent mutations in coding
sequence at or near splice sites, splicing enhancers or inhibitors may cause
unwanted effects. In some cases, the use of additional mutations can be avoided by
simply choosing guide RNAs where the intended sequence change doubles as a
blocking mutation (if they lie within the PAM or guide RNA target sequence) but this
is not universally applicable. Therefore, there was a need to develop a strategy that
takes advantage of the efficacy of CRISPR/Cas9 but can be utilized for scarless
introduction of specific sequence changes by HDR, with the absence of additional
CRISPR/Cas-blocking mutations. The following work is adapted from our recent
publications (Kwart & Paquet et al,. 2017; Paquet & Kwart et al., 2016).

Scarless genome editing using CORRECT

To address this limitation, we devised a two-step gene editing strategy termed
“CORRECT” (Consecutive Re-Guide or Re-Cas steps to Erase CRISPR/Cas90

blocked Targets), which, by taking advantage of CRISPR/Cas-blocking mutations in
both steps enables efficient “scarless” introduction of a single intended mutation
sequence, while minimizing clone picking. Moreover, each step of CORRECT is
compatible with manipulating cut-to-mutation distance or using a mixed oligo
approach (see Chapter II) to favor homo- or heterozygous mutation incorporation.
We have developed two variants of CORRECT: re-Guide (Figure 26A) and re-Cas
(Figure 26B).

Figure 26. Schematic describing scarless editing using CORRECT by
re-Guide and re-Cas.
(A) For re-Guide editing a CRISPR/Cas-blocking mutation B in the guide
RNA target sequence is introduced in addition to the intended mutation M
with the MB template by HDR. B is subsequently removed in the second
Phase using a modified guide RNA (re-sgRNA) with Cas9 and the CORRECT
template, resulting in scarless introduction of the intended mutation M. (B)
For re-Cas editing a PAM-altering CRISPR/Cas9 blocking mutation is
introduced in addition to the intended mutation M with the MB template by
HDR. The altered PAM is targeted by VRER-Cas9 in Phase 2 resulting in
scarless introduction of M alone. In Phase 1 and Phase 2 of both CORRECT
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variants CRISRP/Cas9-blocking mutations enable efficient and accurate
scarless mutation incorporation.

In both re-Guide and re-Cas, a blocking mutation B is introduced at both
alleles together with the intended mutation M by an ssODN template (MB template)
in the first phase, thus preventing unwanted indels. In the second phase a modified
“CORRECT template” is used to remove the blocking mutations but preserve the
intended mutation. While the re-Guide blocking mutations are located in the guide
RNA targeting sequence and therefore prevent further targeting of the single guide
RNA (sgRNA), the re-Cas blocking mutation prevents PAM detection by mutating
the NGG (e.g., to NGCG). Targeted re-editing of the blocked locus is achieved in the
second phase with a modified set of reagents: For re-Guide, a modified sgRNA (“resgRNA”, targeting the 20bp sequence containing the introduced CRISPR/Casblocking mutations) is used in combination with wildtype (WT) Cas9. For re-Cas, the
sgRNA from phase 1 is reused, but WT-Cas9 is replaced by a Cas9 variant (e.g., the
recently described VRER-Cas9) (Kleinstiver et al., 2015), which targets the modified
PAM sequence introduced as a blocking mutation in the first step (Figure 26A-B).
Both variants utilize a modified repair template in phase 2 (CORRECT template),
which removes the blocking mutations by HDR, but leaves the pathogenic mutation
in place. By choosing guide RNAs with specific cut-to-mutation distance or using
mixed repair templates strategically as described in the previous chapter, each step
of CORRECT allows homo- or heterozygous incorporation of the intended mutation.
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Assessing CORRECT feasibility in pooled gene editing experiments

To test the feasibility and efficiency of CORRECT by both re-Guide and reCas we selected two mutations to introduce (APPswe and APP-A673T) by either
CORRECT variant based on the situation of the mutation site around the PAM or
sgRNA target sequence (Figure 27). We also determined restriction endonuclease
sites that would be uniquely introduced by MB and CORRECT templates, which
enable RFLP screening for accurately edited clones in each phase of CORRECT
(Figure 27).

Figure 27. Experimental design for scarless mutation introduction
using CORRECT.
Design of MB and CORRECT ssODN repair templates that were designed for
re-Guide (A) and re-Cas (B) experiments such that MB and CORRECT
templates introduce different restriction sites for RFLP screening (shown with
black underlines).
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We began by generating two homozygous “MB” iPSC lines containing (1) the
homozygous APPswe pathogenic mutation and a CRISPR/Cas-blocking mutation in
the guide RNA target sequence, or (2) the APP-A673T (a protective APP mutation)
and NGCG PAM-altering mutations (Figure 28A-B). Using both the wildtype parent
iPSCs as well as these MB iPSCs, we showed by SURVEYOR assay, combinations
of WT-Cas9 and sgRNAs were highly active on their respective targets in wildtype
unedited iPSCs, whereas combinations of WT-Cas9/re-sgRNA or VRERCas9/sgRNA were not (Figure 28C, E). In contrast, WT-Cas9/re-sgRNA efficiently
targeted the modified locus in APPswe MB iPSCs, and VRER-Cas9/sgRNA
efficiently targeted the modified locus in APP-A673T MB iPSCs (Figure 28C, E). As
anticipated, WT-Cas9/sgRNAs combinations were virtually inactive on modified loci,
illustrating efficient blocking of unwanted re-editing after HDR in all cases. We then
attempted to specifically remove the blocking mutations from both MB cell lines by
introducing CORRECT-templates and the above-mentioned combinations of WTCas9/re-sgRNA or VRER-Cas9/sgRNA (Figure 28A-B), respectively, and measured
the resulting allele frequencies by NGS. Strikingly, we detected the expected
scarless genome editing events with high efficiency (Figure 28D, F). Thus, in this
preliminary test of CORRECT, we demonstrated this approach enables increased
editing accuracy provided by blocking mutations in each step, and at the same time
allows scarless introduction of intended pathogenic mutations.
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Figure 28. Assessing feasibility of CORRECT by pooled re-Guide or reCas editing.
A-B) Schematics depicting details of the two tested CORRECT approaches:
In step 1 of re-Guide (A) the APPswe mutation was introduced together with a
CRISPR/Cas-blocking guide RNA target mutation, which is to then be
removed in step 2 using a re-sgRNA specific for the mutated sequence and
WT-Cas9. In step 1 of re-Cas (B) the APP-A673T mutation was introduced
together with a CRISPR/Cas-blocking PAM-altering NGCG mutation that is
then removed in step 2 using the VRER Cas9 variant, which specifically
detects the NGCG PAM. We chose to incorporate the APP-A673T mutation
using the very active APP-sgRNA12 to test CORRECT by re-Cas since the
APPswe mutation is located in the target sequence of this sgRNA, which may
block re-editing by CRISPR/Cas and could therefore complicate the
interpretation of results. The APP-A673T mutation lies outside of the target
sequence (B). In both cases, the blocking mutations were removed using a
CORRECT ssODN repair template, which restored the original sequence at
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the site of the blocking mutation (which blocks further re-cutting in this step)
but retained the pathogenic APP mutation. C, E) SURVEYOR assays
showing specificity of WT-Cas9/WT-sgRNAs for WT targets, and WTCas9/re-sgRNA (C) or VRER-Cas9/WT-sgRNA (E) for mutated loci. D, F)
NGS quantification of genomes with intended incorporation of CORRECT
templates by HDR in pooled iPSCs (n=2).

Increasing HDR rates as a strategy to improve CORRECT efficiency

The greatest drawback of CORRECT is the need for two rounds of gene
editing, single cell sorting, colony picking, screening and expansion. All of these
steps together add additional time, albeit most of this time is not “hands-on”. As
described in the previous chapter, bi-allelic HDR rates in single cell-derived iPSC
clones was approximately 2%, which means in the first phase of CORRECT editing
picking hundreds of colonies to obtain a handful of clones for subsequent quality
control analysis and expansion prior to the next round of editing. To minimize
needing to pick hundreds of colonies more than one time, we sought to determine a
simple strategy to significantly increase the rate of isolating HDR clones with minimal
additional optimizations. One approach we tested was to alter the FACS sorting
paradigm we had previously established to isolate iPSCs that were electroporated
with Cas9, sgRNA and ssODN repair templates. As described above (and in
Appendix I), we sorted out electroporated iPSCs that were expressing GFP, which
is co-expressed from the Cas9 plasmid (we assumed GFP+ cells would have also
taken up sgRNA plasmid and ssODNs as these other DNAs are significantly smaller
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than the pCas9_GFP plasmid). In all of our early experiments we simply sorted out
the entirety of the GFP+ population and analyzed all of those cells together, which
would yield the approximately 2-3% biallelic HDR clones as described above (see an
example in Figure 29)

Figure 29. Original approach for FACS enrichment of gene edited iPSCs
and RFLP analysis.
A-B) Enrichment of GFP-expressing iPSCs by FACS sorting. Note setup of
gates based on GFP/DAPI-negative and GFP positive samples. Only live
single GFP-positive cells were collected (top right panel). C) RFLP
screening strategy (example for APPswe incporporation). Bi-allelic HDR
clones are pointed to by red arrows (~2%). HDR/HDR clones were confirmed
to have accurate mutation incorporation by Sanger sequencing (not shown).
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Given that the overall level of HDR depends on both CRISPR/Cas9 activity as
well as presence of the ssODN repair template, we hypothesized that perhaps the
population of cells that have the most CRISPR/Cas9 and repair template would also
be the cells that have undergone the most number of desired HDR-mediated
changes. We tested what HDR rates would be in sorted GFP+ cell populations split
based on either low, medium, or high GFP fluorescence intensity (Figure 30A). In
this proof-of-principle experiment, we chose to target the APPswe locus using APPsgRNA12 described in the previous chapter. After isolating single cell-derived
colonies and performing RFLP analysis to screen for HDR clones we noticed striking
differences in the sorted populations (Figure 30B-C). Specifically, both mono-allelic
and bi-allelic HDR clones were most rare in the GFP low population (1% for each).
In the GFP middle population there were more of both mono-allelic (7%) and biallelic (2%) HDR clones. Most strikingly, however, was the GFP high population,
which had a remarkably high number of both mono-allelic (18%) and bi-allelic (17%)
HDR clones. Together, in the GFP high population, 47% of all clones picked had
undergone HDR at one or more alleles. (Figure 30B-C). These data were exciting,
as we demonstrated that simply by changing the FACS gating strategy, we could
dramatically increase the frequency of HDR clones thereby dramatically reducing the
number of colonies that would need to be picked and screened to identify accurately
edited iPSCs. This approach has become an invaluable development that has
enabled us to rapidly generate isogenic iPSCs by either a one-step or two-step (via
CORRECT) CRISPR/Cas9 editing approach.
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Figure 30. Enriching for high GFP intensity in electroporated iPSCs by
FACS dramatically increases probability of identifying bi-allelic
accurately edited HDR clones.
A) FACS gating strategy to sort low, medium, or high GFP+ expressing
iPSCs. B) RFLP analysis from GFP low, medium and high expressing
populations. Red arrows indicate bi-allelic HDR clones. Example shown for
TfiI digestion indicating APPswe incorporation. C) Quantification of monoallelic and bi-allelic HDR clones from 2 96-well plates of picked iPSC clones.
HDR/HDR clones were confirmed to have accurate mutation incorporation by
Sanger sequencing (not shown).

Using CORRECT for generation of scarless mutant iPSCs

With the confidence that CORRECT is a feasible method for scarless editing
gained from the pooled analysis combined with the novel FACS gating approach we
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identified for making identification of HDR clones more efficient, we set out to fully
utilize CORRECT by re-Guide and re-Cas to generate scarless homozygous
APPswe (re-Guide) and APP-A673T (re-Cas) iPSC lines. We took the two “MB”
clones we generated (see Figure 28 and Figure 31) and completed the second
phase of CORRECT by re-editing the MB locus using the “CORRECT template”
(Figure 31A-B). After screening single cell-derived iPSC clones by RFLP analysis
for incorporation of the CORRECT template, we successfully identified a number of
accurately edited “M clones” that only contain the pathogenic or protective APP
mutation and no other CRISPR/Cas-blocking mutations. We picked only a few
hundred clones in both phases of re-Guide and re-Cas and were able to efficiently
identify several accurately edited clones in each step (Figure 31C). Taken together,
this work demonstrates that CORRECT, which, by exploiting the use of highly
efficacious CRISPR/Cas-blocking mutations in two rounds of genome editing,
enables accurate, efficient and scarless introduction of specific base changes in
difficult to edit cell lines such as iPSCs.
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Figure 31. Derivation of scarless APP mutant isogenic iPSC clones by
CORRECT.
Genotypes of selected re-Guide (A) and re-Cas MB and M clones (B) were
confirmed by Sanger sequencing. C) Number of single-cell derived clones
that had bi-allelic incorporation of the MB or CORRECT template for both reGuide and re-Cas experiments, as determined by RFLP assay and confirmed
by Sanger sequencing.

When to use CORRECT: Re-Guide or re-Cas

The first decision to make is whether or not CORRECT is required to achieve
the desired gene editing outcome. If scarless editing is not required, for example at
protein-coding loci where silent CRISPR/Cas-blocking mutations in PAM or sgRNA
target sequence are effective and compatible (see above), the desired change can
be achieved in a single round of gene editing without CORRECT. When this is not
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possible, such as when studying a defined genetic mutation requires scarless
editing, CORRECT is advisable.
Next, one should determine whether the re-Guide or re-Cas variation is more
suitable. While PAM-blocking mutations utilized by the re-Cas variant may be more
universally applicable, in our hands the re-Guide variant seemed to yield more
efficient CORRECT editing (Figure 28D, F and Figure 31C). We therefore
recommend to choose re-Guide or re-Cas based on the editing efficiencies of the
available guide RNAs (for example, by performing Surveyor nuclease assays) and
the position of their targeting site relative to the intended mutation M (Figure 32). In
the rare instance that the intended mutation falls within the two guanines of the NGG
PAM site or within the guide RNA seed sequence (the first 7 to 13 bases upstream
of the NGG (Jinek et al., 2012; Semenova et al., 2011)) the mutation itself will likely
be blocking, making re-Guide or re-Cas unnecessary (unless one wishes to
introduce a specific screening mutation for RFLP analysis). However, CORRECT
should be used when the intended mutation is upstream of the guide RNA seed
sequence or downstream of the PAM. First, a guide RNA should be chosen that
minimizes the distance between cut site and intended mutation to ensure efficient
incorporation (as described in Chapter II). This also means the distance between
the intended mutation M and the blocking mutation B should be minimized, as
increasing the distance between these two mutations, for example by placing them
on opposite sides of the Cas9 cut site, reduces probability of incorporation of both
mutations together. When the intended mutation is located within the first base of
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the PAM or downstream of it, re-Cas should be utilized, whereas re-Guide should be
employed when the intended mutation falls within or upstream of the 20-nt guide
RNA sequence. A useful guide summarizing these experimental design tips is
highlighted below (Figure 32).

Figure 32. Schematic summarizing criteria for selecting re-Guide versus
re-Cas CORRECT variants.
(A) Selection of the re-Guide or re-Cas variant of CORRECT depends on the
intended mutation M position at the locus being targeted. Asterisk (*): If the
intended mutation is not blocking, use re-Guide.

Considerations for ssODN design: MB and CORRECT templates

For both re-Guide and re-Cas, an MB and a CORRECT template should be
obtained. These templates can be ordered as custom synthetic oligos ready for use
with CORRECT. We use 100-nt ssODN templates centered around the cut site,
using the sequence of the non-targeted strand, i.e. the strand that has the same
sequence as the guide RNA, to avoid base-pairing of guide RNA and repair oligo.
However, recent evidence suggests that HDR repair can be further improved by
using the sequence of the targeted strand and by optimizing repair template position
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relative to the edited locus (Richardson et al., 2016). For re-Guide, the MB template
should contain the intended mutation plus the CRISPR/Cas-blocking mutations in
the guide RNA targeting site. For re-Cas, the MB template should contain the
intended mutation plus the NGG>NGCG (for VRER Cas9) PAM-altering
CRISPR/Cas-blocking mutation. For both re-Guide and re-Cas, the CORRECT
template should retain the intended mutation sequence, but replace the
CRISPR/Cas-blocking mutations with the original guide RNA or NGG PAM
sequence (for re-Guide and re-Cas, respectively).
Ultimately, Sanger sequencing of the edited loci of individual iPSC clones
must be performed to confirm accurate CORRECT editing. However, to minimize
the number of clones to be sequenced, we recommend incorporating restriction
endonuclease sites by the intended or CRISPR/Cas-blocking mutation(s) in both the
MB and CORRECT templates. Alternatively, loss of a restriction endonuclease site
by incorporation of either MB or CORRECT templates can be used to indicate
accurately edited clones, however this may lead to identification of more falsepositive clones since indel mutations arising from NHEJ could also disrupt a
restriction site if near the Cas9 cut site. Following RFLP analysis only clones that
demonstrate the expected DNA fragment lengths on an agarose gel will be
sequenced. If necessary, unwanted additional mutations introduced in the MB
template for screening purposes in the first round of editing can be removed with the
CORRECT template in the second round of editing, and loss of restriction
endonuclease cleavage can be used to identify edited clones.
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Using re-Guide allows changing multiple bases in the guide RNA target
sequence, which gives more flexibility for the introduction and/or removal of a
restriction endonuclease site for clone screening by RFLP analysis. re-Cas requires
a specific mutant Cas9 PAM in the MB template (e.g., NGCG for the VRER-Cas9),
which may make the introduction of restriction endonuclease sites for screening
more difficult to determine. As illustrated above, we have applied re-Cas to
introduce the A673T mutation in the wildtype APP locus with sgRNA12, and used
RFLP-mediated screening to identify MB and M clones: First, we incorporated the
VRER PAM and A673T mutation by the MB template (Figure 27). These two
changes (TGGATGC > TGCGTAC) generated a RsaI site (GTAC). In the second
phase of editing, correcting the PAM back to the wildtype TGG sequence with the
CORRECT template (TGCGTAC > TGGATAC) introduced a BciVI site (GGATAC).
Alternatively, we could have used several other strategies. For example, we could
have used APP sgRNA2 for re-Cas (used for re-Guide scarless introduction of
APPswe) by changing the wildtype PAM to incorporate the VRER PAM in the MB
template (CTCAGGATAT>CTCCGCGTAT), which introduces a BstUI site (CGCG),
and removes a DdeI site (CTNAG). The DdeI site can then be restored by correcting
the PAM back to the wildtype AGG sequence by the CORRECT template. In
summary, we believe CORRECT is a framework for efficient scarless genome
editing that can be broadly utilized at virtually any genomic loci in a variety of model
systems.
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Applications of CORRECT and comparison with other methods

Here we present the use of CORRECT for scarless introduction of diseaseassociated homo- and heterozygous mutations into wildtype human iPSCs. We
have demonstrated that generating knock-in mutant iPSCs cell lines makes it
possible to study disease-associated mutations in disease-relevant cell types, which
has great impact on the broader field of disease modeling (Paquet et al., 2016).
Moreover, CORRECT makes it possible to use CRISPR/Cas9-mediated gene
editing to efficiently edit non-coding genomic sequence, where silent blocking
mutations cannot be utilized. CORRECT also provides alternatives for more
effective editing of coding sequence, especially in cases where using silent blocking
mutations is not possible either due to incompatibility with the reading frame or
insufficient blocking activity. Instead of generating knock-in cell lines, researchers
may choose to obtain patient samples with known genomic mutations. To generate
isogenic wildtype control cell lines, CORRECT can easily be modified to replace
patient-specific mutations with wildtype sequence by incorporating these
modifications in the MB and CORRECT templates. Furthermore, CORRECT has
the added benefit that customizable sequences, such as restriction endonuclease
recognition sites, can be introduced into MB templates, which allow simple RFLP
screening analysis to identify correctly targeted clones.
Gene editing with CORRECT is advisable when scarless editing is imperative
to faithfully study a defined genetic mutation. If silent blocking mutations are effective
and compatible with the locus, the desired change can be achieved in a single round
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of gene editing without CORRECT. When scarless mutation introduction is desired,
this can also be achieved in a single step using a repair ssODN containing only the
intended sequence change, but no blocking mutation. However, except in the rare
case that the intended mutation doubles as a CRISPR/Cas-blocking mutation we
would not recommend the latter strategy, because accurate editing efficiencies could
be reduced up to 10-fold per allele (see Chapter II). Although accurately edited
clones can still be identified at this low editing efficiency by other cellular enrichment
strategies such as sib-selection (Miyaoka et al., 2014), this requires laborious
sequential cellular selection, clonal expansion and genomic analysis and therefore
the overall time required for this approach is similar to CORRECT editing.
Alternatively, one could use a different scarless genome editing approach
such as the piggyBac transposon, which has been shown to be effective in human
iPSCs (Yusa, 2013). Similar to CORRECT, this method requires two rounds of
genetic manipulation, clone picking and screening. Therefore, generating scarlessly
edited clones with piggyBac would take approximately the same time as CORRECT.
Since the piggyBac transposon system uses antibiotic resistance markers for
screening, it facilitates isolating larger genomic changes, such as gene or exon
insertions, or deletion of protein domains, which are usually very rare events.
However, for smaller edits, such as base changes, CORRECT performs better in our
hands for several reasons: (1) transfection of the large piggyBac repair template in
iPSCs and its genomic incorporation is inefficient; (2) editing with piggyBac requires
a TTAA sequence near the target site of interest, which is more restrictive than the
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NGG PAM requirement for Cas9 and could severely limit the number of targetable
loci; (3) construction and cloning of the piggyBac targeting vector containing the
intended sequence changes is laborious compared to simply ordering custom
synthetic ssODNs, which are used as repair templates for CORRECT. Finally,
excision of the piggyBac transposon can be inefficient and lead to integration
elsewhere in the genome, which requires subsequent southern blot analysis for
quality control.
More recently, a new CRISPR-based technology has been developed for
scarless mutation incorporation called “base editing” (Gaudelli et al., 2017; Komor et
al., 2016). Briefly, this approach negates the necessity for Cas9-mediated DSB
generation. Specifically, a catalytically inactive version of Cas9 is tethered to a
cytidine or adenosine deaminase, which can mediate C-G to A-T or A-T to C-G
changes without DNA cleavage when targeted to a genomic locus by an sgRNA.
This approach has its many advantages, namely, by bypassing DNA cleavage there
is no NHEJ that occurs and therefore no problem of additional unwanted indels
alongside desired changes or need for CRISPR/Cas-blocking mutations. This
means base editing can be performed in a single round of gene editing. Although
the efficacy of base editing in human stem cells remains to be adequately tested,
studies in other cell types have shown high C to T and A to C editing efficiencies (up
to 75% of cells). While base editing holds great promise for use wide use in multiple
scientific fields, it does have its disadvantages over our described one- or two-step
gene editing approaches using Cas9-mediate HDR. Specifically, the greatest
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disadvantage is that base editing is unspecified, only occurring between a predicted
sequence range near the sgRNA target site. To adjust the editing window, different
deaminases tethered to inactive Cas9 must be used. This of course means that in
order to be able to use base editing one would need the guide RNA sequence to
match the necessary location for the optimal base editing range for a given
deaminase, which may not always be possible depending on the genomic sequence.
Furthermore, because the exact base being edited cannot be specified (only a 4-5
nucleotide window (Gaudelli et al., 2017; Komor et al., 2016)) every single clone
picked will have to be sequenced, as there is no way to introduce specific RFLP
screening sites in addition to the desired mutation by base editing. Lastly, while
base editing may be effective for engineering a single C-G to A-T or A-T to C-G
mutation, introducing multiple specific base changes (such as the double base
change seen for the APPswe mutation) is difficult without two rounds of base editing.
Therefore, while base editing holds great promise, any desired gene-edit involving
more than one base change at this point should be done using CRISPR/Cas9mediated HDR in a one-step (using blocking mutations) or two-step (using
CORRECT) approach.

Limitations of CORRECT

CORRECT currently works best in dividing cells in culture, limiting its use in
vivo in animal models. The two rounds of genomic manipulations and clone picking
required to generate pure cultures of accurately edited human stem cell lines with
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CORRECT take approximately 3 months, twice as long as scarless editing without
the benefit of blocking mutations. However, because CORRECT may increase the
editing efficiency up to 100-fold, the longer time required is made up for by less
manual labor, especially during the clone picking steps. In an extreme case,
CORRECT would require picking only a couple hundred clones, while tens of
thousands may be required if a CRISPR/Cas9 blocking-mutation strategy is not
used. In the future CORRECT may be further streamlined by multiplexing both
editing steps in a single cell pool, for example by using cell lines with inducible forms
of wildtype or variant Cas9 (Dow et al., 2015).
The two rounds of genome editing required for CORRECT may potentially
increase the risk of off-target modifications. However, this potential increase will
likely not expand the number of potential off-target sites, since the same (for re-Cas)
or very similar (for re-Guide) guide RNAs are used in both editing steps.
Furthermore, since using blocking mutations significantly increases editing accuracy,
CORRECT facilitates isolating multiple clones for phenotypic comparison. Finally,
the VRER Cas9 variant used in phase 2 of re-Cas has only more recently been
engineered and is far less studied. Therefore, the degree of on-target activity and
specificity at multiple genomic loci in a variety of cell types remains to be elucidated.
We expect that as CRISPR/Cas9 technologies are further developed, variant Cas9
enzymes will be enhanced with improved on-target activity and specificity
(Kleinstiver et al., 2015) and may make re-Cas the future CORRECT variant of
choice.
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Our two variants of CORRECT offer the choice of either using wellcharacterized wildtype Cas9 in both steps together with a modified guide RNA (reGuide) or a Cas9 variant with altered PAM specificity in step 2, which benefits from
using the same sgRNA in both steps, and potentially more robust blocking effects by
the PAM mutation (re-Cas). In our laboratory, however, we have noticed reduced
rates of HDR using the VRER Cas9 compared to wildtype Cas9 when employing
CORRECT to target the amyloid precursor protein (APP) gene (see Figure 28D, F
and Figure 31C). Prior to choosing CORRECT by re-Guide or re-Cas the HDR
efficiency for wildtype and mutant Cas9 can be determined at the intended locus of
interest in a pool of transfected cells by either NGS detection of intended sequence
incorporation (Paquet et al., 2016) or RFLP detection of a restriction endonuclease
site introduced by an HDR template (Cong et al., 2013). We recommend using the
CORRECT variant that yields the highest HDR rates to minimize manual clone
picking during each gene editing phase. Regardless of Cas9 variant used,
CORRECT can be combined with novel NHEJ inhibitor and HDR improvement
strategies (Chu et al., 2015; Lin et al., 2014; Maruyama et al., 2015; Richardson et
al., 2016; Yu et al., 2015), as well as other recently published cellular enrichment
methods (Miyaoka et al., 2014) to minimize clone picking and improve recovery of
accurately edited clones in each step of the protocol.
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CHAPTER IV: STUDYING ISOGENIC MUTANT APP AND PSEN1
IPSC-DERIVED NEURONS REVEALS CONSERVED CELLULAR AD
MECHANISMS

Background and Rationale

The “amyloid cascade hypothesis” is the most prominent theory describing
the pathogenesis of AD (Hardy and Higgins, 1992), and places Ab as the early key
initiator of all downstream changes necessary for the development of AD. This
notion is most significantly supported by genetics, as more than 200 fAD mutations
in APP, PSEN1 and PSEN2 – all genes associated with the generation of Ab – have
been described to date. While the effects of many of these mutations on Aβ
production have been studied extensively, a common unifying mechanism by which
fAD mutations lead to the development of AD has yet to be determined. For
example, fAD mutations in APP appear to have variable effects on Aβ production.
fAD caused by APP duplication or N-terminal mutations, such as the widely studied
APP Swedish mutation (APPswe), indiscriminately increase Aβs (Citron et al., 1992;
Mullan et al., 1992; Rovelet-Lecrux et al., 2006). In contrast, APP C-terminal
mutations that cluster around the g-secretase processing site appear to increase the
amount of longer, more hydrophobic Aβs (such as Ab42), relative to shorter Aβs
(such as Ab40), resulting in an increase in the Aβ 42:40 ratio with variable effects on
total Ab production (Eckman et al., 1997; Herl et al., 2009) (Figure 7). Similarly, it is
now widely agreed upon that mutations in PSEN1 also act to increase the Aβ 42:40
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ratio, in some cases even decreasing total Ab production (Borchelt et al., 1996;
Citron et al., 1992; Duff et al., 1996; Scheuner et al., 1996b). However, whether
these relative changes correspond with increased total Ab42 production, decreased
Ab40 production, or a combination of both remains debated (Kelleher and Shen,
2017b). Taken together, it remains unclear whether specific changes in APP
processing are common amongst all APP and PSEN1 fAD mutations, and whether
these potential common changes may be disease-relevant.
Aberrant changes in intracellular trafficking and the endocytic system have
become another plausible common underlying pathological mechanism in AD.
Genome-wide association studies and other human genetics approaches have
consistently identified variants in genes associated with endocytic trafficking to be
significantly associated with sAD risk (Giri et al., 2016; Karch and Goate, 2015).
Endosomal pathologies have also been observed in post-mortem sAD patient brains
and more recently in some cellular fAD models, and found to precede Aβ
accumulation (Cataldo et al., 2000; 2008; Israel et al., 2012; Raja et al., 2016;
Woodruff et al., 2016). Some studies have reported that early endosomal
abnormalities seen in AD, such as enlargement of Rab5+ early endosomes, may be
driven not by Aβ, but by b C-terminal fragments of APP (b-CTFs) (Jiang et al., 2010;
Kim et al., 2015; Woodruff et al., 2016; Xu et al., 2016), but others have reported Aβdependent endocytic trafficking defects (Treusch et al., 2011). These studies are
confounded by their use of non-human and/or non-neuronal cellular systems that
rely on massive overexpression of AD-associated proteins. Consequently, it
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remains to be determined in human neurons with physiologically relevant APP and
PSEN1 protein expression whether early endosomal abnormalities are a broadly
unifying disease-relevant phenotype associated with different fAD mutations.
With these open questions in mind we took advantage of our established
CRISPR/Cas9 gene editing frameworks described in Chapter II and Chapter III to
generate and study a comprehensive panel of isogenic homozygous and
heterozygous APP and PSEN1 fAD mutant human iPSCs. Upon differentiation into
human cortical neurons expressing APP and PSEN1 at endogenous levels, we
tested whether these mutations result in any common disease-associated
phenotypes. To address this question in an unbiased manner, we performed global
transcriptomic profiling of APP and PSEN1 mutant neurons, which revealed common
dysregulation in overlapping networks of AD-implicated genes as well as in
endocytosis-associated genes. Directed by these global pathway changes, we
identified functional early endosomal abnormalities in every homozygous pathogenic
fAD mutant iPSC-derived neuron line we generated, as measured by Rab5+ early
endosome enlargement, suggesting an effect of altered APP processing on the
endosomal system. We show that while APP and PSEN1 mutations have
discordant effects on the precise processing of APP and production of Ab peptides,
all fAD mutations studied cause a robust accumulation of longer Ab species (Ab43
and/or Ab42) as well as b-CTF. Taking advantage of established small molecules,
we show that early endosome enlargement could be rescued by inhibition of bsecretase (BACE), but not modulation of γ-secretase. Importantly, we also confirm,
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for the first time in human cortical neurons, that AD-associated Rab5+ early
endosome enlargement is associated specifically with endogenous accumulation of
b-CTF, and not longer Ab peptides or other APP CTF fragments. Together, our
study amplifies the relevance of Ab-independent endosomal defects as a common,
early pathological feature of fAD, and supports growing evidence that β-CTF may be
a significant contributor to AD pathology.

Unbiased molecular profiling of fAD mutant neurons reveals transcriptional
dysregulation of AD- and endocytic-associated genes.

As outlined in Chapter II, we employed our novel CRISPR/Cas9 gene editing
framework (Kwart et al., 2017; Paquet et al., 2016) to introduce two of the most
widely studied fAD mutations (APPswe and PSEN1-M146V) in wildtype human
iPSCs. In a preliminary analysis of differentiated disease-vulnerable neurons (details
of differentiation can be found in Appendix I), we noticed disease-associated Abrelated phenotypes that were different in APPswe neurons compared to PSEN1M146V neurons (Paquet et al., 2016). To investigate whether these two different
canonical fAD mutations result in any common disease-relevant phenotypes we
performed unbiased global transcriptomic profiling of wildtype, homozygous APPswe
and homozygous PSEN1-M146V iPSC-derived neurons by RNA sequencing (RNAseq). Additionally, to exaggerate cellular and molecular changes in pathways
affected by both APP and PSEN1 mutations, we profiled neurons from an additional
Swe/M146V “double knock-in” iPSC line (also shown as “dAP” below) that we
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generated (Figure 33), which contains both homozygous APPswe and PSEN1M146V fAD mutations.

Figure 33. Strategy for molecular profiling of isogenic APP and PSEN1
fAD mutant neurons.
Schematic describing strategy for generation of Swe/M146V double knock-in
iPSCs and molecular profiling strategy. APPswe and PSEN1-M146V iPSCs
were generated using the CIRSPR/Cas9 strategy outlined in Chapter II (and
see Appendix I). Swe/M146V iPSCs were generated by re-editing PSEN1M146V homozygous iPSCs and introduction of the APPswe mutation using
CRISPR/Cas9. All iPSCs were differentiated and cultured until DIV80 then
were used for molecular profiling.

We isolated RNA from mature (days in vitro 80 (DIV80)) wildtype and mutant
iPSC-derived neurons and performed RNA sequencing (RNA-seq) (see Appendix I
for sequencing library quality control analyses). We wished to determine at the
whole-genome level what types of genes and gene pathways are being differentially
regulated in mutant cells. Therefore, we performed a differential expression analysis
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to decipher all significantly differentially expressed genes in the three different
mutant neuron cell lines compared to wildtype (FDR < 0.05 and |Log2FC| >1)
(Figure 34A). Intriguingly, over 32% of all differentially expressed genes (856
genes) were common between one or more mutant cell lines, suggesting
overlapping gene expression and pathway perturbations may be an underlying
feature of both APP and PSEN1 fAD mutation pathogenicity (Figure 34B). To get a
handle on what these common differentially expressed genes are, we performed an
unbiased gene-ontology (GO) pathway analysis on the 856 genes commonly
dysregulated in the mutants compared to wild-type. The top most significantly
enriched GO-terms were related to synaptic functioning, GPCR signaling, and
neuronal development (Figure 34C). Interestingly, we noticed that a handful of the
genes in the top Synaptic Signaling GO-term hit were genes known previously to be
involved in AD (e.g., CLU, APOE, SORL1, GRIN3A, etc.). This lead us to wonder
whether there may be a more generalized change in expression of known ADassociated genes in fAD mutant neurons compared to wildtype. To assess
expression patterns of AD-associated genes in our fAD mutant cell lines we curated
a list of 114 putative “AD genes”, with identified AD-linked variants as determined by
GWAS (downloaded from https://www.ebi.ac.uk/gwas/) (see Appendix I for complete
list). We then determined the base Mean expression of these AD genes in our data
to give us an overview of similarities and differences in AD gene expression between
genotypes. Hierarchical clustering analysis revealed that P1SEN1-M146V and
Swe/M146V double mutant neurons had more similar expression patterns of AD
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genes, while APPswe neurons clustered more closely with wildtype neurons (Figure
34D). All mutant neurons were notably less correlated with wildtype cells. By
performing a hypergeometric statistical test, we found that AD genes were
significantly enriched amongst all genes differentially expressed in APPswe, PSEN1M146V and Swe/M146V neurons compared to wildtype. In fact, between 20-25% of
analyzed AD genes were differentially expressed in each mutant cell line compared
to wildtype (Figure 34E-G). Individual gene expression of these 39 differentially
expressed AD genes is shown (Figure 34F). These data suggest APP and PSEN1
fAD mutations may commonly perturb an AD-associated gene network.
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Figure 34. RNA-seq differential expression analysis reveals ADassociated genes as dysregulated in fAD mutant neurons.
A) MA-plots depicts the Log2FC (Y axis) and expression (TPM, X axis) of
differentially expressed genes in mutant neurons compared to wildtype cells.
B) Venneuler diagram showing the overlap of significantly differentially
enriched genes in mutant neurons as compared to wild-type. Determined by
R package DESEQ2. FDR < 0.05 & absolute Log2FC > 1. C) Metascape GO
analysis, plotted significance (log10 q-value) of top 500 enriched GO terms
determined by overlapping gene lists (B). X-axis = Ranked GO-term number;
Y-axis = -log10 q-value per GO-term. D) Heatmap of p value for Euclidean
distance analysis of AD gene expression in wildtype and mutant neurons.
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Each tile represents a single replicate (n=3); as expected replicates from each
genotype cluster closest together. Scale represents the Euclidean distance
between samples, calculated using the rlog-transformed values to avoid
dominating the distance measure by a few highly variable genes. E) Plotted
hypergeometric p-values of AD genes enriched within all significantly
differentially expressed genes (FDR < 0.05 & absolute LFC > 1). Numbers in
bars indicate number of AD genes enriched in differentially expressed gene
sets. F) Heatmap depicting expression (Log2 TPM) of all AD genes
significantly differentially expressed in mutant neurons (from E). G) Table of
AD genes differentially expressed in mutant cells compared to wildtype.
Column headers indicate in which mutant neurons listed AD genes are
differentially expressed (all compared to wildtype). Determined by R package
DESEQ2. FDR < 0.05 & absolute Log2FC > 1. dAP = Swe/M146V double
mutant.

Given that we were most interested in deciphering the molecular pathways
commonly perturbed by both APP and PSEN1 mutations, we next sought to
determine what gene expression differences are driven by APP and PSEN1
mutation combination in Swe/M146V double mutant neurons compared to APPswe
and PSEN1-M146V neurons alone. Using our differential expression analysis data,
we compared Swe/M146V neurons to APPswe and PSEN1-M146V single mutant
neurons independently and noticed a considerable number of differentially
expressed genes in each comparison. There were substantially more significantly
differentially expressed genes that either increased or decreased expression in
double mutant neurons compared to single mutant neurons than in single mutant
cells compared to wildtype. For example, we found PSEN1 mutant cells had 963
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differentially expressed genes compared to wildtype cells, but over 1.5 times more
(1465 genes) when compared to Swe/M146V cells (Figure 35A-B compared to
Figure 34A). These patterns of gene expression differences suggest that the
combination of fAD mutations in Swe/M146V neurons may be exaggerating or
augmenting AD-relevant transcriptomic changes. Interestingly, 60-70% of genes
differentially expressed in double mutant cells compared to single mutant cells are
non-overlapping, implying some unique “double-mutant effect” gene expression
signature may exist compared to when mutations are expressed alone (Figure 35C).
To better understand the nature of these changes, we performed another GO
analysis, this time inputting the list of all genes significantly differentially expressed
in Swe/M146V cells compared to single mutant neurons. Remarkably, we noticed
that of all the significant GO-terms identified a substantial number were associated
with endocytosis and lipid trafficking (Figure 35D). Of these enriched terms, the
largest gene-sets included the annotated ontologies “early endosome” (P = 10-4),
“endocytic vesicle” (P = 10-8) and “early endosome membrane” (P = 10-4).
Moreover, between 20 and 30% of all genes that comprise these GO-terms were
differentially expressed in our analysis. Together, approximately 100 unique
differentially expressed endocytic-related genes were included in these enriched
gene sets (see complete list of genes in Appendix I). When we compared
expression of these endocytic genes across all genotypes by hierarchical clustering,
we found that PSEN1-M146V and Swe/M146V neurons cluster more closely
together than with APPswe or wildtype neurons (Figure 35E), implying a similar
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pattern of endocytic gene expression between these two genotypes. Interestingly,
APPswe neurons showed patterns of endocytic gene expression that were markedly
uncorrelated with PSEN1-M146V and Swe/M146V neurons (see differences in
Figure 35E heatmap), supporting the idea that while both fAD mutations may
commonly affect endocytosis and endosomal related processes, they may do so by
influencing different molecular pathways. Expression levels of the top 45 expressed
endocytic genes is shown in Figure 35F.
Intriguingly, in addition to pinpointing the endocytic pathway, by comparing
genes differentially expressed in double mutant neurons compared to single mutant
neurons we also identified a substantial number of significantly enriched GO-terms
associated with known AD processes and neurodegeneration (Figure 35G). These
data indicate that the combination of APP and PSEN1 mutations may further interact
to activate AD-relevant downstream molecular neurodegenerative signaling
pathways.

Taken together, these transcriptomic analyses indicate that our APP

and PSEN1 fAD mutant human neurons demonstrate a common signature of ADassociated molecular phenotypes, which, in part, may converge on endocytic
dysfunction.
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Figure 35. Genes differentially expressed in Swe/M146V neurons are
associated with endocytic processes.
A-B) Volcano plots representing adjusted p value (-Log10) over the Log2 fold
change of Swe/M146V neurons compared to PSEN1-M146V (A) and
APPswe (B) neurons. Each dot is representative of a gene ID. Differential
analysis performed with R package DESEQ2. Blue and purple dots represent
genes that show significantly increased or decreased expression,
respectively. C) Venneuler diagram showing the overlap of significantly
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differentially enriched genes in Swe/M146V mutant neurons as compared to
PSEN1-M146V and APPswe neurons. Determined by R package DESEQ2.
FDR < 0.05 & absolute Log2FC > 1. D) Metascape GO analysis, plotted
significance (log10 q-value) of enriched endocytic/trafficking GO terms
determined by gene lists derived from (C). Y-axis = -Log10 q-value per GOterm. Size of spot and number indicate number of differentially expressed
genes enriched in each GO term. E) Heatmap of p value for Euclidean
distance analysis of endocytic gene expression in wildtype and mutant
neurons. Each tile represents a single replicate (n=3); as expected replicates
from each genotype cluster closest together. Scale represents the Euclidean
distance between samples, calculated using the Log-transformed values to
avoid dominating the distance measure by a few highly variable genes. F)
Heatmap depicting expression (Log2 TPM) of top 45 expressed endocytic
genes significantly differentially expressed in Swe/M146V mutant neurons
compared to single mutant cells (from D). dAP = Swe/M146V double mutant;
PS = PSEN1-M146V.

Early endosomal abnormalities are a unifying common phenotype in multiple
APP and PSEN1 fAD mutant iPSC-derived neurons.

Although APPswe and PSEN1-M146V are two of the most widely studied
mutations, they represent only a small fraction of the hundreds of fAD mutations that
have been identified, many of which alter amino acids within different gene domains
and contribute to variable clinical manifestations (Giri et al., 2016; Shea et al., 2016).
In order to better understand whether endosomal dysfunction is a shared common
phenotype across a variety of fAD mutations, we set out to generate a large and
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comprehensive panel of isogenic mutant human iPSCs. We strategically chose to
include in our study 3 different known APP mutations that are differentially
distributed across the APP gene and predicted to differentially influence b-secretase(APPswe), a-secretase- (APP-A692G) or g-secretase- (APP-V171G) related
processing (Chartier-Harlin et al., 1991; Hendriks et al., 1992; Mullan et al., 1992)
(Table 2 and see schematic in Figure 7). Four PSEN1 mutations (PSEN1-M146V,
PSEN1-L166P, PSEN1-M233L and PSEN1-A246E) distributed across the gene with
different predicted severities were also selected for our analyses (Aldudo et al.,
1999; Alzheimer's Disease Collaborative Group, 1995; Moehlmann et al., 2002;
Sherrington et al., 1995) (Table 2). Mutant iPSC lines were all generated by
CRISPR/Cas9-mediated mutation knock-in using our established common wildtype
parental cell line (see Appendix I), therefore making all additional cell lines studied
completely isogenic and avoiding any contribution of non-specific phenotypes due to
background genetic heterogeneity. iPSCs were then differentiated into human
cortical neurons to study endosomal phenotypes (differentiation procedure described
in Appendix I).
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Table 2. List of all isogenic mutant iPSC lines and mean age of AD
onset.

1- From DIAN study (Ryman et al., 2014)
2- From (Moehlmann et al., 2002)

It has now been demonstrated in a variety of different model systems that
early endocytic dysfunction, such as an aberrant enlargement of Rab5+ early
endosomes, may be a common upstream pathological hallmark feature of AD
(Cataldo et al., 2000; 2008; Israel et al., 2012; Raja et al., 2016; Woodruff et al.,
2016). However, it is unclear whether early endosome pathology can be assayed in
isogenic mutant human iPSC-derived neurons, and not known whether it is common
to multiple different APP and PSEN1 fAD mutations. To explore this, we used high
resolution and quantitative immunofluorescence to study Rab5+ early endosome
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morphology in all our APP, PSEN1 and double knock-in mutant iPSC-derived
neurons. Strikingly, we noticed in all homozygous mutant neurons a significant
increase in the size of Rab5+ early endosomes (Figure 36A-B), which also
corresponded with increased fluorescence intensity (Figure 36C). Interestingly, we
did not see any consistent differences in the total number of Rab5+ early
endosomes per cell across our panel of isogenic mutant iPSC-derived neurons
(Figure 36D). This endosome size change is specifically driven by an overall
decrease in the number of small endosomes (<0.5µm2) and a much larger increase
in the number of larger (>1µm2) endosomes (Figure 36E). Interestingly, Rab5+
endosome enlargement was significantly exaggerated in the Swe/M146V double
knock-in neurons compared to single homozygous and wildtype cells (Figure 36AB), suggesting the mutations in these two genes may pathologically converge on a
common cellular mechanism. While heterozygous mutant cells did not all
demonstrate significant differences in mean endosome area or frequency of
enlarged endosomes, many heterozygous mutant neurons displayed intermediate
phenotypes compared to homozygous counterparts (Figure 36F-G).
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Figure 36. Early endosomal abnormalities are a shared APP-dependent
common phenotype in APP and PSEN1 fAD mutant iPSC-derived
neurons.
A) Representative immunofluorescence images from homozygous mutant
human neurons stained for Rab5 (green), MAP2 (red) and Hoechst (blue).
The sizes of Rab5+ puncta were quantified using Imaris. B) All mutant cells
demonstrate increased mean Rab5+ endosome size compared to wildtype.
C) Mean fluorescence intensity of Rab5+ punta increases in all fAD mutatnt
cells compared to wildtype. D) Total number of Rab5+ early endosomes per
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cell does not consistently change in each fAD mutant line. Values represent
mean ± SEM. **P < 0.05 and ***P < 0.001, ****P < 0.0001, one-way ANOVA
with comparison to wildtype.

##P

< 0.05 and ###P < 0.001, ###P < 0.0001, one-

way ANOVA with comparison to Swe/M146V. E) The size distribution of
Rab5+ puncta of all fAD mutant neurons compared to wildtype shows a shift
from smaller to larger Rab5+ early endosomes. Values represent mean ±
SEM and P values represent two-way ANOVA with comparisons to wildtype.
Mean endosome size (F) and frequency of large endosomes (G) of all
heterozygous APP and PSEN1 mutant neurons compared to wildtype.
Values represent mean ± SEM. **P < 0.05 and ***P < 0.001, ****P < 0.0001,
one-way ANOVA with comparison to wildtype.
###P

##P

< 0.05 and ###P < 0.001,

< 0.0001, one-way ANOVA with comparison to Swe/M146V WT =

wildtype. n=12-20 cells analyzed. Scale bar, 10µm.

APP and PSEN1 fAD mutations increase accumulation of longer Abs and APP
b-CTFs in human neurons.

It is widely thought that fAD mutations contribute to AD pathogenesis by
aberrantly affecting APP processing and Ab production. Therefore, we next sought
to characterized how APP and PSEN1 mutations affect APP metabolism and to
pinpoint which APP peptides may represent a common correlate associated with
endosomal dysfunction. APP is cleaved initially and most often by a-secretase at the
cell surface, which, by cleaving within the amyloid portion of the protein, precludes
the generation of Ab (Figure 37A). To generate Ab, APP is first endocytosed, and
within an early endocytic vesicle is subsequently cleaved by b-secretase cleavage
enzyme (BACE), as the activity of BACE is favored by the acidic endocytic
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environment. BACE cleavage of APP produces APP b-CTF, which is then further
processed by g-secretase to yield Abs of varying length (Figure 37A-B). It is now
widely accepted that the mechanism by which γ-secretase cleaves APP b-CTF is
processive in nature. In short, γ-secretase cleaves b-CTF in 3-4 amino acid
increments generating Abs of different lengths, most commonly 38 or 40 amino
acids in length (Figure 37B) (Szaruga et al., 2017; Takami et al., 2009).
When we analyzed various species of Ab secreted by mutant human cortical
neurons, we noted only one common trend across all pathogenic fAD mutant lines.
Levels of longer Abs, namely Ab43 and/or Ab42, were increased in cell culture
supernatants of all APP and PSEN1 mutant neurons compared to wildtype cells
(Figures 37C-D). Levels of shorter Ab, however, were not changed in a consistent
way across APP and PSEN1 mutant neurons. Specifically, all APP mutants had
increased Ab38 compared to wildtype, whereas all PSEN1 mutants significantly
decreased Ab38 (Figure 37E). Similarly, the APPswe and APP-A692G mutants
increased Ab40, whereas all PSEN1 mutants decreased Ab40 (Figure 37F).
Interestingly, the APP-V717G mutant, which lies at the g-secretase cleavage site,
decreased Ab43 and Ab40 compared to wildtype, highlighting how this mutation
shifts g-secretase processing toward the Ab42 and Ab38 pathway (Figures 37B, D
and F). When levels of all Ab species measured were summed together to quantify
total Ab levels compared to wildtype, APP and PSEN1 mutant cells again had
opposite effects, with APPswe and APP-A692G mutants increasing total Ab, and all
PSEN1 mutants decreasing total Ab (Figure 37G).
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We next calculated the Ab 42:40 ratio, which has been widely used to
determine AD severity in cases of both sAD and fAD. We observed that the
APPswe and APP-A692G mutants had no effect on the Ab 42:40 ratio, whereas the
APP V717G mutants, and all PSEN1 mutants increased the Ab 42:40 ratio (Figure
37H). PSEN1-L166P most dramatically affected the Ab 42:40 ratio (~14-fold
increase compared to wildtype), which corresponds with how clinically severe this
mutation is known to be (age of onset in 20’s, Table 2). Interestingly, Swe/M146V
double knock-in neurons demonstrated an Ab profile consistent with combinatorial
effects of both the APPswe and PSEN1-M146V mutation, i.e., Swe/M146V neurons
had substantially higher levels of all Ab peptides measured, as well as elevated Ab
42:40 ratio (Figure 37C-H).
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Figure 37. APP and PSEN1 mutations increase production of longer Ab
peptides.
A) Schematic of APP processing and representation of distribution of APP
mutations engineered as described in Table 1. B) Schematic of g-secretase
processing of b-CTF to generate Abs of varying length. PSEN1 mutations
depicted to represent the g-secretase cleavages processes that may be
affected. C-H) Ab measurements in APP, PSEN1 and Swe/M146V double
mutant neurons (DIV60-70) compared to wildtype. Represented as foldchange compared to wildtype. Supernatants analyzed for C) Ab42, D) Ab43,
E) Ab38 and F) Ab40 by ELISA. G) All Abs measured were summed together
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to determine total Ab, and H) the ratio of Ab 42:40 was calculated. Values
represent mean (n=3 biological replicates) ± SEM **P < 0.05 and ***P <
0.001, ****P < 0.0001, one-way ANOVA, outliers identified by ROUT method
(Q = 1%).

Amyloidogenic processing of APP for Ab generation depends on b-secretasemediated generation of b-CTF, whereas non-amyloidogenic processing occurs when
APP is instead first cleaved by a-secretase to generate a 16 amino acid shorter
peptide called a-CTF. Both b- and a-CTF are substrates for subsequent cleavage by
g-secretase. Therefore, in addition to Ab production, fAD mutations, by affecting a-,
b- and g-secretase cleavage, may also affect the metabolism of b- and/or a-CTF.
When examining APP CTFs by Western blot, we noted the presence of five distinct
bands, which have previously been reported to be the phosphorylated and
dephosphorylated b-CTFs (C99/p-C99 and C89/p-C89) and a-CTFs (C83/p-C83),
with C89 and p-C83 overlapping (Buxbaum et al., 1998) (Figures 38A-B). We
noticed that APP and PSEN1 mutants demonstrated variable effects on a-CTF
metabolism (Figure 38C). However, all APP and PSEN1 mutant human neurons
exhibited an accumulation of b-CTF (Figure 38D). Swe/M146V neurons further
demonstrated an additive effect of the PSEN1 and APP mutations on CTF
accumulation, resulting in substantially higher levels of accumulated b-CTF
compared to all single mutant and wildtype neurons (Figure 38).
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Figure 38. APP and PSEN1 fAD mutations increase accumulation of
APP b-CTFs.
a-CTF and b-CTF levels were analyzed by western blot in APP (A) and
PSEN1 (B) mutant neurons and were quantified using densitometry (C and
D). Swe/M146V double mutant neurons were included in both blots for
comparison. Western blot densitometry values represent mean (n=3
replicates) ± SEM **P < 0.05 and ***P < 0.001, ****P < 0.0001.

Taken together, these data demonstrate that although different APP and
PSEN1 fAD mutations may variably affect APP processing and Ab generation,
common trends across all mutations do exist. Specifically, in all APP and PSEN1
fAD mutant cells we detected increased levels of longer Abs and b-CTF, which are
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therefore candidates for being critical APP-derivatives most relevant to the
development of AD.

Early endosomal enlargement in human fAD mutant neurons is dependent on
APP processing and can be rescued by BACE inhibition.

fAD mutant iPSC-derived neurons all demonstrate endosome
enlargement as well as elevated longer Abs and accumulation of b-CTF. Therefore,
if these cellular and biochemical changes are related, then genetic manipulations to
lower Abs and b-CTF may reverse the endosomal phenotype. To test this we used
our isogenic mutant iPSC line with the protective APP-A673T mutation knocked-in at
both alleles (Jonsson et al., 2012; Kwart et al., 2017; Paquet et al., 2016). The APPA673T mutation is directly adjacent to the APPswe mutation near the b-secretase
processing site of APP (Figure 37A and Figure 7). When we examined the various
b-CTFs, we noted no change in total b-CTFs between APP-A673T and WT (Figure
39B and D). However, APP-A673T mutant neurons demonstrated a shift in APP
processing that trended (albeit not significantly) towards an increase in the
production of non-amyloidogenic C89 b-CTFs (Figure 39B-C), along with a
reduction in total Ab (Figure 39A). In addition, we studied an isogenic APP knockout
(APP-KO) iPSC line that we generated using CRISPR/Cas9-mediated deletion of the
conserved APP transcription start-site (see details on APP-KO iPSC generation in
Appendix I). As expected, APP-KO iPSC-derived neurons had undetectable levels
of Ab (Figure 39A). When studying endosome morphology, APP-KO neurons
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demonstrated a highly significant reduction in Rab5+ endosome size compared to
wildtype; APP-A673T neurons also showed a trend towards reduction, but it was not
significant (Figure 39E-F). When analyzing the frequency distribution of endosome
size, we found APP-KO neurons have a significant increase in the number of small
endosomes (<0.5µm2) and reduction in the number of medium-sized endosomes
(0.5-1µm2) (Figure 39G). These results support the view that endosome pathology
seen in APP and PSEN1 mutant neurons is indeed dependent on APP and its
altered processing caused by fAD mutations, confirming recent findings. Taken
together, these data further support the notion that amyloidogenic APP processing is
capable of causing endocytic abnormalities seen in mutant human neurons.
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Figure 39. Rab5+ early endosomes enlargement is APP-processing
dependent.
Total Ab (A), Ab 42:40 ratios (B) as well as FL-APP and APP-CTFs (C) were
measured in protective APP-A673T mutant and APP-KO neurons by ELISA
and western blot, respectively. D) APP-A673T shifts APP processing towards
a-CTF generation. E) Representative immunofluorescence images from
wildtype, APP-A673T and APP-KO stained for Rab5 (green), MAP2 (red) and
Hoechst (blue). F) Mean Rab5+ endosome area per cell (n=18-23 cells), and
G) frequency distribution of endosome size. Values represent mean ± SEM.
**P < 0.05 and ****P < 0.0001, one-way ANOVA (F) or two-way ANOVA (G)
with comparisons to controls.

##P

< 0.001, one-way ANOVA compared to

wildtype. Scale bar, 10µm.

In pathogenic fAD mutant neurons, endogenous Ab and b-CTF levels can be
manipulated by treatment with a b-secretase inhibitor (BACEi), which should prohibit
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amyloidogenic processing of APP. We confirmed in Swe/M146V neurons, which
demonstrated the largest increase in Ab production, that BACEi treatment
significantly decreases total Ab production (Figure 40A), and almost completely
prevents the generation of b-CTF in L166P homozygous neurons, which showed the
largest increase in all detectable APP-CTFs (Figure 40B). Interestingly, endosome
enlargement seen in all APP and PSEN1 mutant iPSC-derived neurons was
significantly rescued by BACEi treatment (Figure 40C-D). Taken together, these
rescue experiments further support that in human neurons, Rab5+ early endosome
morphological changes seen in fAD are mediated by endogenous changes in APP
processing caused by APP and PSEN1 mutations and can be rescued
pharmacologically by BACEi treatment.
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Figure 40. Rab5+ early endosomes enlargement can be rescued by
BACEi treatment in fAD mutant neurons.
A) Compared to DMSO control, BACEi treatment of Swe/M146V double
mutant neurons nearly abolishes Ab production with concomitant reduction of
b-CTF, as determined by western blot (B). Representative images of Rab5
(green), MAP2 (red) and Hoescht (blue) staining (C) and quantification (D)
showing BACEi treatment of homozygous mutant APP and PSEN1 neurons
significantly reduces endosome size (n=10-20 cells). The sizes of Rab5+
puncta were quantified using Imaris. Values represent mean ± SEM. **P <
0.05 and ****P < 0.0001, two-way ANOVA with comparisons to controls.
Scale bar, 10µm.
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Rab5+ early endosomes enlargement is not rescued by reducing longer Ab
peptides with a γ-secretase modulator.

Although some previous studies have also implicated APP b-CTF as a
plausible contributor to intracellular trafficking defects in AD (Jiang et al., 2010; Kim
et al., 2015; Woodruff et al., 2016; Xu et al., 2016), other studies suggesting longer
Abs are relevant to endocytic dysfunction have also been reported (Treusch et al.,
2011). Many of these studies did not investigate AD-related endosomal defects in
human neurons, were confounded by their use of non-physiological APP (or b-CTF
or Ab) overexpression, or did not precisely separate the contribution of Abs from that
of b-CTF. We therefore aimed to determine in mutant iPSC-derived neurons with
endogenous APP and PSEN1 expression whether endosome enlargement seen in
fAD neurons is specifically associated with longer Abs and/or b-CTF.
We tested the contribution to endosome dysfunction of longer Abs by treating
neurons with a g-secretase modulator (GSM). GSMs are a class of AD therapeutics
engineered to alter g-secretase function without blocking activity (Crump et al., 2013)
(inhibitors of g-secretase were found to be ineffective in clinical trials and actually
made patient symptoms worse). We tested the effect of a GSM on PSEN1-M146V,
PSEN1-L166P and Swe/M146V homozygous mutant neurons, all of which
accumulate longer Abs through a consistent loss of g-secretase processivity
(Figures 37 and 38). Wildtype neurons were treated for comparison. GSM
treatment had no apparent effect on total Ab production (Figure 41A), but in
wildtype, M146V and Swe/M146V cells GSM resulted in a robust reduction of longer
140

Ab production concomitant with an increase in production of shorter Ab (Figure 41BF). Interestingly, GSM treatment did not result in any significant overall changes in
longer versus shorter Ab levels in PSEN1-L166P homozygous mutant neurons
(Figure 41B). This result is of particular interest, since the PSEN1-L166P mutation
is the most severe mutation we studied (see Table 2), and suggests that this
mutation is so detrimental to g-secretase that the GSM had no effect.
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Figure 41. Ab analysis of GSM treated wildtype and fAD mutant iPSCderived neurons.
A) Wildtype and mutant neurons treated with a GSM does not alter total Ab
production (Ab 38+40+42+43) but shifts processing to increase longer Abs
(42+43) relative to shorter Abs (38+40) (B) compared to DMSO control. C)
Treatment of GSM results in Ab42 levels to be significantly reduced in all
neurons except for PSEN1-L166P homozygous cells. D) GSM treatment
results in a corresponding increase in Ab38 levels. E) Ab43 is more subtly
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reduced in all neurons with treatment of GSM. F) Ab40 levels are relatively
unchanged by GSM treatment compared to DMSO. Values represent mean
(n=3 biological replicates) ± SEM. **P < 0.05 and ***P < 0.001, ****P <
0.0001, two-way ANOVA, outliers identified by ROUT method (Q = 1%).

GSM treatment did not affect b-CTF (or a-CTF) levels as analyzed by western
blot (Figure 42A-B), highlighting how this class of drug selectively affects gsecretase processivity (carboxypeptidase) and not endopeptidase (e) cleavage in
human neurons (Figure 37B). Remarkably, treatment with GSM failed to rescue the
Rab5+ endosome enlargement in mutant neurons compared to control conditions
(Figure 42C-D), suggesting that endogenous accumulation of longer Ab in fAD
mutant neurons alone does not contribute to the early endocytic dysfunction in AD.
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Figure 42. GSM treatment does not affect APP-CTF levels nor rescue
endosome enlargement in mutant neurons.
GSM treatment does not alter a-CTF and b-CTF, as analyzed by western blot
(A) and quantified by densitometry (B). Representative images of Rab5
(green), MAP2 (red) and Hoescht (blue) staining (C) and quantification (D) for
GSM treated PSEN1-M146V, L166P and Swe/M146V double mutant neurons
(n=10-20 cells). Values represent mean ± SEM. ns = not significant, two-way
ANOVA with comparisons to control. Scale bar, 10µm.

144

Increasing endogenous APP b-CTF in wildtype human neurons causes early
endosome enlargement.

Recent studies have relied on using overexpression of APP b-CTF in either
rodent neurons or non-neuronal cell lines to test whether APP b-CTF is sufficient to
cause early endosome dysfunction (Jiang et al., 2010; Kim et al., 2015; Xu et al.,
2016). APP b-CTF is a rare and transient intermediate APP metabolite, and its
generation and trafficking is tightly regulated by concerted b-, a- and γ-secretase
activity (Haass et al., 2012). Therefore, b-CTF overexpression is not only nonphysiological, but more importantly may inadequately recapitulate the normal
trafficking and biological relevance of the peptide. We therefore aimed to study the
effect of increasing endogenous APP b-CTF on early endosome morphology without
overexpression in wildtype human iPSC-derived neurons pharmacologically.
Wildtype neurons were treated with a γ-secretase inhibitor (GSi), which effectively
eliminates secreted Ab production (Figure 43A). Since g-secretase cleaves b-CTF
to generate Ab, g-secretase inhibition also results in an accumulation of b-CTF in
wildtype neurons (Figure 43B). In wildtype neurons, g-secretase more commonly
cleaves a-CTF, which exists at much higher levels than b-CTF. Therefore, GSi
treatment also much more robustly increases the levels of a-CTF compared to bCTF in human neurons (Figure 43B). b-CTF only subtly differs from a-CTF, which
lacks the N-terminal 16 amino acids of b-CTF. To be able to separate b-CTF from
a-CTF, we combined GSi and BACEi treatment, which results in an increase in
levels of endogenous a-CTF but not b-CTF (Figure 43B). We found that GSi and
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BACEi treatment together did not affect endosome size, however treatment with GSi
alone was sufficient to induce the enlargement of Rab5+ early endosomes
compared to DMSO (Figure 43C-E).

Figure 43. Increasing endogenous APP b-CTF in wildtype human
neurons causes Rab5+ early endosome enlargement.
A) Wildtype neurons treated with a GSi nearly abolishes total Ab production.
B) GSi treatment of wildtype neurons dramatically increases both a-CTF and
b-CTF, while co-treatment of wildtype neurons with GSi and BACEi results in
an increase of only a-CTF measured by western blot. Representative images
of Rab5 (green), MAP2 (red) and Hoescht (blue) staining (C) and
quantification (D) showing wildtype neurons treated with GSi results in
significantly increased mean Rab5+ endosome size and number of larger (>1
µm2) endosomes (E), while co-treatment with GSi and BACEi has no effect.
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F) and G) treatment of APP KO neurons with GSi has no effect on endosome
size compared to DMSO control. The sizes of Rab5+ puncta were quantified
using Imaris. Values represent mean ± SEM (n=16-19 cells). **P < 0.05 and
***P < 0.001, **** P < 0.0001, one-way ANOVA (D), two-way ANOVA (E and
G) or t-test (A and F) compared to control. Comparisons in F and G are all
not significant. Scale bar, 10µm.

Lastly, to confirm that GSi and BACEi treatment are on-target and influencing
endosome morphology through APP b-CTF, we repeated the GSi treatment in APPKO iPSC-derived neurons. GSi treatment had no effect on Rab5+ early endosome
size in APP-KO neurons (Figure 43F-G), indicating that GSi-induced endosome
enlargement depends on APP and therefore most likely b-CTF. In summary, these
data confirm that pathological endogenous APP b-CTF accumulation seen in fAD
mutant human neurons may be both sufficient and necessary for common early
endosome dysfunction associated with AD.

Conclusions

It has been known for nearly 30 years that mutations in APP and PSEN1
cause AD, but precisely how these mutations in two distinct genes result in the same
disease remains incompletely understood. In this study we generated a large panel
of isogenic fAD mutant iPSC-derived neurons to study underlying common ADrelevant pathological processes in human neurons. Guided by unbiased molecular
profiling, we found that select APP and PSEN1 mutant neurons share common sets
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of dysregulated genes enriched in pathways associated with AD and with
endocytic/endosomal processes. We expanded on these transcriptomic analyses to
show functionally that all fAD mutant neurons studied displayed early endosome
abnormalities, as assessed by assaying Rab5+ early endosome morphology. Since
APP and PSEN1 converge mechanistically on APP processing, we studied APP
metabolism in fAD mutant neurons to decipher the precise common diseaseassociated APP peptide correlates, which may be relevant to endosome biology.
We found that while APP and PSEN1 mutations tend to have largely dissimilar
effects on APP metabolism, all mutations increase levels of longer, more
hydrophobic Abs, as well as b-CTF. Most importantly, we showed in human
neurons that fAD-associated endosomal dysfunction is correlated specifically with
accumulation of β-CTF, not increased longer Aβ peptide production. These results
expand the understanding of disease-relevant phenotypes shared between APP and
PSEN1 mutations and contribute to a growing body of literature implicating
endosomal-lysosomal dysfunction and elevated b-CTF as a common underlying
pathological feature of both fAD and sAD (Nixon, 2017; Small et al., 2017).

Discussion

Our study relied on recently developed CRISPR/Cas9 technology to generate
one of the largest and most diverse panel of human iPSC lines carrying autosomal
dominant fAD APP and PSEN1 mutations knocked into a single wildtype parental
cell line. This approach has many advantages, including the ability to study
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phenotypes in disease-relevant cell types by differentiating iPSCs into AD-vulnerable
cortical neurons and studying these phenotypes under endogenous and more
physiological levels of mutant protein expression. Most importantly, this approach
eliminates potential off-target contribution of reprogramming or differences in genetic
background when comparing cell lines from non-isogenic donors. To date, multiple
groups have used iPSC-derived neurons to study fAD, but these past investigations
either used non-isogenic controls (Israel et al., 2012; Liu et al., 2014a; Moore et al.,
2015; Nieweg et al., 2015; Sproul et al., 2014; Yagi et al., 2011), used
overexpression of mutant transgenes (Honda et al., 2016; Koch et al., 2012), or
narrowly focused on only one or two different fAD mutations (Karch and Goate,
2015; Maloney et al., 2014; Oksanen et al., 2017; Ortiz-Virumbrales et al., 2017;
Paquet et al., 2016; Woodruff et al., 2016; 2013). In our study, using a
CRISPR/Cas9 gene-editing framework that we recently described (Kwart et al.,
2017; Paquet et al., 2016), we engineered and studied 16 different isogenic iPSC
lines with different mutations in APP and PSEN1 (Table 1), including an APP
protective mutation and APP knock-out. Additionally, using CRISPR/Cas9-mediated
“double knock-in”, we report findings from an APPswe/PSEN1-M146V double
mutant iPSC-line. As with mouse models, we found that the combination of APPswe
and PSEN1-M146V mutations causes more robust AD-relevant phenotypes, such as
aberrant changes in APP processing and endosomal morphology. In the future, this
cell line may serve as a valuable platform for basic disease mechanism discovery as
well as novel drug testing. With this comprehensive collection of fAD stem cell lines
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in hand, we are well positioned to compare the effects of multiple different fAD
mutations and identify relevant changes in APP metabolism and downstream cellular
consequences that may have not previously been fully appreciated.
We took advantage of these isogenic lines to carry out unbiased genomewide molecular profiling of mutant cells. Our RNA-sequencing data, comprising
differential expression and pathway analyses, will soon be made publicly available.
These comprehensive datasets will assist future studies probing differential gene
expression and pathway dysregulation in AD. In the present study, we aimed to
identify commonly perturbed disease-associated cellular processes. The fact that
there are distinct genes differentially expressed in APP and PSEN1 mutant iPSCderived neurons is interesting but not entirely unexpected, since both APP and
PSEN1 are integral to a variety of overlapping but also distinct cellular processes. It
was of interest, then, that we found multiple common endocytic/endosomal
trafficking-associated genes that were significantly differentially expressed in all fAD
mutant neurons. Many of these trafficking-related genes have previously been
implicated in late-onset AD risk (e.g., SORL1, CLU, APOE, etc.), suggesting there is
a common network of cellular and molecular changes that may underlie both sAD
and fAD pathogenesis.
Our molecular profiling data support the emerging view that intracellular
trafficking defects may be an important common pathological process associated
with AD and other neurodegenerative diseases (Wang et al., 2014). Less clear,
however, is whether trafficking deficits broadly characterize both sAD and fAD
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caused by APP and PSEN1 mutations. Previous clinical work has strongly
implicated early endosome dysfunction in sAD as a preclinical change preceding
amyloid plaque and tangle deposition (Cataldo et al., 2000). A few studies
investigating early endosomal-related defects in fAD have been reported, though
they are limited by use of non-human and non-neuronal cell lines with
overexpression or non-isogenic human iPSC-derived neurons, and are all limited by
studying only a small number of fAD mutations (Israel et al., 2012; Kim et al., 2015;
Muratore et al., 2014; Xu et al., 2016). Our analysis using multiple different isogenic
fAD APP and PSEN1 knock-in mutant human iPSC-derived neurons revealed the
presence of significant Rab5+ early endosome enlargement in all lines, supporting
endocytic changes as a potentially unifying pathological hallmark of AD.
When characterizing the effects of APP and PSEN1 mutations on APP
processing, we found that the total amounts of longer Ab species (Ab43 and/or
Ab42) as well as b-CTFs were consistently elevated in a zygosity-dependent manner
for all fAD mutant cell lines studied. We found in neurons that mutations in APP at
the b-secretase and a-secretase sites generally increase the total amount of Ab, as
seen in the APPswe and APP-A692G mutants, respectively. Furthermore, by
shifting secretase processing, both APPswe and APP-A692G mutations increase
levels of b-CTFs. Interestingly, mutations at the g-secretase site of APP, such as
APP-V717G, result in altered g-secretase processing of b-CTF, shifting the
processing of Ab towards Ab42 and Ab38. In addition, we found that the APP-
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V717G mutation also causes an accumulation of both a- and b-CTFs, suggesting
that the mutation also globally impairs g-secretase peptidase cleavage.
We strategically chose to study 3 different APP mutations, as these represent
the vast majority of known APP fAD mutations which confer pathogenicity by
modifying APP processing by either b-, a- or g-secretase. Interestingly, there are a
few APP mutations very close to the APP-A692G site (E693 and D694) that in past
studies have been shown not to affect secretase cleavage of APP at all. In fact,
these mutations tend to result in clinically distinct versions of AD, namely, cerebral
amyloid angiopathy (CAA), which unlike more widely studied forms of AD involves
more vascular defects including strokes, hemorrhages and resulting cognitive
decline (Bugiani et al., 2010; Grabowski et al., 2001; Levy et al., 1990; Van
Broeckhoven et al., 1990). In CAA, Ab (typically Ab40) accumulates in cerebral
vessels and plaques are diffuse in the brain parenchyma (Bugiani et al., 2010;
Timmers et al., 1990). Past studies have mostly shown that these mutations have
no effect on Ab production, but instead alter the propensity of Abs to aggregate and
fibrillize (Van Nostrand et al., 2001; 2002; Wisniewski et al., 1991). These mutations
therefore should not affect production of b- or a-CTF and therefore may not
influence endosome morphology, however this hypothesis has yet to be adequately
tested. Given the marked differences in clinical and symptomatic presentation
between APP E693/D694 mutations and other APP fAD mutations near secretase
processing sites, it is possible these different types of mutations reflect distinctly
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different diseases, and endosome dysfunction/b-CTF may commonly underlie the
pathogenicity of non-CAA types of AD.
In contrast to APP, all PSEN1 mutations appear to alter the processing of
APP by impairing g-secretase activity. Previous studies probing the effects of
PSEN1 fAD mutations have often converged on a common increase in the Ab 42:40
ratio. However, multiple conflicting studies have led to a debate whether this change
in the ratio is caused by increasing Ab42, decreasing Ab40, or a combination of
both. Moreover, given that multiple APP mutations have little or no effect on the Ab
42:40 ratio, it is unclear how relevant this measure is to pathology. Furthermore,
recent studies have shown that some PSEN1 mutations may be so severe they
result in complete loss of Ab40 and Ab42 generation (Veugelen et al., 2016; Xia et
al., 2015), thereby underscoring the need to understand how all Ab peptides,
including longer Abs such as Ab43, are affected by mutations in human neurons.
Our analysis of specific Ab peptides is consistent with a growing appreciation
in the field that PSEN1 mutations confer a partial loss of g-secretase processivity. In
all PSEN1 mutant neurons, Ab42 and Ab43 were increased, while Ab38 and Ab40
were correspondingly decreased, suggesting the mutations impair g-secretase ability
to adequately process b-CTF and Abs into the shortest possible peptides.
Furthermore, all PSEN1 mutant neurons displayed decreased production of total
measured Ab, which may be a result of overall reduced g-secretase activity. On the
other hand, this may reflect a shift in production towards longer Ab peptides (e.g., 45
or 46 amino acids) that our assay did not detect (Szaruga et al., 2017). Interestingly,
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mutant neurons harboring the L166P mutation (one of the most aggressive fAD
mutations known (Moehlmann et al., 2002)) demonstrated the most severe
alterations in Ab production, particularly in a drastic increase in Ab43, and
corresponding reduction in Ab40 and Ab38. As a result of these alterations in Ab
production, the Ab 42:40 ratio, and even more so the Ab 42:38 and Ab 43:40 ratios
(data not shown), were significantly increased. In addition, all PSEN1 mutants
showed increased levels of b-CTF, which likely explains the corresponding reduction
in total amount of Ab generated. Importantly, a-CTF is also consistently increased in
all PSEN1 mutant neurons, further suggesting global impairment of g-secretase
processivity. In this study we only analyzed 4 different PSEN1 mutations, however
to date over 150 pathological PSEN1 fAD mutations have been discovered. While
new experimental evidence (including ours) continues to overwhelmingly converge
on a common mechanism of pathogenicity involving loss of g-secretase processivity,
it would still be meaningful to continue to assess how consistent our detected
changes in Ab, CTF and endosome morphology are with other PSEN1 mutations, for
example mutations that are known to more severely alter g-secretase activity and Ab
production.
Our study compared multiple mutations known to cause fAD in both APP and
PSEN1 genes. As mentioned before, mutations in another gene, PSEN2, have also
been found to cause fAD. Therefore, one outstanding question is whether or not the
effects we see in APP and PSEN1 mutant neurons would also be seen in PSEN2
mutant cells. PSEN2 and PSEN1 are highly homologous and each can form the

154

catalytic subunit of the g-secretase complex (De Strooper et al., 2012). In neurons
expression of PSEN2 is much lower than PSEN1 (we also found this in our RNA-seq
analysis) and many believe that there may be different substrate specificities for
PSEN1- versus PSEN2-containing g-secretase (De Strooper et al., 2012; Sannerud
et al., 2016). There are over 150 mutations in PSEN1 known to cause fAD, whereas
only about a dozen have been identified in PSEN2 (An et al., 2015). As a result,
PSEN1 has been much more studied in the literature. Furthermore, PSEN2
mutations tend to result in disease with later onset age and are less penetrant (An et
al., 2015). Many studies including in human iPSC-derived neurons, have concluded
that similar to PSEN1 mutations, many mutations in PSEN2 also result in an
increase in the Ab 42:40 ratio, which is most likely due to increased Ab42 and
reduced Ab40 production (Ortiz-Virumbrales et al., 2017; Walker et al., 2005). If this
is indeed true, it is likely that impaired PSEN2-containing g-secretase would also
result in an increase of both a- and b-CTF. It has been recently shown that PSEN1
and PSEN2 may most greatly differ in their subcellular localization and trafficking,
with PSEN2-containing g-secretase complexes being much more highly
concentrated in endosomal and lysosomal compartments (Sannerud et al., 2016).
Given this differential localization it would be expected that impaired activity of
PSEN2-containing g-secretase within endosomes may cause a significant
accumulation of b-CTF within these compartments, since it is predominantly within
endosomes where b-CTF is cleaved by g-secretase. If this prediction holds true, I

155

would predict PSEN2 mutations disrupt endosome morphology similarly or even
more severely than PSEN1 mutations.
We strategically combined widely available pharmacological agents to
manipulate endogenous levels of both Abs and APP CTFs in our wildtype and
mutant human neurons. Specifically, under endogenous gene expression, we were
able to isolate the effect of longer Abs from that of APP CTFs by using GSMs, and
showed the effect of b-CTF could be discriminated from that of a-CTF using the
combination of g-secretase inhibitor and b-secretase inhibitor. Such simple
pharmacological manipulations could easily be applied to other cellular systems that
are similarly difficult to manipulate, such as primary rodent neurons. Using these
approaches, we show that Rab5+ endosome enlargement is associated with
elevated b-CTF, not a-CTF or Ab.
It is interesting that b-CTF and a-CTF can have such dramatically different
effects on early endosome morphology considering the two peptides only differ by
16 N-terminal amino acids. One recent study speculated that this difference in
phenotype may be attributed to a unique gain of function by the 16 amino acids (Xu
et al., 2016), whereas another similar study instead suggests the C-terminal
YENPTY domain of APP (present in both a- and b-CTF) induces endosome
enlargement by recruiting APPL1 and stabilizing Rab5 activity (Kim et al., 2015).
Regardless of mechanism, a-CTF is known to mostly be generated at the cell
surface, whereas b-CTF is mostly generated in the endosome (Haass et al., 2012).
Therefore, compartmentalization of b-CTF in the endosome may enable specific
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protein interactions that induce endosome abnormalities, while a-CTF at the cell
surface may have no such effect.
Further studies are needed to help decipher the cellular consequences of
early endosome morphological changes and how early endosome enlargement
phenotypes contributes to neurodegeneration. Rab5+ early endosomes are
important for the retrograde trafficking of trophic signals (such as NGF or BDNF)
from the axon towards the cell body. Recent overexpression studies in rodent
neurons demonstrated that APP-mediated Rab5+ early endosome enlargement
slows normal axonal retrograde trafficking, potentially impinging on delivery of prosurvival signals to the soma (Kim et al., 2015; Xu et al., 2016). In one example,
researchers found evidence of neuronal atrophy as a consequence of early
endosome enlargement (Xu et al., 2016). Whether similar results will be seen in
human neurons or in vivo remains to be tested, and whether such deficits can trigger
neurodegeneration is unclear.
It is also possible that early endosome enlargement can feed into AD
pathology in a different way. Specifically, it is possible that enlarged dysmorphic
early endosomes provide a site for seeding aggregation of pathological proteins.
For example, Ab, which is mostly generated within endocytic compartments, may be
better able to form oligomers or fibrils in enlarged endosomes prior to extracellular
release, augmenting plaque deposition. Furthermore, tau, which has recently been
shown to be endocytosed and degraded through the endosomal-lysosomal system
in human neurons (Evans et al., 2018), may also be more likely to aggregate within
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enlarged early endosomes. As well, it has been shown that important lysosomal
hydrolases, which normally traffic to the lysosome through the early to late
endosome to carry out normal protein degradation, are dysregulated in cells with
enlarged endosomes (Cataldo et al., 2008). Impaired trafficking of essential
lysosomal hydrolases not only would impair overall proteostasis but may also
augment pathological amyloid and tau protein aggregation or spreading. Human
neurons provide a valuable system to evaluate the physiologically-relevant
consequences of early endocytic defects.
In this study we interrogate a specific Ab-independent cellular phenotype
driven by b-CTF. Although increasing attention is being directed towards b-CTF as a
plausible key contributor to AD, a majority of studies continue to focus on the
amyloid cascade hypothesis and the neurotoxicity of Ab. We found that levels of
longer Abs are elevated in all fAD mutations studied. Longer Abs, such as Ab42 and
Ab43, are more hydrophobic and have greater propensity to aggregate and deposit
within plaques. Although we ruled out the contribution of longer Abs to Rab5+
endosome enlargement, the effect of changes in Ab secretion and aggregation on
neurodegeneration was not addressed. Interestingly, from the molecular profiling
experiments, we also noticed that sets of genes associated with synaptic functioning
and neurodegeneration were significantly differentially expressed in APPswe,
PSEN1-M146V, and Swe/M146V mutant neurons compared to wildtype (Figure 34
and 35). Ab is thought to potentially be neurotoxic by impeding normal synaptic
function, so the gene expression changes we detected in mutant cells may reflect a
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compensatory change in gene expression to overcome the neurotoxic effect of
pathological Ab production. It is also possible that the neurotoxicity of Ab is in part
mediated through a non-cell autonomous mechanism, which was also not addressed
in our study. Specifically, it has been shown recently that longer Ab peptides are
capable of initiating an inflammatory response, for example through microglia
activation (Hong et al., 2016; Sondag et al., 2009). Such an immune response has
been suggested to lead to synapse degeneration and ultimately cell death. Future
studies, such as co-culturing fAD mutant iPSC-derived neurons with wildtype and
mutant human microglia, are necessary to determine whether the increased longer
Abs produced by human fAD mutant neurons are capable of causing an immune
response and neurodegeneration.
Our study raises the concern that GSMs and other anti-Ab therapies which
are being developed and tested in the clinic all fail to target b-CTF and therefore
may have no effect on rescuing endosomal abnormalities in AD. We and others
have shown that inhibiting b-secretase, which reduces both Ab and b-CTF, rescues
endosomal defects (Jiang et al., 2010; Woodruff et al., 2016). Recent BACEi clinical
trials have been prematurely ended as no significant positive outcomes were evident
(Mullard, 2017), but these trials focused on patient groups that either already had
significant AD neuropathology, or patients in a “prodromal” AD stage. The
endosomal phenotypes we see in iPSC-derived neurons are detectable very early in
development. Since early endosome dysregulation precedes any amyloid or tau
pathology, it is likely that to target endosomal dysregulation, patients may need to be
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treated prior to detectable AD pathology presentation. While future studies are
necessary to understand the precise pathway through which b-CTF results in Rab5+
early endosome enlargement and dysregulation, interventions targeted at this
pathway deserve consideration as a therapeutic strategy.

Chapter V: Concluding Remarks

The work presented in this thesis is all focused on addressing an open
question in the field of AD, namely, how a multitude of mutations in APP and PSEN1
genes commonly contribute to a singular pathological disease state. We
hypothesized that studying these different fAD mutations in a human neuronal model
system with the absence of any transgenic overexpression would provide valuable
insights and help clear up outstanding mechanistic debates. However, first we
needed to take the time necessary to generate the tools needed to develop such a
“gold-standard” model system. In doing so, we began to learn a lot about iPSCs and
gene editing using CRISPR/Cas9. We developed strategies to improve outcomes of
CRISPR-mediated knock-in in human stem cells by studying how HDR-mediated
repair works in these cells after a CRISPR edit. In addition, we developed a novel
framework for gene editing in iPSCs called “CORRECT”, which enables efficient and
scarless mutation incorporation. These findings have broad implications for multiple
different scientific fields as useful tools for model system development and disease
modeling. More recently we have implemented our CRISPR/Cas9 framework to
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study common features of diverse APP and PSEN1 mutations, as we initially
intended to do. By generating a comprehensive panel of 16 different fAD mutant
iPSC lines, we deciphered how APP and PSEN1 mutations commonly contribute to
early endosome dysfunction, which we showed to be correlated with APP b-CTF,
rather than a-CTF or longer Abs.
In our analysis we looked at 3 different representative pathogenic APP
mutations as well as 4 different PSEN1 mutations using isogenic human iPSCderived neurons. Although there were some phenotypes that were not consistent
across the APP and PSEN1 mutant cells, we did identify 3 common features that
were similar across all mutant lines:
1) Increased production of longer Abs (Ab43 and/or Ab42);
2) Increased levels of APP b-CTF;
3) Increased Rab5+ early endosome size.
The identification of these common changes in APP processing across all mutant
lines studied is significant, as past studies that may have simply focused on looking
at the effect of mutations on total Ab or the Ab42:40 ratio would fail to capture these
results. What’s more, levels of these two types of APP-derived peptides may be
more meaningful biomarkers than any other APP metabolite. These phenotype
consistencies, and more so the correlation between b-CTF and endosome
dysfunction, provide compelling evidence that Ab may not be the only pathological
player in development of AD, although the degree to which longer Ab peptides and
endosome enlargement may synergize in neurodegenerative pathways has yet to be
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studied. Our results from studying 7 different mutations lays the groundwork
necessary for pursuing additional studies that should assess for different mutations
whether APP processing and endosome morphology is similarly affected.
Previous studies have demonstrated that overexpression of full-length APP or
b-CTF is capable of inducing early endosome dysfunction, however all of this work
had been performed in non-human and/or non-neuronal cellular systems.
Furthermore, overexpressing APP or APP b-CTFs would also indiscriminately result
in increased production of a-CTF and Abs in these cells, as both a-secretase and gsecretase are fairly ubiquitously expressed. Our approach has the advantage not
only that we are studying phenotypes in human neurons with the absence of
overexpression, but also, we can manipulate and precisely compare the effects of
endogenous levels of both b-CTF versus a-CTF as well as longer versus shorter
Abs on endosome dysfunction using pharmacology alone. Specifically, we were
able to separate the contribution of longer Abs from that of b-CTF by using GSM,
which specifically reduces longer Ab levels without affecting b-CTF levels. These
experiments allowed us to conclude that increased longer Abs seen in mutant cells
was unrelated to the common endosome enlargement phenotype we identified.
Moreover, we were able to strategically isolate the effect of b-CTF from that of aCTF, which only differ in composition by their N-terminal most 16 amino acids.
Specifically, we could increase both a-CTF and b-CTF levels using a g-secretase
inhibitor, which we showed induces endosome enlargement. However, this
phenotype was fully rescued by the additional treatment of a b-secretase inhibitor,
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which we showed depletes b-CTF without affecting a-CTF. How b-CTF specifically
contributes to endosome dysfunction while a-CTF has no effect remains a particular
fascinating aspect of APP biology and needs be further investigated using human
neurons in the future.
As described at length in previous chapters, a growing number of AD genetic
studies have pointed to variants in endocytic-associated genes as important risk
factors for sporadic AD development, including GWAS-identified trafficking-related
genes such as SORL1, BIN1, PICALM. Our study of fAD mutations in APP and
PSEN1 and our finding of consistent changes in Ab, b-CTF and endosomes, begs
the question of whether or not variants in AD risk-associated endocytic genes also
lead to similar or even the same changes. Future studies should take advantage of
our CRISPR/Cas9 gene editing and iPSC platform to expand on our results by
engineering disease-associated mutations in AD-relevant endocytic genes in iPSCs
and studying APP processing and endosome dysfunction in differentiated neurons.
Such future studies will help clarify whether our findings of common changes in Ab,
b-CTF and early endosomes are unique to familial forms of AD or are more widely
relevant to both genetically defined as well as spontaneous late-onset AD.
Other major questions remain unanswered, namely, what the cellular
consequences of enlarged early endosomes may be and how endosome
dysfunction contributes to neurodegeneration. Our human iPSC-derived neuron
model has its advantages, namely, the ability to study the effect of many different
fAD mutations on APP processing and subtle cellular changes in a controlled
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manner. However, in its current state, the technology is ill-equipped to assess
neurodegeneration. Even in the most severe mutant iPSC-derived neurons we
engineered with both APP and PSEN1 mutations present, cells can be maintained in
culture for hundreds of days. This is not so surprising, as it normally takes decades
before fAD mutations result in noticeable disease phenotypes in humans.
Therefore, it remains open in the field to determine ways to accelerate aging in these
human neurons and to promote or activate pro-neurodegenerative pathways. It
would also be valuable to decipher novel strategies to mimic cellular stresses
associated with AD, which may also be useful for actively promoting degeneration in
these cells. Once such technological advances are made, it would be valuable to
see whether and how endosomal dysfunction contributes to neurodegeneration and
degenerative signaling pathways. Developing an in vitro platform to address the
effect of endosomal dysfunction on neurodegeneration would be valuable in many
ways, namely, for the discovery of novel AD-relevant cellular pathways as well as
new targets for the development of better AD therapeutics.
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Appendix I: Materials and Methods

sgRNA & Cas9-VRER plasmid design and construction.

sgRNAs were designed using the Zhang lab CRISPR design tool
(crispr.mit.edu). sgRNA sequences targeting APP or PSEN1 (Table 3) were cloned
into plasmid MLM3636 (a gift from Keith Joung, Addgene # 43860) as previously
described (Fu et al., 2013).

Table 3. List of sgRNAs sequences used in Chapters I, II and III.

To generate the Cas9-VRER variant (Kleinstiver et al., 2015) with human
codon usage, we introduced the 4 mutations into pCas9_GFP (a gift from Kiran
Musunuru, Addgene plasmid # 44719). Briefly, we amplified fragments around the
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intended mutation sites by PCR with mutated primers (Table 4), digested the
plasmid with BamHI/BsrGI and fused all fragments by Gibson assembly.

Table 4. Primers for Gibson assembly of Cas9-VRER plasmid.

Design of ssODN repair templates.

100-nt ssODN repair templates (PAGE-purified, IDT) were designed with
homologous genomic flanking sequence centered around the predicted
CRISPR/Cas9 cleavage site and containing pathogenic and/or CRISPR/Casblocking mutations. CRISPR/Cas-blocking silent mutations (i.e. that do not alter the
amino acid sequence) were selected based on codon-usage of the edited gene by
changing the codon to another codon already used in the same mRNA for the
respective amino acid. All ssODNS used in the work described in this thesis are
summarized below in Tables 5-10.
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Table 5. ssODNs used for analysis of CRISPR/Cas-blocking mutation
efficacy (Chapter II).

Table 6. ssODNs used for oligo scan for “distance effect” (Chapter II).
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Table 7. ssODNs used to verify distance effect with independent
sgRNAs (Chapter II).

Table 8. ssODNs used for single cell-derived clonal analysis of distance
effect (Chapter II).

Table 9. ssODNs used for oligo mixing strategy for increasing
heterozygous clones (Chapter II).

Table 10. ssODNs used for CORRECT (Chapter III).
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Generation of long ssDNA and dsDNA repair templates.

To generate 200bp and 400bp ssDNA and dsDNA repair templates for repair,
a 1000bp piece of the PSEN1 locus around the edited locus was first PCR-amplified
and TOPO-cloned. Then, a library of 20 ssODN oligos or gBlocks (IDT) containing
the required mutations was integrated into the TOPO-vector by Gibson assembly
(NEB), resulting in a library of 20 plasmid templates, each containing CRISPR/Casblocking barcode mutations and an intended mutation at varying cut-to-mutation
distances (as described in Figure 19). From each plasmid template, 200 bp and
400 bp dsDNA PCR amplicons were generated (primers in Table 11) and mixed in
equal amounts to generate pools of either size PCR template amplicons. Template
pools were then gel extracted to remove residual plasmid. These were then reamplified by PCR and concentrated prior to transfection. To generate ssDNA
templates, dsDNA amplicons were generated as described above with 5’
phosphorylated forward primers. Re-amplified dsDNA amplicons were then digested
with Lambda Exonuclease (NEB) to generate ssDNA. Reactions were column
purified prior to transfection (see Figure 20 for graphical illustration).

Table 11. Primers used for amplificatin of 200/400bp repair templates
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Wildtype iPSC line

iPSCs were reprogrammed from human skin fibroblasts (Coriell Institute,
Catalog ID: AG07889) of an 18-year old male individual using the Cytotune-iPS
Sendai Reprogramming Kit (Life Technologies) according to the manufacturer’s
instructions, following Rockefeller University Institutional Review Board approval.
Informed consent was obtained from all subjects upon sample submission to Coriell
Institute. Fibroblasts were confirmed to be wildtype for all studied loci by genotyping.
Multiple clones were selected based on characteristic morphology. Genetic
fingerprinting confirmed iPSCs were derived from corresponding fibroblast lines.
Expression of pluripotency markers Oct4, Tra160, SSEA4 and Nanog was confirmed
by immunofluorescence (Figure 44A). Clone 7889SA possessed a normal
karyotype (Cell Line Genetics) and was characterized for typical iPSC properties and
absence of Mycoplasma contamination (Figure 44B).
Expression of pluripotency genes was analyzed by NanoString nCounter
gene expression system using a pre-designed codeset (Kahler et al., 2013) (Figure
44C). Data was normalized to the geometric mean of three housekeeping genes
(ACTB, POLR2A, ALAS1) using the nSolver Analysis Software v1.0 (NanoString).
100 ng of total RNA from line 7889SA was compared to RNA extracted from the
human ESC lines HUES9 (Cowan et al., 2004). Gene expression for 7 pluripotency
markers and the 4 Yamanaka factors introduced as Sendai transgenes (s-t) was
compared. Note that the s-tSox2 probe detects some expression of endogenous
Sox2, leading to larger values for both lines.
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In vivo pluripotency was confirmed by teratoma analysis as described (Kahler
et al., 2013; Sproul et al., 2014). Briefly, undifferentiated iPSCs were embedded into
Matrigel and subcutaneously injected into the dorsal flank of immune-compromised
mice (NOD-SCID Il2rg-null mice, Jackson Laboratory). Paraffin sections of the
teratomas were subjected to hematoxylin and eosin (H&E) staining and structures
characteristic for the three germ layers (ectoderm, mesoderm and endoderm) were
identified by microscopy (Figure 44D). Animal work was approved by the Columbia
Institutional Animal Care and Use Committee.
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Figure 44. In vitro and in vivo characterization of the wildtype 7889SA
human iPSC line.
A) Immunofluorescence stainings of pluripotent stem cell markers. B) iPSCs
possess a normal human male karyotype. C) Nanostring expression analysis
of pluripotent stem cell genes in reprogrammed iPSCs compared to HUES9.
D) In vivo differentiation and analysis of iPSC-derived teratoma containing
tissues of all germ cell layers. Scale bars, 100 µm.
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Cell culture and transfection.

iPSCs were maintained on irradiated MEFs (Globalstem) plated on cell
culture plates coated with 0.1% gelatin and grown in HUESM (Knock-out Dulbecco’s
modified Eagle’s Medium (KO-DMEM), 20% knock-out serum, 0.1 mM non-essential
amino acids, 2 mM Glutamax, 100 U/mL-0.1 mg/mL penicillin-streptomycin (all Life
Technologies), 0.1 mM 2-Mercaptoethanol (Sigma-Aldrich), 10 ng/mL FGF2
(Stemgent), at 37 °C with 5% CO2. Prior to transfection, iPSCs were transferred to
Geltrex-coated (Life Technologies) cell culture plates and grown in MEF-conditioned
HUESM containing 10 µM ROCK inhibitor (Stemgent).
iPSCs were transfected with Cas9- and sgRNA-expressing plasmids, and
ssODNs by electroporation. 2 million cells were resuspended in 100 µL cold
BTXpress electroporation buffer (Harvard Apparatus) with 20 µg pCas9_GFP, 5 µg
sgRNA plasmid, and 30 µg ssODN (100bp ssODN, PAGE-purified, IDT). Cells were
electroporated at 65 mV for 20 ms in a 1 mm cuvette (Harvard Apparatus). After
electroporation cells were transferred to Geltrex-coated cell culture plates and grown
in MEF-conditioned HUESM containing ROCK inhibitor for 2 days. In all
transfections, 7889SA-derived iPSCs wildtype at genome-edited loci were used.
Human embryonic kidney (HEK) 293T cells (Life Technologies) were maintained in
DMEM with 10% FBS, 2 mM Glutamax and 100 U/mL-0.1 mg/mL penicillinstreptomycin (all Life Technologies) at 37 °C with 5% CO2. HEK293 cells were
seeded on 12-well plates at 250,000 cells/mL. When approximately 70% confluent,
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HEK293 cells were transfected with 800 ng Cas9 plamid, 400 ng sgRNA plasmid
and 1 µg ssODN Cells using X-tremeGENE 9 (Roche).

Fluorescence activated cell sorting.

All GFP positive cells regardless of expression levels were collected in the
Rockefeller University Flow Cytometry Resource Center using a FACSAria II flow
cytometer (BD Biosciences). 48h following transfection, cells were resuspended in
PBS with 0.5% BSA fraction V solution, 10 mM HEPES, 100 U/mL-0.1 mg/mL
penicillin-streptomycin (all from Life Technologies), 0.5 M EDTA, 20 mM glucose, 10
ng/L DAPI in the presence of ROCK inhibitor for iPSC sorts. For pooled cell NGS
analysis 150,000 to 250,000 cells were collected and immediately frozen in liquid N2
for further study. For single-cell derived iPSC clonal analysis 30,000-60,000 GFP+
cells were immediately plated on a 10 cm plate of MEFs in HUESM and ROCK
inhibitor following cell sorting.

NGS analysis of HDR-mediated mutation incorporation.

Genomic DNA was extracted from sorted cells and the genomic region
around the CRISPR/Cas9 target site for APP and PSEN1 genes was amplified by
PCR with primers positioned outside of the HDR repair template sequence to avoid
template amplification for 25 cycles using Q5 polymerase (NEB) according to the
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manufacturer’s protocol (PCR primers listed in Table 12). Primers contained
additional sample-specific barcodes. 25 cycles were previously determined to be
optimal for exponential amplification of the template as well as visibility for gel
extraction (data not shown). To eliminate PCR byproducts and genomic DNA, PCR
products were gel purified. 25-100 ng of pooled barcoded PCR products were
submitted to the Rockefeller University Genomics Resource Center for targeted
MiSeq (Illumina) 300 bp paired-end next generation sequencing with library
preparation using the v3 reagent kit (Illumina).

Table 12. PCR primers for amplification of genomic targets for NGS
analysis.

Data analysis was performed using Galaxy (Blankenberg et al., 2010b;
Goecks et al., 2010) (usegalaxy.org) or Unix-based software tools listed below
(summarized in Figure 45). First, quality of paired-end sequencing reads (R1 and
R2 fastq files) was assessed using FastQC
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc). Raw paired-end reads
were combined using Paired End ReAd MeRger (PEAR) (Zhang et al., 2014) to
generate single merged high quality full-length reads. Reads with sample-specific
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forward and reverse barcodes were de-multiplexed using the FASTX-Toolkit
(Pearson et al., 1997) barcode splitter. The barcodes were then trimmed using seqtk
(https://github.com/lh3/seqtk). Reads were then filtered by quality (using Filter
FASTQ (Blankenberg et al., 2010a)) removing reads with a mean PHRED quality
score under 30 and a minimum per base score under 24. Only reads shorter than or
equal to the length of the PCR amplicons plus 40bp (to account for insertions) were
considered for analysis.
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Figure 45. Next-generation sequencing data analysis pipeline for HDR
and indel detection.
A) For all NGS experiments, raw forward and reverse paired NGS reads were
first merged to obtain single high quality reads (tool: pear), de-multiplexed to
separate experiment-specific barcoded reads (seqtk) then filtered to remove
low quality reads. B) For experiments using pooled oligos containing
CRISPR/Cas-blocking mutations, reads were separated into wildtype (WT)
and edited reads, which were then filtered to include only reads that had
incorporated the pathogenic mutation (M+) (i.e. containing a pathogenic and
CRISPR/Cas-blocking mutation). To account for multiple HDR events after
re-editing, reads were then separated into 32 unique categories covering
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every possible combination of CRISPR/Cas-blocking mutations. C) Reads
were aligned (bwa mem) and accurate HDR (perfect alignment) or indel
distribution was reported (bam-readcount, R). HDR reads that had
incorporated multiple CRISPR/Cas-blocking mutations were separately
analyzed. D) For the mutation incorporation analyses performed in all other
figures reads were filtered for the expected sequence and counted.

For the accurate HDR and indel analysis in Chapter II reads were filtered to
assess the presence of HDR or NHEJ-induced indels. To isolate sequences with
HDR, reads were first filtered to remove unedited wildtype reads. Next, HDR reads
containing intended APP or PSEN1 mutations were isolated by matching a 6-nt HDR
motif around the pathogenic mutation. HDR reads were then analyzed for
incorporation of CRISPR/Cas-blocking mutations by matching 6 to 8-nt HDR motifs
around each mutation and categorized into unique groups of reads containing all
possible combinations (32) of CRISPR/Cas-blocking mutations to account for
measurable HDR after re-editing (Figure 45B). Each group of reads was then
aligned to a corresponding reference sequence using bwa mem (Li and Durbin,
2010) (which has been successfully used for this purpose by others (Dow et al.,
2015)) to determine the rate of accurate HDR and indel or substitution mutations
(Figure 45C). Reads with multiple blocking mutations were analyzed separately.
Accurate HDR reads were calculated in each group as the percentage of HDR reads
without indels. To determine indel frequency, size and distribution, all edited reads
from each experimental replicate were combined and aligned, as described above.
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Indels were then marked at each base using bam-readcount
(https://github.com/genome/bam-readcount), quantified in R (www.R–project.org)
and plotted using Graphpad Prism.
In all other experiments assessing mutation incorporation for establishing the
distance effect, reads were first filtered for experiment-specific barcode and quality
as described above. Next, reads were considered to have HDR if they matched the
repair ssODN template plus an additional 3-nt genomic sequence on each side to
ensure proper genomic context during HDR and contained the pathogenic mutation
and/or CRISPR/Cas-blocking silent mutation (Figure 45D). n values represent
independent biological replicates.
To exclude a significant contribution of oligo synthesis and sequencing errors
to our analysis, we sequenced PSEN1 PCR amplicons from APP-edited iPSCs, and
repair ssODNs annealed to a complementary ssODN. Errors introduced by
sequencing were 2.7% ± 0.1% per 100bp, and 2.3% ± 1.7% of the 100bp ssODN
sequences contained errors.

Calculation of optimal distance ranges for homo- or heterozygous genotypes.

Mutation scan data for APP and PSEN1 loci determined by NGS for iPSCs
from were combined to determine single allelic mutation incorporation probabilities
pa as a function of cut-to-mutation distance (pamut). The probability of wildtype
incorporation (pawt) was determined as (pawt= 1-pamut). Assuming gene editing and
HDR at each allele in a single cell are independent events, we calculated the
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zygosity probabilities (pz) for each allele combination given two alleles per cell.
Specifically, probability of a homozygous, wildtype, and heterozygous zygosity was
calculated as pzmut/mut=pamutxpamut, pzwt/wt=pawtxpawt and pzwt/mut = 2x(pawtxpamut),
respectively. These calculations were made using the entire range of data derived
from Figure 19B, extrapolated for distance values above 36 and plotted in Figure
22A as fit curve ± SD of raw values.

RFLP analysis and Sanger sequencing for genotyping of single cell clones
(Chapter II).

To facilitate single cell clone genotyping, the ssODN HDR templates used for
gene editing were designed to introduce a restriction endonuclease motif with the
blocking or pathogenic mutation. Genome edited single cell-derived iPSC clones
grown on MEF-containing 10 cm plates (in HUESM + ROCK inhibitor) were manually
picked into a single well of a U-bottom 96-well tissue culture plate in 100 µL HUESM
+ ROCK inhibitor. Cells were pelleted by centrifugation, and plates were
immediately frozen in liquid N2 and stored at -80 °C. Genomic DNA was extracted as
previously described44. Briefly, cells were resuspended in 25 µL lysis buffer (0.75 µL
10 mg/mL Proteinase K (Ambion), 2.5 µL 10X PCR buffer (Sigma-Aldrich),
transferred to 96-well PCR plates and incubated at 55 °C for 4 h. Proteinase K was
inactivated by incubating plates at 96 °C for 10 min.
To identify clones with HDR events the genomic region surrounding the
APPswe or PSEN1-M146V, loci were amplified (see primers in Table 13) by Taq
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polymerase (Roche) and digested with restriction enzymes to screen for a novel
restriction site introduced by the blocking or pathogenic mutation (primers, repair
ssODNs and restriction enzymes used are listed in the above tables). Digested
DNA was analyzed by agarose gel electrophoresis. The zygosity of the pathogenic
mutation in clones that had undergone incorporation of the silent CRISPR/Casblocking mutations was determined by Sanger sequencing (Genewiz).

Table 13. Primers used for RFLP and Sanger sequencing of single-cell
derived clones (Chapter II)

To determine the frequency and distribution of indels in mono-allelic HDR
single cell clones with NHEJ at the other allele, Sanger sequencing reads were
separated into single reads for HDR and indel-containing alleles using PolyPeak
Parser (Hill et al., 2014). Indel-containing reads were then combined into a single
fasta file and analyzed for indel distribution by aligning to the reference sequence as
described above.
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CORRECT

Re-Guide and re-Cas utilize a two-step gene editing workflow: 2 million iPSCs
were electroporated with sgRNA and Cas9 plasmids. In addition, during the first
step a ssODN containing the intended mutation (M) and a CRISPR/Cas blocking
mutation (B) was introduced (MB template). Cas9-eGFP expressing cells were
FACS sorted and single cell iPSC clones were derived. The presence of B and M
mutations was detected by RFLP. A single clone containing homozygous B and M
mutations was then expanded for use in the second step of CORRECT. These “MB
iPSCs” were then electroporated with re-sgRNA and wildtype Cas9 plasmids (for reGuide) or wildtype sgRNA and mutant VRER Cas9 plasmids (for re-Cas). In
addition, at this step the CORRECT template was provided to remove blocking
mutation B. The efficacy of CRISPR/Cas blocking mutation removal was first
determined by NGS. To isolate scarless edited “M iPSC clones” the second step of
CORRECT editing was performed and single-cell-derived colonies were picked and
expanded as described above. Genotypes were confirmed by sanger sequencing.

SURVEYOR assays

gDNA was extracted from gene edited iPSCs as described above. 300-500
bp around the gene edited locus were amplified by PCR using Herculase II (Agilent)
and column purified. PCR amplicons were rehybridized and treated with
SURVEYOR nuclease according to the manufacturers directions (IDT). Digested
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DNA was separated on a 4-20% TBE polyacrylamide gel (BioRad) and imaged using
SYBR Gold (Life Technologies). Densitometry was performed using Image J.
Percent indel quantification was based on relative band intensities using the formula
100 x (1-(1-(b+c)/(a+b+c)1/2, where a is the undigested PCR product intensity and b
and c are the intensities of each cleavage product (Ran et al., 2013).

Isogenic APP and PSEN1 mutant iPSC lines.

Generation of heterozygous and homozygous APP and PSEN1 isogenic
mutant iPSC lines was done using a combination of “distance effect” and oligo
mixing based approaches as described above. Briefly, sgRNA sequences (see
sgRNA sequences for Chapter IV in Table 3) were selected and cloned into plasmid
MLM3636. 100-nt PAGE-purified ssODN repair templates were designed with
homologous genomic flanking sequence centered around the predicted CRISPR cut
site and containing pathogenic and/or CRISPR-blocking mutations (Table 14).

Table 14. ssODNs used for generation of isogenic APP and PSEN1
mutant iPSC lines (Chapter IV).
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iPSCs were transfected with Cas9-GFP and gRNA-expressing plasmids, and
ssODNs by electroporation. After electroporation, GFP+ cells were FACS sorted and
grown until single cell-derived colonies were detectable and picked. Identification of
accurately edited iPSCs by RFLP analysis and Sanger sequencing was performed
as described in (Kwart et al., 2017) using PCR amplification primers listed in Table
15. In all electroporations, 7889SA-derived iPSCs wildtype at genome-edited loci
were used. Swe/M146V “double mutant” iPSCs were generated by a two-step
editing approach. Homozygous PSEN1-M146V were re-edited to introduce the
homozygous APPswe mutation.

Table 15. Primers used for RFLP analysis and Sanger sequencing of
single-cell derived clones (Chapter IV).

PSEN1-L166P, PSEN1-A246E and PSEN1-M233L iPSCs were generated in
collaboration with Andrew Gregg, who recently presented preliminary data on these
lines in his thesis (Gregg, 2017). To generate the APP-KO iPSC line, wildtype
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iPSCs were electroporated with Cas9-GFP and gRNA-expressing plasmid only and
identification of clones with frame-shift deletions was carried out by TOPO-cloning
(Figure 46).

One iPSC line per genotype was isolated and characterized. The

newly established gene-edited lines displayed normal karyotypes and expressed
pluripotency markers Oct4, Tra160, SSEA4, Nanog and Alkaline Phosphatase (data
not shown).
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Figure 46. Generation of an APP-KO iPSC line.
A) Schematic describing the main steps in generating an isogenic APP
knockout iPSC clone using CRISPR/Cas9. (1) We targeted the first
conserved transcription start site (red) by using a sgRNA targeting a double
stranded break at the indicated site. This ATG start site is adjacent to the
Cas9 cleavage site, and therefore following non-homologous end joining
mediated random deletion, we expected at some alleles the ATG would be
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deleted. After isolating single cell-derived iPSC clones we can test loss for
loss of ATG using an RFLP assay. We utilized the restriction enzyme NruI,
which has a recognition sequence that includes the A of the ATG transcription
start site. Therefore, we can look for loss of NruI cleavage as an indication of
loss of ATG (2). (3) Following identification of putative knockout (loss of intact
ATG) clones we utilized TOPO cloning technology to be able to analyze the
editing outcome at each allele by Sanger sequencing. (4) Finally, to confirm
knockout we performed a screen by western blot on iPSC lysates. B) An
example of the RFLP assay from our gene editing experiment. Putative KO
clones are highlighted in red. The clone we used in our experiments “P2A8” is
indicated. C) TOPO cloning and Sanger sequencing alignment for each allele
from the P2A8 KO clone compared to wildtype. Both alleles have a complete
loss of the ATG sequence. D) Western blot analysis for full length APP (FLAPP) for wildtype and P2A8 iPSCs.

Cortical neuron differentiation

iPSC-derived cortical neurons were generated as previously described
(Paquet et al., 2016) with modifications. Briefly, iPSCs were plated on 12-well tissue
culture plates coated with Geltrex (Life Technologies) in MEF-conditioned HUESM
with ROCK inhibitor. When cells were 100% confluent, medium was replaced with
neural induction (NI) medium (day in vitro 0 (DIV0)) and maintained for 8 days. On
DIV8 day cells were dissociated using Accutase (Life Technologies) and
resuspended in NI medium at 30 million cells/mL. Cells were plated on dried poly-Lornithine (Sigma-Aldrich) and laminin-coated (Life Technologies) 6-well plates in 200
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µL spots. Cells were left to adhere for ~45 min and NI medium was added. On
DIV10 NI was replaced with neural maintenance (NM) medium. Upon the
appearance of neural rosettes, 20 ng/mL FGF2 was added for 2 days. When
neurons started to form (~DIV21), rosettes were isolated manually after treatment
with STEMdiff Neural Rosette Selection Reagent (STEMCELL Technologies) for 1 h.
Rosettes were washed and plated on poly-L-ornithine/laminin-coated 6-well plates
and grown for approximately 7 days. For cortical neuron maturation, ~675,000
NPCs/mL were plated on 6- or 12-well poly-L-ornithine/laminin-coated plates and
maintained in Neurobasal medium supplemented with B-27 serum-free supplement,
2 mM Glutamax and 100 U/mL-0.1 mg/mL penicillin-streptomycin (all Life
Technologies). For imaging experiments cells were plated in 24-well plates onto
poly-L-ornithine/laminin-coated coverslips. During the first 7 days after plating, cells
were treated with 10 µM DAPT (Sigma-Aldrich) to augment neuronal maturation,
which was subsequently washed out with normal Neurobasal/B-27 medium.

Cortical neuron characterization

Canonical neural precursor cell markers (Nestin, Pax6, FoxG1, Otx2) and
mature cortical neuronal markers (Tbr1, CTIP2, Satb2) were analyzed by
immunofluorescence staining at DIV10 and DIV65, respectively (Figure 47A-B).
Synapse marker expression was also analyzed by immunofluorescence at DIV65
(Figure 47C). Electrophysiological properties of iPSC-derived cortical neurons were
assessed between DIV71 and 85 using a submerged recording chamber mounted
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on an Olympus BX51 microscope equipped for infrared-DIC microscopy (Figure
47D-H). Neurons were perfused with 95% 02/5% CO2 equilibrated ACSF (in mM):
119 NaCl, 2.5 KCl, 1.3 MgSO4, 2.5 CaCl2, 1 NaH2PO4, 26 NaHCO3 and 11 glucose.
Whole-cell patch clamp pipettes (5 MΩ) were filled with (in mM): 123 K-gluconate,
10 HEPES, 0.2 EGTA, 8 NaCl, 2 Na2ATP, 0.3 Na3GTP. Action potentials were
elicited by step current injections and recorded in current-clamp mode (-65 mV).
Properties (threshold, overshoot) of the largest action potential elicited in each cell
were measured. Spontaneous synaptic activity was recorded in voltage-clamp
mode (-70 mV). Data was digitized at 10 kHz and recorded using a Multiclamp 700B
amplifier and Clampex 10.3.0.2 software (Molecular Devices). We also performed
an analysis of Ab production as a function of differentiation state. It was determined
that Ab production is considerably maturation-dependent and therefore we chose to
analyze Ab profiles from neurons at ~DIV70 (Figure 47I).

189

Figure 47. Characterization of iPSC-derived cortical neurons.
A-C) Immunofluorescence stainings of markers for neural precursors at
DIV10 (A), cortical neurons at DIV65 (B) and functional synapses at DIV65
(C). Scale bars, 100 µm in A, B, 10 µm in C. D) Evoked action potentials
recorded in a neuron current-clamped to -65 mV. E) Mean (± SEM) resting
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membrane potential (Vrest), action potential threshold and action potential
overshoot (DIV 71 – 85; n = 18). Properties of the largest action potential
elicited in each cell were measured. F) Mean number of evoked action
potentials increases with increasing stimulus strength. G) Spontaneous
synaptic activity recorded in a neuron voltage-clamped to -70 mV. H) Mean
(± SEM) frequency and amplitude of spontaneous excitatory postsynaptic
currents (EPSCs) (DIV 71 - 85; n = 8). I) Total secreted Ab levels from cells
at different stages of the differentiation protocol.

Drug treatments

In all experiments, neurons were treated for 48h with 1 µM of drug in 0.1%
DMSO. DMSO treatment alone was used as a vehicle control. Drugs used were bSecretase inhibitor IV (Millipore), Compound E (Millipore). GSMs were obtained from
Dr. Yeuming Li. A previously published GSM, GSM-I, was used in all experiments
(Crump et al., 2011).

Whole transcriptomic RNA sequencing (RNA-seq)

RNA from DIV80 iPSC-derived neurons was extracted using Trizol
(Invitrogen) and ribosomal RNA was removed with Ribo-Zero (Epicentre). RNA was
DNAse-treated (Roche) sequencing libraries were generated as recommended by
the Illumina High-throughput TruSeq sample preparation guidelines. 3 biological
replicates, each consisting of 2 technical replicates, were used for sequencing.
Stranded RNAseq was performed using an Illumina HiSeq 2500 at the New York
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Genome Center generating 125-bp paired-end reads. Reads were aligned to the
hg19 build of the human genome using Kallisto. All read counts, TPM and
differential expression analysis was performed on R (www.R-project.org) using
packages “Tximport” and “DESEQ2” (bioconductor.org). RNA-seq analysis was
performed using R packages “ggplot”, “venneuler”, “pheatmap” or “pcaexplorer”.
Quality control assessment of all RNA-seq libraries was performed as shown in
Figure 48. P-values to assess statistically significant overlap between the AD gene
lists was calculated with a hypergeometric test. The list of genes with AD-linked
variants was obtained from https://www.ebi.ac.uk/gwas/ and is shown in Table 16.
Gene expression heatmaps were generated using Prism. Metascape (Tripathi et al.,
2015) (metascape.org) was used for GO pathway analysis and we included enriched
terms down to q < 0.01 (p adjusted for multiple comparisons). The list of
differentially expressed endocytic-related genes determined from metascape and
used for RNA-seq analyses is shown in Table 17. Gene lists from Tables 16 and 17
were used for hierarchical clustering analysis. A summary of Metascape GO terms
identified when studying differentially expressed genes in Swe/M146V neurons
compared to single mutant APPswe or PSEN1-M146V is shown in Table 18.
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Figure 48. RNA-seq library quality control analysis.
A) Read depth (number of unique reads detected) of each biological replicate
used for RNA-seq analysis. B) Diagonal: Distribution of each variable is
shown via histogram for each of the respective iPSC-derived neuron
genotypes of the RNA-sequencing libraries. Bottom panel: Scatter plot of logtransformed read counts per gene, displaying the relationship between each
genotype. Upper panel: Correlation between RNA sequencing libraries per
genotype, R = Pearson correlation coefficient. Abundance (TPM) averages
per gene for all iPSC-derive neurons analyzed. C). Principal component
analysis (PCA) plot displaying the projections of sample expression profiles
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demonstrating overall effects of experimental and batch effects. Each of the
12 samples are plotted and spanned by their first two principle components.
D) Scree plot of PC computed across samples. E) Top and bottom loadings
of genes contributing to overall variances in the data. dAP = Swe/M146V
double mutant.

Table 16. AD-linked genes used for hypergeometric test and
hierarchical clustering analysis.
AD-linked genes (from EMBL-EBI “GWAS Catalog”)
ABCA7

APP

EPHA1

MAPT

RYR3

ABCA1

APPBP2

FAT1

MARK4

SEMA5A

ACE

ARAP3

FBXL7

MEF2C

SLC24A4

ADAM10

ARHGAP18

FERMT2

MS4A4A

SLC25A21

ADAM17

ATP5H

FGF1

MTHFD1

SORCS1

ADAM9

BAALC

FHIT

MTOR

SORCS2

ADAMTS20

BACE1

FSHR

MYO18B

SORCS3

ADAMTS9-AS2

BCHE

GAB2

NCSTN

SORL1

ADARB2

BIN1

GLIS3

NEGR1

SORT1

ADCY2

BLOC1S3

GRIN2B

NME8

TEK

AFF1

CADPS2

GRIN3A

NPAS3

TFAM

APBA1

CASS4

GRINL1A

NR3C2

TNK1

APBA2

CD2AP

GRM1

PARK2

TP53INP1

APBB1

CD33

HLA-DRB1

PDE1A

TP73

APBB2

CDH13

HLA-DRB5

PDGFD

TTBK2

APBB3

CELF1

HS3ST1

PICALM

UNC5C

APH1A

CELF2

IDE

PLXNA4

VPS35

APH1B

CLSTN2

IGHV1-67

PSEN1

XKR4

APLP1

CLU

IGSF21

PSEN2

ZCWPW1

APLP2

CR1

IL1B

PSENEN

APOE

CST3

INPP5D

PTK2B

DLC1

KCTD2

PTPN5

DSG2

KIRREL3

PTPRD

DYNC1I1

LRP1

RAB20

EFNA1

MAB21L1

RIN3
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Table 17. Differentially-expressed endocytic-associated genes used for
RNA-seq analysis.
Endocytic-associated genes (form Metascape GOs)
ABCA1

CLU

GSN

NAPSA

SLC35D3

ACKR2

CLVS1

HIST1H1A

NRP1

SMO

ACKR3

CPNE6

HLA-A

NTRK1

SNCA

ADAM8

CTSH

HLA-B

OCLN

SPARC

ADRB1

CUBN

HLA-C

PDLIM4

STXBP2

ADRB2

CXCR4

HLA-E

PGA3

SYNDIG1

AMOT

CYBA

HLA-F

PLA2G4B

TAP1

ANGPT1

DIAPH2

IL12A

PLEKHG5

TAPBP

ANXA1

DKK1

ITGA2

PRLR

TCIRG1

ANXA11

DNER

ITGAV

PTX3

TLR4

ANXA2

DOCK2

ITGB5

RAB27A

TLR6

AP4B1

DRD2

KCNH1

RAB31

TLR7

APLN

EGF

KDR

RAB32

TMEM108

APOE

EGFR

KIAA0319

RAB34

TMEM163

ATP6V0E1

EPHA3

KIF16B

RAB38

TMEM184A

AXL

EPHB1

KIFC1

RAB8B

VCAM1

BOK

F2RL1

LAMP1

RAB3B

VEGFA

C3

FCGR1A

LAMP5

RAB27A

VIM

C4A

FGD5

LDLRAD4

RAB13

WLS

CALY

FLOT2

LIPG

RET

WNT1

CCL2

FZD4

LITAF

RFTN1

WNT3

CD163

FZD5

LPAR1

SAMD9

WNT4

CD207

GJA1

LRP2

SAMD9L

WNT5A

CD36

GPC3

MAGEL2

SCGB3A2

WNT7A

CD47

GPER1

MERTK

SELE

WNT7B

CFTR

GRIA1

MFGE8

SERPINE1

GRIA4

MSR1

SH3GL2
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Table 18. Sample of Metascape GO terms using input list of genes
differentially expressed genes in Swe/M146V versus APPswe or PSEN1M146V neurons.
Endosomal-lysosomal & Lipid trafficking GO terms
Description

GO
GO:0012506
GO:0030139
GO:0045055
GO:0030666
GO:0043087
GO:1905954
GO:0005769
GO:0045807
GO:0060627
GO:0031901
GO:0043547
GO:0005764
GO:0005085
GO:1905952
GO:0006869
GO:0032370
GO:0043202
GO:0010876
GO:0031904
GO:0030276
GO:0006897
GO:0005096

vesicle membrane
endocytic vesicle
regulated exocytosis
endocytic vesicle membrane
regulation of GTPase activity
positive regulation of lipid localization
early endosome
positive regulation of endocytosis
regulation of vesicle-mediated transport
early endosome membrane
positive regulation of GTPase activity
lysosome
guanyl-nucleotide exchange factor activity
regulation of lipid localization
lipid transport
positive regulation of lipid transport
lysosomal lumen
lipid localization
endosome lumen
clathrin binding
endocytosis
GTPase activator activity

GO
GO:0043408
GO:0010942
GO:0043065
GO:0034599
GO:0051403
GO:1901214
GO:0001540
GO:0070997
GO:0007568
GO:0043523
hsa04730
GO:0007254

regulation of MAPK cascade
positive regulation of cell death
positive regulation of apoptotic process
cellular response to oxidative stress
stress-activated MAPK cascade
regulation of neuron death
amyloid-beta binding
neuron death
aging
regulation of neuron apoptotic process
Long-term depression
JNK cascade

LogP # Genes
-17.336
162
-12.425
139
-9.9273
123
-6.6819
62
-6.2771
58
-6.1453
60
-5.8169
21
-5.3607
63
-5.0603
59
-5.0166
43
-4.7259
19
-3.8813
32

GO
GO:0007268
GO:0098916
GO:0099537
GO:0099536
GO:0044456
GO:0050808
GO:0050804
GO:0099177
GO:0098793
GO:0098794
GO:0097060
GO:0007416
GO:0050807
GO:0045211
GO:0050806
GO:0048167
R-HSA-112315
GO:0051965
GO:0042133
GO:0021766
hsa04724
R-HSA-112314
GO:0051588
GO:0022843

Synapse function
Description
chemical synaptic transmission
anterograde trans-synaptic signaling
trans-synaptic signaling
synaptic signaling
synapse part
synapse organization
modulation of chemical synaptic transmission
regulation of trans-synaptic signaling
presynapse
postsynapse
synaptic membrane
synapse assembly
regulation of synapse organization
postsynaptic membrane
positive regulation of synaptic transmission
regulation of synaptic plasticity
Transmission across Chemical Synapses
positive regulation of synapse assembly
neurotransmitter metabolic process
hippocampus development
Glutamatergic synapse
Neurotransmitter receptors and postsynaptic signal transmission
regulation of neurotransmitter transport
voltage-gated cation channel activity

LogP # Genes
-25.663
163
-25.663
163
-25.495
163
-25.495
163
-18.953
162
-15.28
84
-14.766
85
-14.766
85
-13.557
91
-11.285
97
-11.014
75
-10.988
48
-9.9973
48
-8.5185
57
-8.0496
39
-7.9323
44
-6.4514
52
-6.2848
23
-6.1851
30
-5.8958
24
-5.514
25
-5.5896
38
-5.3923
26
-5.3309
35

GO
R-HSA-500792
GO:0007187
GO:0007188
GO:0007264
R-HSA-418594
GO:0051057
GO:0016907
GO:0007189
R-HSA-1296059
R-HSA-1296041
GO:0008528
GO:0038037
GO:0097648
GO:0015467
R-HSA-418597
GO:0038042
GO:0045028
GO:0035589
GO:0001608

AD/Neurodeeneration GO terms
Description

GPCR signalling
Description
GPCR ligand binding
G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger
adenylate cyclase-modulating G-protein coupled receptor signaling pathway
small GTPase mediated signal transduction
G alpha (i) signalling events
positive regulation of small GTPase mediated signal transduction
G-protein coupled acetylcholine receptor activity
adenylate cyclase-activating G-protein coupled receptor signaling pathway
G protein gated Potassium channels
Activation of G protein gated Potassium channels
G-protein coupled peptide receptor activity
G-protein coupled receptor dimeric complex
G-protein coupled receptor complex
G-protein activated inward rectifier potassium channel activity
G alpha (z) signalling events
dimeric G-protein coupled receptor signaling pathway
G-protein coupled purinergic nucleotide receptor activity
G-protein coupled purinergic nucleotide receptor signaling pathway
G-protein coupled nucleotide receptor activity
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LogP # Genes
-9.3237
142
-8.2469
53
-6.9176
132
-6.4054
33
-6.1699
90
-4.791
18
-4.4905
63
-4.3651
30
-4.321
84
-4.2981
32
-4.1397
72
-3.9922
82
-3.7662
45
-3.758
24
-3.6272
60
-3.5763
13
-3.5514
23
-3.4713
64
-3.4072
10
-3.3195
18
-3.1425
111
-2.9432
50

LogP # Genes
-17.532
118
-15.145
67
-12.724
58
-11.322
106
-9.4897
88
-5.8572
20
-5.4821
5
-5.3308
27
-5.2913
12
-5.2913
12
-4.7783
32
-4.5999
5
-4.5999
5
-4.6988
7
-3.5995
12
-3.262
4
-3.1683
5
-3.1683
5
-3.1683
5

Immunocytochemistry and microscopy

Cells were fixed in 4% paraformaldehyde, permeabilized in PBS/0.1%
TritonX-100 and stained with primary and secondary antibodies (see below). For low
resolution microscopy (all experiments excluding endosome analyses) stained cells
were imaged on a Nikon Eclipse Ti inverted microscope and acquired using NIS
Elements imaging software (Nikon). For endosome analysis, stained cells were
imaged on a DeltaVision inverted Olympus IX-70 microscope using a 100X oil
objective with deconvolution. Rab5+ puncta quantifications were done using Imarus.
Briefly, surface masks using the MAP2 staining to indicate neurons. Rab5+ puncta
detection and quantification was automated and programmed using the Imarus spot
detection function. Fiji (www.Fiji.sc / National Institutes of Health) and Adobe
Photoshop were used to pseudo-color images, adjust contrast, and add scale bars.

Antibodies

The following antibodies were used: Oct4 (1:500, Stemgent S090023),
Tra160 (1:500, Millipore MAB4360), SSEA4 (1:500, Abcam ab16287), Nanog
(1:500, Cell Signaling 4903), MAP2 (1:2000, Abcam 5392), Pax6 (1:300, Covance
PRB-278P), Tuj1 (mouse 1:1000, Covance MMS-435P / rabbit 1:1000, Covance
MRB-435P), Otx2 (1:100, Millipore AB9566), Nestin (1:200, Millipore 2C13B9),
FoxG1 (1:300, Abcam ab18259), CTIP2 (1:300, Abcam ab18465), Tbr1 (1:500,
Millipore AB2261), SatB2 (1:100, Abcam ab51502), MAGUK (1:100, NeuroMab
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K28_86), Synapsin (1:200, Cell Signalling Technologies 5297), APP C-term
(1:10000, Abcam Y188 ab32136) Rab5 (1:200, Cell Signalling Technologies), antimouse/rabbit/rat/chicken Alexa Fluor 488/568/647 (Invitrogen 1:500.

Amyloid-β measurements

Aβ was measured in cell supernatant conditioned for 7 days (DIV62-72
cortical neurons). Experiments were performed in 3 biological replicates.
Supernatants from experiments collected at different time points were frozen at -80
˚C. Secreted Aβ1-38, Aβ1-40 and Aβ1-42 was measured with MSD Human (6E10)
Aβ V-PLEX kits (Meso Scale Discovery) according to the manufacturer’s directions.
Aβ1-43 was measured using a colormetric ELISA (Takara) according to the
manufacturer’s directions. Secreted sAPPα and sAPPβ were also measured
simultaneously, and from matching supernatants, with MSD sAPPα/sAPPβ kit (Meso
Scale Discovery) according to the manufacturer’s directions. For all experiments, Aβ
levels were normalized to total sAPP levels unless otherwise stated.

Western Blotting

Neurons were lysed using the NucleoSpin RNA/Protein kit (Macherey Nagel)
and total protein was isolated according to the manufacturer’s instructions. Samples
were run on Criterion™ Tris-Tricine 16.5% precast gels for SDS-PAGE at 125V (BioRad). Gels were then blotted using standard techniques onto an Odyssey
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nitrocellulose membrane (LI-COR). Membranes were blocked in 5% non-fat dairy
milk in TBS-T, and were probed with primary antibodies listed below. IRDye
conjugated secondary antibodies (LI-COR) were used at 1:10,000. Proteins were
detected using the Odyssey CLx Imaging System (LI-COR).

Statistical Analysis

Experimental data was analyzed for significance using Graphpad Prism.
P < 0.05 was considered statistically significant. Sample sizes were chosen to be
large enough to allow meaningful statistical analysis. In Chapter II, all experiments
except the oligo scan were analyzed by one-way ANOVA followed by post testing
with either Tukey’s test, if multiple values were compared to each other, or Dunnett’s
method, if alterations were compared to controls. For the oligo scan, nonlinear
regression analysis was performed to fit exponential decay equation model curves to
experimental values; R square values were determined to test goodness of fit. To
analyze if distance-incorporation relationships were significantly different for
genomic loci, the rate constant k was determined for each individual data set and the
k values of the two loci were compared using the unpaired t-test. For experiments in
Chapter IV, data were analyzed by one-way or two-way ANOVA (as indicated)
followed by post testing with Dunnett’s method, as alterations were compared to
controls. Outliers were identified by the ROUT method (Q=1%). T-tests were
performed when only a single experimental group was being compared to control.
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Appendix II: Rights and Permissions

Figure 4. Reprinted by permission from Cold Spring Harbor Laboratory Press: Cold
Spring Harbor Perspectives in Medicine. Haass, C., Kaether, C., Thinakaran, G.,
and Sisodia, S. (2012). Trafficking and proteolytic processing of APP. Cold Spring
Harb Perspect Med 2, a006270–a006270., copyright (2012).

Figure 6. Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews
Neuroscience. Bu, G. (2009). Apolipoprotein E and its receptors in Alzheimer's
disease: pathways, pathogenesis and therapy. Nat. Rev. Neurosci. 10, 333–344.,
copyright (2009).
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